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Abstract 
 
 
Dementia is an increasing health concern for Australia with rates of diagnoses of dementia 
predicted to rise within our ageing population (Prince, Albanese, Guerchet, & Prina, 2014). 
The potential effects are widespread not only at the individual level but at a socioeconomic 
level with associated medical costs (Cerejeira, Lagarto, & Mukaetova-Ladinska, 2012; 
Wimo, Jonsson, Bond, Prince, & Winblad, 2013). Overall, this highlights the importance for 
medical professionals and researchers alike to focus on methods of risk reduction. One 
method of risk reduction will be to investigate predictors of preclinical dementia syndromes, 
with the aim of implementing earlier intervention to prevent or delay progression to cognitive 
disorders.  
Past research indicates that depression is predictive for the onset of dementia and cognitive 
impairment/decline (Diniz, Butters, Albert, Dew, & Reynolds, 2013; Gao et al 2013). 
However a minimal amount of research has investigated whether specific depressive 
symptoms and positive or negative affect are predictive of preclinical dementia syndromes.  
Overall, this gap in the literature suggests that further research is needed within this area.  
The current research was conducted in conjunction with the Personality and Total Health 
(PATH) Through Life Study which is a population based prospective longitudinal study.   
Study 1 and Study 2 consisted of a total of 2551 participants in the 60+ cohort study. The 
Brief Patient Health Questionnaire (BPHQ), Goldberg Anxiety Depression Scale (GADS) 
and Positive and Negative Affect Scale (PANAS) were administered to measure baseline 
symptoms of depression and positive and negative affect. A two-staged sampling design was 
implemented to diagnose Mild Cognitive Impairment (MCI) and Any- Mild Cognitive 
Disorders (Any-MCD). 
Study 1 (Chapter 3) examined whether baseline depressive symptoms predicted progression 
to MCI or Any-MCD from wave 1 to 2 and wave 2 to 3. The results suggest that depressive 
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symptoms of lacking energy/tired, loss of interest/pleasure, loss of confidence, difficulties 
concentrating, feeling down, depressed or hopeless and feeling bad about oneself were 
significant predictors of MCI from wave 1 to 2. Depressive symptoms of lacking 
energy/tired, loss of interest/pleasure, loss of confidence, difficulties concentrating, feeling 
down, depressed or hopeless and feeling bad about oneself, psychomotor slowing, felt worse 
in the morning and poor appetite or overeating were significant predictors of progression to 
Any-MCD from wave 1 to 2. Specific symptoms including lacking energy/feeling tired, lost 
interest/pleasure in doing things and difficulties concentrating were stronger predictors of 
progression to cognitive disorders from wave 1 to 2. These symptoms remained significant 
when adjusting for demographics of gender and education and covariates (employment, 
physical activity, anxiety and depression medication, partner status smoking, high blood 
pressure, diabetes, stroke and heart disease); and were cross validated between two 
depressive measures. The results suggest that specific symptoms are more predictive of 
progression to cognitive disorders at distinct time points. The findings for depressive 
symptoms as predictors of progression to cognitive impairment from wave 2 to 3 were 
intriguing, indicating that endorsing “yes” to GADS items “lacking energy” and “felt slowed 
up” significantly decreased the odds of progressing to Any-MCD. While GADS items “lost 
interest,” “lost confidence,” “felt hopeless” and “lost weight” were excluded from the current 
analyses due to participants in the healthy/cognitive groups not endorsing “yes” to these 
symptoms at baseline. The BPHQ items were excluded from analyses from wave 2 to 3 due 
to participants not endorsing “yes” to these symptoms at baseline. Covariates including 
gender and partner status were significant predictors of progression to cognitive impairment.  
Study 2 (Chapter 4) examined whether baseline measures of positive and negative affect 
predicted progression to MCI or Any-MCD from wave 1 to 2 and wave 2 to 3. Positive and 
negative affect were not significant predictors of MCI or Any-MCD from wave 1 to 2 or 
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wave 2 to 3. Demographics including gender and education were significant predictors of 
progression to cognitive impairment.  
Overall, the results suggest that specific depressive symptoms are predictive of progression to 
cognitive disorders.  Our findings suggest that additional research is needed within the field 
to increase our understanding of the role of depressive symptomology and affect in predicting 
cognitive impairment. The current findings are preliminary however with further research this 
area could have important clinical implications particularly that depressive symptoms may 
need to be monitored in individuals aged 60 years and above with the intent of earlier 
detection, and prevention/delay of the onset of cognitive disorders 
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Cognitive Disorders in Australia  
Dementia is an increasing health problem within Australia, evidenced through our 
ageing population and associated medical costs (Australian Institute of Health and Welfare, 
2012). Past research highlights the future progression of dementia rates within Australia, with 
an estimate that dementia will be the largest burden of disease for women and the fifth largest 
for men in Australia by 2016 (Access Economics, 2003). While the rates of dementia are 
predicted to increase, the focus of individuals and medical professionals alike will 
undoubtedly be primarily on treatment, though also on risk reduction. It is particularly 
important to focus on methods to reduce/prevent the onset of cognitive disorders (e.g. 
dementia) given that the number of people with dementia will exceed 730 000 by the year 
2050 if no risk reduction occurs at the population level (Jorm, Dear, & Burgess, 2005). One 
method of implementing risk reduction will be to investigate predictors of pre-clinical 
dementia syndromes, with the intention of delivering early intervention to prevent or delay 
the onset of cognitive disorders. The next section will discuss preclinical dementia syndromes 
that are important to consider within the context of predicting dementia and risk reduction. 
Any-Mild Cognitive Disorder (MCD) and Mild Cognitive Impairment (MCI) 
Any-MCD is a broad category of criteria used to diagnose adults with cognitive 
impairment as being pre-clinical to dementia (Anstey et al., 2008). Any-MCD consists of 6 
criteria including Age Associated Memory Impairment (AAMI), Age Associated Cognitive 
Decline (AACD), Other Cognitive Disorder (OCD), Clinical Dementia Rating (CDR), and 
Mild Cognitive Impairment (MCI). AAMI represents healthy individuals who report memory 
impairments across activities of daily living (ADLs) which are validated by performance on 
psychometric measures (Crook & Sudilovsky, 1987). AACD, indicates specific disturbances 
in senescent memory which are associated with ageing. The first impairment is a slow 
progression and represents an inability to recall relatively unimportant details of past 
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experiences while the second impairment progresses rapidly and represents a loss of recent 
memories, disorientation and confabulationKral, 1962). Other Cognitive Disorder (OCD), is a 
cognitive dysfunction associated with the direct physiological effect of a medical condition 
and does not meet criteria for other cognitive disorders (APA, 2000); Mild Neurocognitive 
Disorder (MND) represents impaired neurocognitive functioning associated with a general 
medical condition (APA, 2000); and the Clinical Dementia Rating (CDR),  is a rating scale 
used to measure normal cognitive functioning to dementia and associated stages (e.g. mild, 
moderate and severe) (Peterson et al., 2004). The category also includes Mild Cognitive 
Impairment (MCI), which is commonly referred to as the transitional stage from which 
individuals progress to Alzheimer’s Disease (AD), to alternate dementias, or remain 
stable/recover (Winbald et al., 2004).   
MCI is a complex disorder characterised by distinct cognitive presentations and 
subtypes (Steffens et al., 2006; Winbald et al., 2004). MCI is divided into two subtypes, 
amnestic and non-amnestic, which are categorised into single or multiple domains based on 
the present number of cognitive impairments (Peterson, 2004). Amnestic MCI (Single 
Domain) represents a single memory deficit, while amnestic MCI (Multiple Domain) refers 
to a memory deficit and other impaired cognitive domains (Petersen, 2004; Steffens et al., 
2006).   Overall, the amnestic MCI subtype is more likely to progress to AD (Peterson, 2004, 
Steffens et al., 2006). In contrast, non-amnestic MCI represents an impaired non-memory 
cognitive deficit (Single Domain) and can also include additional non-memory cognitive 
deficits (Multiple Domain) (Peterson, 2004). Apart from memory impairments, other 
cognitive impairments evident in the subtypes of MCI can include language, 
attention/executive functions and visuospatial abilities (Peterson, 2004).  
MCI is also formally recognized as Mild Neurocognitive Disorder (MND) within the 
new Diagnostic and Statistic Manual of Mental Disorders, 5
th
 edition (DSM-V; American 
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Psychological Association, 2013) which is implemented in the assessment/diagnosis of 
cognitive and mental health disorders by clinicians. The addition of MCI within the DSM-V 
suggests the importance of acknowledging MCI within the context of assessment/diagnosis of 
cognitive disorders and in conjunction with considering comorbid mental health disorders. 
Although MCI has received greater attention over the past decade, further research is needed 
to identify potential predictors for MCI and associated disorders, specifically within the 
category of Any-MCD. Knowledge of predictors for MCI and other similar disorders may 
help to prevent or delay the onset of transitional stages, which may progress to dementia. The 
present study aims to investigate this topic further by including the category of Any MCD in 
conjunction with MCI alone; on the basis that Any-MCD is considered more stable across 
time in comparison to the inclusion of MCI status alone (Anstey et al., 2008). Past research 
indicates poor to fair stability for individuals diagnosed with MCI with 29% re-diagnosed 
after 4 years (Anstey et al., 2008). In comparison individuals with a diagnosis of Any-MCD 
had a 89% chance of receiving a cognitive disorder diagnosis at a 4 year follow up (Anstey et 
al., 2008). Overall the previous research supports the inclusion of the 2 categories Any-MCD 
(which includes MCI as a subset) and MCI alone.  
Depression as a Predictor of Cognitive Impairment/Decline 
Depression is a complex illness consisting of a range of distinct symptoms (APA, 
2013). The DSM-V (APA, 2013) outlines individuals must fulfill five out of nine symptoms 
to meet a diagnosis for Major Depression Disorder (MDD), which includes at least a 
depressed mood/loss of interest or pleasure, evident most of the day, nearly every day, and a 
further four or more symptoms. The additional symptoms may include: significant weight 
loss when not dieting or weight gain, or an increase/decrease in appetite nearly every day; 
insomnia/hypersomnia nearly every day; psychomotor agitation or retardation nearly every 
day; fatigue or loss of energy nearly every day; experiencing worthlessness or excessive guilt 
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that is inappropriate, nearly every day;  a diminished ability to think or concentrate, or 
indecisiveness, nearly every day; and recurrent thoughts of death, or suicidal ideation without 
a plan (APA, 2013).  A diagnosis of MDD can also be given in accordance with a specifier, 
for example, “with melancholic features” (APA, 2013). One of the criteria for a DSM-V 
diagnosis of MDD with melancholic features includes depression regularly being worse in the 
morning (APA, 2013).   
Neurological research investigating biomarkers of AD may offer an explanation for 
mood changes evident prior to the onset of AD. Jack and colleagues (2010) propose a model 
of Dynamic Biomarkers of the Alzheimer’s Pathological Cascade. The model outlines a 
specific cascade of five biomarkers representative of physiological, biochemical and 
anatomical changes evident prior to AD (Jack et al., 2010). The biomarkers include two 
categories of Brain A-plaque deposition, for example decreased CSF A and PET amyloid 
imaging and neurodegeneration including increased CSF tau, decreased flurodeoxyglucose 
uptake on PET (FDG-PET), and structural MRI measures of cerebral atrophy (Jack et al., 
2010).  The model proposes that abnormalities in biomarkers are present prior to clinical or 
cognitive symptoms; for example, A plaque accumulation may be present two decades prior 
to onset of clinical symptoms (Jack et al., 2010). It is also proposes that biomarkers present in 
a temporal sequence with A deposition evident earlier than neurodegeneration and neuronal 
injury, dysfunction (Jack et al., 2010). Jack and colleagues (2010) illustrate the temporal 
order/changes of biomarkers in relation to the development of the cognitive disease in 
conjunction with changes in brain structure, memory and clinical function (see Figure 1.1).  
 
 
 
 
20 
 
 
 
 
 
 
 
 
 
 
 
 
 
Overall, Jack and colleagues (2010) propose a model that suggests a slow progression  
 
Overall Jack and colleagues (2010) propose a model that suggests a slow progression 
to clinical AD, which is preceded by a significant degree of neurological changes that occur 
in a sequential order. It is hypothesised that the range of neurological changes evident prior to 
clinical manifestation would have a widespread effect on other emotional and behavioural 
domains, specifically, mood related changes including depression. This could offer an 
explanation for depression often being evident prior to the onset of AD or other cognitive 
disorders (i.e. MCI); however, further research is needed and a full review of the literature in 
this area is beyond the scope of this thesis.  
 
 
 
 
 
 
Figure 1.1. Dynamic Biomarkers of the Alzheimer’s Pathological Cascade.  
A is identified by CSF or PET amyloid imaging. Tau-mediated neuronal injury and 
dysfunction is identified by CSF tau or fluorodeoxyglucose-PET. Brain structure is 
identified by use of structural MRI.  
A = -amyloid; MCI = Mild Cognitive Impairment  
Adapted from “Hypothetical Model of Dynamic Biomarkers of the Alzheimer’s 
Pathological Cascade,” by Jack et al., 2010, Lancet Neurology, 9, p.122.  
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Past research investigating depression and cognitive disorders/impairment 
Research on depression and cognitive impairment has largely been limited to 
investigating the development or presentation of depression in individuals. These studies 
focus on the time course of depression (i.e. late life depression), episodes of depression, 
number of depressive symptoms and the severity of depression indicated by scores on 
depressive measures and is discussed in detail in the sections below (Barnes et al., 2012; Gatz 
et al., 2005; Diniz et al., 2013; Dotson et al., 2012; Ravaglia et al., 2008; Rosenberg et al., 
2010; Yaffe et al., 1999). There is minimal research including depressive measures to analyse 
the role of specific depressive symptoms in relation to cognitive disorders/impairment. 
Furthermore, past research has focused on investigating depression as a predictor/risk factor 
for cognitive impairment/decline by including a formal diagnosis of Dementia, AD, Vascular 
Dementia, Mild Cogntive Impairment or a comparison of cognitive testing (Barnes et al., 
2012; Gatz et al., 2005; Diniz et al., 2013, Dotson et al., 2012, Ravaglia et al., 2008, 
Rosenberg et al., 2010, Yaffe et al., 1999). However, these studies have not included a 
clinical assessment of other cognitive disorders for which depression symptoms may have a 
predictive role.  
Time course of depression and cognitive impairment 
 A review of the literature supports a relationship between depression and cognitive 
disorders (Barnes et al., 2012; Diniz et al., 2013; Gao et al., 2013). Previous meta-analyses 
indicate that depression is a risk factor for dementia and MCI (Diniz et al., 2013; Gao et al., 
2013). One study indicated that depression in late life is an independent risk factor for 
dementia, specifically AD and Vascular Dementia (VaD) (Diniz et al., 2013), while a 
retrospective cohort study found that depressive symptoms evident in midlife or late life are 
associated with an increased risk of developing dementia (Barnes et al., 2012). Findings from 
this study also suggest that chronic depression evident throughout the life course may 
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increase the risk of developing VaD, in contrast to depression commencing in late life which 
may be a prodromal feature of AD (Barnes et al., 2012). The suggestion of depression as 
prodromal to AD reflects the contra argument to the present review of depression being a risk 
factor for dementia, which has been substantiated in a past meta-analysis (Ownby, Crocco, 
Acevedo, & Loewenstein, 2006). An analysis of the literature on depression as prodromal is 
beyond the scope of this review; however it should be considered when reviewing this area of 
research.  
Episodes of depression and cognitive impairment 
Other longitudinal research supports single and double depressive episodes as 
predictive of dementia (Dotson, Beydoun, & Zonderman, 2010). In a previous study, 
participants with a baseline age of 55 were followed for a median of 24.7 years, with 
subsequent results indicating that a history of one depressive episode was associated with a 
87-92% increase in dementia risk and two or more depressive episodes were associated with 
approximately double the risk (Dotson et al., 2010). Findings from this study suggest that 
repeated episodes of depression are associated with repeated neural damage to the brain, 
which contribute to the development of dementia (Dotson, et al., 2010).  
Number of depressive symptoms and cognitive impairment 
Past research suggests that an increased number of baseline depressive symptoms        
(> 2) is associated with an impaired performance across cognitive tests and cognitive decline. 
A prospective study including women (age > 65 years) measured participants over four years 
across measures of cognitive function (Yaffe et al., 1999). The results indicated that 
participants with 3-5 and > 6 baseline depressive symptoms scored lower across baseline and 
follow up cognitive tests in comparison to participants with a total of 0-2 baseline depressive 
symptoms. Similarly, participants with 3-5 baseline depressive symptoms and > 6 depressive 
symptoms were associated with a 2 fold and 3 fold increase in a diagnosis of dementia, 
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respectively, in comparison to participants with 0-2 baseline depressive symptoms (Yaffe et 
al., 1999).  
Scores on depressive measures and cognitive impairment 
Another longitudinal study that followed female participants (age > 70 years) for up 
to nine years also found depression to be a risk factor for cognitive decline (Rosenberg et al., 
2010). The results from this study indicate that a one point increase on the Geriatric 
Depression Scale (GDS) resulted in a 6-7% increase in the annual risk of cognitive 
impairment across cognitive domains, and that depression evident at baseline (GDS > 9) 
doubled this risk for three of the four cognitive domains, specifically on tests of episodic, 
immediate and delayed memory, psychomotor speed and executive functions (Rosenberg, 
Mielke, Xue, & Carlson, 2010). Another study found that participants without a prior history 
of depression, but with higher scores of depression measured from the Centre for 
Epidemiological Studies Depression Scale (CES-D), were a marginal predictor for the 
development of AD and dementia across five years (Gatz, Tyas, St. John, & Montgomery, 
2005). 
Depression and MCI 
Other cognitive research indicates a relationship between depression and MCI. A 
previous longitudinal-cohort study was conducted on participants (age > 65 years) over a four 
year follow up period (Ravaglia et al., 2008). The study concluded that participants with 
baseline depressive symptoms were more likely to be diagnosed with MCI at four years, 
particularly the non-amnestic MCI subtype (Ravaglia et al., 2008). Similarly, another 
prospective longitudinal study of participants (age > 65 years), followed up at six years, 
found that adults with moderate or higher levels of depressive symptoms at baseline were 
twice as likely to develop MCI at follow up (Barnes, Alexopoulos, Lopez, Williamson, & 
Yaffe, 2006). 
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Hypotheses for Depression as a Predictor of Cognitive Impairment/Decline 
Several hypotheses have been proposed for depression as a risk factor of cognitive 
decline or impairment (Jorm, 2001). One hypothesis is that depression affects the threshold 
for manifesting dementia, suggesting that depression is associated with significant cognitive 
deficits which may cumulate with those caused by dementing diseases to push forward a 
clinical diagnosis (Jorm, 2001). Related to this hypothesis is the “reserve threshold theory”, 
in which depression is associated with various neurological processes (i.e. amyloid deposition 
and neurofibrillary formation) which collectively result in cognitive dysfunction, thus 
lowering the brain reserve and resulting in the earlier onset of cognitive impairment (Butters 
et al., 2008). Findings associated with this hypothesis include a past study in which more 
recent episodes of depression increased the risk of dementia, suggesting a decrease in the 
threshold for exhibiting cognitive decline and developing dementia (Fuherer, Dufouil, & 
Dartigues, 2003).  
A second hypothesis is that depression leads to hippocampal damage through a 
glucorticoid cascade, suggesting that glucortocoid hypersecretion occurring in depression 
leads to neuronal death in the hippocampus, disturbing memory and contributing to dementia 
(Jorm, 2001). Past findings associated with this hypothesis indicate that recurrent depression 
is associated with an increased risk of dementia, suggesting that recurrent episodes of 
depression cause repeated glucortocoid hypersectretion that leads to dementia (Dotson et al., 
2010). Further research indicates that recurrent depressive episodes are associated with 
hippocampal atrophy (Videbech & Ravnkilde, 2004), which may also contribute to recurrent 
depression being predictive of cognitive impairment/decline. Other neuroimaging findings 
show that reduced hippocampal volumes are associated with later-life depression (Videbech 
& Ravnkilde, 2004), which may explain why older adults with depression are more 
susceptible to progressing to cognitive decline/impairment than non-depressed adults.  
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Another hypothesis proposed is that depression is prodromal to dementia, suggesting 
that individuals initially diagnosed with depression will progress to dementia (Jorm, 2001). 
This hypothesis is consistent with past research indicating that depressive symptoms and late 
life depression are prodromal to dementia (Chen, Ganguli, Benoit, Mulsant, & DeKosky, 
1999; Geerlings et al., 2000; Li et al., 2011).  
A final hypothesis includes depression being prodromal of cognitive 
impairment/decline due to inflammation of the brain (Leonard, 2007). It is suggested that 
individuals with depression or dementia experience inflammatory changes within the brain 
along with a reduction in the synthesis of neurotrophic factors (which are a result of increased 
brain glucocorticoids). It is proposed that the inflammatory changes that occur first as a result 
of chronic depression predispose the individual to the development of dementia due to the 
neurological changes that occur.  
It is also important to acknowledge that other research on cognitive impairment and 
depression suggests that depressive symptoms may overlap with cognitive impairment for 
example concentration difficulties (Barnes et al., 2006). This research suggests that certain 
depressive symptoms may not only be specific to depression therefore it is important to 
ensure a sample free of cognitive impairment at baseline to attribute these symptoms to 
depression alone. A review of the literature on depressive symptoms which overlap between 
cognitive impairment and depression is beyond the scope of the current thesis however 
should be considered. 
Limitations of Previous Research on Depression as a Predictor of Cognitive 
Impairment/Decline 
A large amount of the research reviewed has focused on depression as a syndrome 
without specifically investigating depressive symptomology in relation to cognitive 
impairment. However, one study found that specific baseline depressive symptoms were 
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predictive of AD in a higher educated population (Geerlings et al., 2000).  This study 
included participants 65-84 years old who were free of cognitive impairment at baseline and 
were followed up at 3.2 years (on average). The Geriatric Mental State Schedule (GMSS) 
was implemented at baseline to measure depressive symptoms, with findings indicating that a 
depressed mood and subjective bradyphrenia (e.g. feeling slowed down in thinking) were 
predictive of AD when adjusting for age, sex and subjective memory complaints (Geerlings 
et al., 2000). Other symptoms significantly predicted AD, including loss of appetite/weight, 
psychomotor agitation and suicidal ideation. However, these symptoms were not significant 
when adjusted for covariates.  
A review of the literature also indicates minimal research investigating positive and 
negative affect as predictors of cognitive impairment despite the two constructs being central 
to depressive disorders (APA, 2013; Nutt et al., 2007). Positive and negative affect represent 
a wide range of positive and negative feelings, respectively. To our knowledge no studies 
have investigated negative affect as a predictor of progression to cognitive impairment 
despite past research indicating negative affect is associated with cognitive decline and 
performance across cognitive tasks (Christodoulou et al., 2009; Maclean, Arnell, & Busseri, 
2010). There is also minimal research investigating positive affect with two previous studies 
indicating lack of positive affect was a marginal risk factor for dementia, while another study 
found symptoms representative of positive affect were elevated 3 years prior to a diagnosis of 
AD (Berger et al., 1999; Gatz et al., 2005). Although there is limited research, the role of 
positive and negative affect within depression and the potential relationship of affect and 
cognitive impairment/performance across cognition suggests further research is necessary 
(see Study 2; Chapter 4).  
Other limitations are evident within the literature reviewed and include the 
predominantly older population (age > 65) and a minimal follow up period (< 9 years) 
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(Barnes et al., 2006; Gatz et al., 2005; Geerlings et al., 2000, Ravaglia, et al., 2008; 
Rosenberg et al., 2010; Yaffe et al., 1999). The inclusion of an older age group is particularly 
limiting given the younger age at which cognitive decline occurs and the importance of 
tracking cognitive changes across the life span from mid until late adulthood. It is also 
important to consider the limits associated with following a population across a minimal 
number of years, due to the natural fluctuations that can occur across the life span. These 
fluctuations are particularly true of cognition, for example of MCI that can change from 
stable to unstable (Winblad et al., 2004), and the severity of depression that can change 
through the influence of external factors, such as negative life events (Spinhoven et al., 
2011). Other limitations include research with samples consisting only of women and no 
formal diagnosis of cognitive impairment/decline (Yaffe et al., 1999; Rosenberg et al., 2010), 
while past research conducted on a specific highly educated population is limited in the 
generalizability of the overall findings to a normal population (Geerlings et al., 2000). 
Furthermore, past research has been limited to investigating progression to cognitive 
disorders at one time point (Gatz et al., 2005; Geerling set al., 2000; Yaffe et al., 1999). 
Failure to assess cognitive changes across more than one time point is particularly important 
given the trajectories of depression and cognitive decline, as mentioned previously.  
Further limitations in past research include the types of depressive measures included 
in it (Barnes et al., 2012). One study assessed for depression through the question “Do you 
often feel unhappy or depressed,” after which participants who answered in the affirmative 
underwent further assessment using the International Classification of Diseases, Ninth 
Revision (ICD-9) and a search of past hospital records (Barnes et al., 2012). Although this 
study provided a clinical diagnosis of depression, the exclusion of immediate psychometric 
measures of depression may have failed to identify individuals who do not meet a clinical cut 
off but endorse specific depressive symptoms and later progress to cognitive impairment. 
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Together, these limitations highlight the necessity for future research to include a 
representative sample consisting of a younger range of ages and to follow participants across 
a longer number of years. Future research should also aim to conduct more than one follow 
up assessment and to provide psychometric measures of depression in conjunction with a 
formal diagnosis of cognitive impairment.  
Limitations of Co-variates Included in Past Research on Depression and Cognitive 
Impairment/Decline  
A review of the literature highlights the inconsistency across studies to include all 
three co-variates associated with depression and cognitive impairment/decline, specifically 
physical activity, employment and medication (anti-depressants and anti-anxiety) (Barnes et 
al., 2006; Berger Fratiglioni, Forsell, Winblad, & Backman, 1999; Geerlings et al., 2000; 
Ravaglia et al., 2008; Yaffe et al., 1999). Physical activity is an important co-variate to 
consider in the context of researching depression and cognition. A past review supports the 
effect of physical exercise in improving mood and reducing symptoms of depression (Penedo 
& Dahn, 2005), whilst further research suggests that self-initiated exercise is associated with 
increasing levels of positive affect in patients diagnosed with Major Depressive Disorder 
(MDD) (Mata, Thompson, Jaeggi, Buschkuehl, & Gotlib, 2012). Other research suggests that 
regular physical activity may be a protective factor against cognitive decline and dementia 
(Laurin, Verreault, Lindsay, MackPherson, & Rockwood, 2001).  
Employment is associated with depression and cognitive impairment/decline. Prior 
research indicates that unemployment affects depression and that being employed is 
associated with lower levels of depression (Christ et al., 2007; Dooley, Prause & Ham-
Rowbottom, 2000). Furthermore, one review suggests a small significant effect of 
employment on cognitive decline (Valenzuela & Sachdev, 2006), while other research 
suggests that the nature and complexity of an individual’s employment is associated with risk 
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of dementia (Dartigues et al., 1992; Kroger et al., 2008) and that working long hours have a 
negative effect across cognitive performance (Virtanen et al., 2009). However this study was 
limited to a middle age group (Virtanen et al., 2009). Past research may fail to include 
employment as a covariate due to the inclusion of an older age group, which results in a 
minimal number of individuals engaging in employment (Ravaglia et al., 2008; Yaffe et al., 
1999). However employment is an important covariate to consider, given that individuals are 
employed for longer periods of time due to increased living costs and the need to support an 
ageing population.  
Medication for the treatment of depression and anxiety is associated with depression 
and cognitive impairment. Medication, including antidepressants and benzodiazepines, is 
commonly used for the treatment of depression/anxiety due to its direct effect upon an 
individual’s mood (World Health Organisation, 2004). Past research indicates that 
antidepressants and benzodiazepines directly affect neuronal substrates, for example neuronal 
plasticity and receptor channels (Castren & Hen, 2013; Levi, Le Roux, Eugene, & Poncer, 
2015), which may explain subsequent changes in depression after pharmacological treatment 
of it, for example, mood and cognitive domains (i.e. concentration). Other research also 
suggests that medication for depression and anxiety is associated with changes in cognition, 
but with an increased risk of cognitive decline (Amado-Boccara, Gougoulis, Poirier Littre, 
Galinowski, & Loo, 1995; Paterniti, Dufouil, & Alperovitch, 2002), while recent studies 
indicate that the use of benzodiazepines is associated with an increased risk of dementia 
(Billioti de Gage et al., 2012; Gallacher et al., 2012). The literature indicates a strong 
relationship between medication and cognition, therefore potential confounding effects of 
medication should needs to be considered in the context of the current research. Together 
these findings highlight the importance of considering physical activity, employment and 
medication as co-variates in the context of researching depression and cognitive impairment.  
30 
 
Past Research on Depression and Cognition and Implications for Future Research 
A vast amount of research supports the relationship between depression and cognitive 
impairment. A review of the literature indicates a focus on the development of and 
presentation of depression including  a history and recurrence of depression (Dotson, et al., 
2012), depression evident at specific life stages (Barnes et al., 2012; Diniz et al., 2013), the 
number of depressive symptoms/severity of depression (Barnes et al., 2006; Gatz et al. 2005; 
Rosenberg et al., 2010; Yaffe et al., 1999) and baseline depression (Ravaglia et al., 2008) as 
predictors of cognitive impairment/decline. While most of the research has included formal 
diagnoses of dementia, MCI and/or cognitive testing to assess cognitive impairment or 
decline at one time point (Barnes et al., 2012; Gatz et al., 2005; Diniz et al., 2013, Dotson et 
al., 2012, Ravaglia et al., 2008, Rosenberg et al., 2010, Yaffe et al., 1999).  Overall, the 
previous studies support hypotheses explaining the link between depression and cognitive 
impairment (Jorm, 2001; Leonard, 2007). Specifically, the evidence of depression, recurrence 
of depressive episodes and severity of depression support hypotheses that depression affects 
the threshold for developing cognitive impairment, depression leads to hippocampal death 
which results in cognitive impairment, and depression as being prodromal to cognitive 
impairment (Jorm et al. 2001; Leonard, 2007).  
To our knowledge there is a limited number of studies investigating which specific 
depressive symptoms measured at baseline are predictive of cognitive impairment/decline 
evident across a range of cognitive disorders and assessed on several follow up assessments. 
This investigation could have implications for hypotheses explaining the link between 
depression and cognitive impairment which primarily focus on the role of depression as a 
construct rather than specific symptoms (Jorm, 2001, Leonard, 2007). This could lead to 
questions of whether specific symptoms play role in lowering the threshold for cognitive 
impairment, leading to hippocampal damage resulting in impairment or whether depressive 
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symptoms are prodromal to cognitive impairment. Overall, these questions highlight the 
necessity for future investigation for clinical and research purposes. On this basis the present 
study will add to this area of research by following a representative sample of participants 
from a 60s age cohort, across 8 years, from which three waves of data were collected, from a 
range of depression assessments and cognitive screenings, measurements, interviews and 
clinical diagnoses. 
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Chapter 2.  Personality and Total Health (PATH) Through Life Study and General 
Method for the Current Study  
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Overview of the Personality and Total Health (PATH) Through Life Study 
The Personality and Total Health (PATH) Through Life project is a population based 
prospective longitudinal study. The study allows for investigation of risk factors and 
cognitive ability throughout the adult lifespan.  The project was approved by the Australian 
National University Ethics Committee and written informed consent was obtained from the 
participants.  
Method for PATH 
 
Study Participants and Sampling Procedures 
Participants were randomly selected from the electoral rolls for Canberra, A.C.T and 
Queanbeyan, N.S.W in Australia for the purpose of the PATH project (Anstey et al., 2008, 
2012). In Australia it is compulsory for all citizens to enroll to vote. The PATH project was 
designed as a 20 year longitudinal study consisting of approximately 2 500 participants in 
each of the three age groups of 20-24 (20+ cohort), 40-44 (40+ cohort) and 60-64 (60+ 
cohort) years (Anstey et al., 2008). The tests were administered by trained interviewers. The 
participants were asked to complete a questionnaire while under the supervision of a 
professional interviewer. Participants also completed a range of basic physical tests, 
including grip strength, blood pressure, visual acuity, lung function and a cheek swab for 
DNA extraction (Anstey et al., 2008).  
Data were collected from the three age groups across three waves, approximately four 
years apart. See Figure 2.1 for a flow chart of participants in the PATH study. At each wave 
participants attended a PATH interview (approximately 1.5 hours) in which information was 
collected about demographics, health, stressor, and social factors, and participants completed 
a range of cognitive, physical and psychological measures and mental health/general health 
self-reports.  Our study focuses on the 60+ cohort and subsequent participants who were 
allocated to the Health and Memory sub study across the first (60-64 years), second (68-71 
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years) and third waves (74-78 years). Data were collected from the 60+ cohort, during 2001-
2002 (58.3% participation rate from random sampling), 2005-2006 (87.1% participants from 
wave 1) and 2009-2010 (88.8% participants from wave 2), respectively.  Initially, 4831 
people were contacted, of whom 2551 were interviewed at the first wave (Males 
=1317/51.6% and Females =1234/48.4%), 2222 at the second wave and 1973 at the third 
wave. 
A two stage sampling design was used to diagnose participants with a cognitive 
disorder. On the basis of their performance across a range of cognitive tests for each of the 
three waves, participants were allocated to and remained in the Health and Memory sub study 
where they underwent further assessment in addition to the PATH interview and measures. 
The sub study included a formal assessment and diagnosis of cognitive disorders (see Method 
for PATH; Clinical assessment section). The number of participants allocated to the Health 
and Memory study across the first, second and third waves was 117, 137 and 210, 
respectively.  
 
 
  
Figure 2.1. Flow Chart of Participants across the Three Waves and Allocation to  
Health and Memory Study  
 
 
 
Random selection from the ACT and Queanbeyan Electoral 
Rolls 
Wave 1 
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P rate=58.3% 
 
Health and Memory 
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Wave 1 (n=117) 
Wave 2 (n=137) 
Wave 3 (n=210) 
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2005-2006 
n=2222 
P rate=87.1% 
  
68-72 years 
2009-2010 
n=1973 
P rate=88.8% 
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Participants were screened at each of the three waves and assigned to the Health and 
Memory sub study. Screening across the three waves included the same predetermined cut off 
score on a cognitive screening battery, after which those meeting the criteria were selected 
for a clinical assessment.  Participants fulfilled the criteria and underwent clinical assessment 
if they met any of the following:  a) a Mini-Mental State Examination (MMSE) score ≤ 25 
(Folstein, Folstein, & McHugh, 1975); b) on the immediate or delayed recall of the California 
Verbal Learning Test (Delis, Kramer, & Kaplan, 1987), on wave 1, a score below the 5
th
 
percentile (e.g. a score of < 4 on immediate and < 2 on delayed); c) a score below the 5
th
 
percentile for two or more of the subsequent cognitive assessments: Symbol Digit Modalities 
Tests (SDMT; < 33) (Smith, 1982), Purdue Pegboard with both hands (Purdue; wave 1: <8; 
wave 2: < 7) (Tifin, 1968), and simple reaction time (SRT; third set of 20 trials; wave 1: > 
310ms; wave 2 > 378ms) (Anstey, Dear, Christensen, & Jorm, 2005).  
Clinical Assessment  
Participants who screened positive in the screening stage, and provided their consent 
to participate, were provided with a Structured Clinical Assessment for Dementia by one of 
two physicians (see Appendix A). Participants were administered a neuropsychological 
assessment and the Clinical Dementia Rating (CDR) scale (Morris, 1993). Consenting 
participants also underwent MRI scans, though some participants refused this assessment.  
Further information was obtained on: medical history in regard to cognitive functioning, 
duration of symptoms, medical history from medical professionals and family, present 
treatment and psychiatric history. Informant interviews were conducted when possible. 
Participants who received a form of clinical diagnosis were referred to their doctor for follow 
up.  
The neuropsychological assessment included: the frontal executive functions (Trails 
A & B, verbal fluency, and clock drawing) (Reitan, 1958; Borkowski, Benton, & Spreen, 
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1967; Borod, Goodglass, & Kaplan, 1980), language (short form of the Boston Naming Test) 
(Kaplan, Goodglass, & Weintraub, 1991), constructional praxis from the Consortium to 
Establish a Registry for Alzheimer’s Disease (Morris, Heyman, & Mohs, 1989), memory 
(Rey Auditory Verbal Learning Test with verbal recall and recognition) (Lezak, 1995), and 
recall of constructional praxis for non-verbal memory and agnosia (Morris, et al., 1989).  
Clinicians formulated a consensus diagnosis through the use of clinical checklists, results of 
the neuropsychological assessment, neuropsychiatric history and medical history. A 
description of the diagnostic criteria for all of the cognitive disorders is included in Appendix 
B. Criteria were implemented from the Diagnostic and Statistical Manual of Mental 
Disorders (4th ed.; DSM–4; American Psychiatric Association, 2000) for the assessment of 
dementia and delirium. Other criteria were applied for the following diagnoses: age-
associated memory impairment (AAMI) (Kral, 1962), ageing-associated cognitive decline 
(AACD) (Crook et al., 1986), Mild Neurocognitive Disorder (MND) (DSM-IV, 2000), 
impairment on the CDR (Morris, 1993), other cognitive disorders (OCD) (DSM-IV, 2000) 
and MCI. The Petersen Criteria (Petersen et al., 1999) were implemented at waves 1 and 2 to 
diagnose MCI and the Winblad Criteria (Winblad et al., 2004) were used at wave 3. Previous 
research indicates that diagnoses of MCI are somewhat unstable across time (Cherbuin & 
Anstey, 2012). Therefore researchers investigated a category of Any Mild Cognitive 
Difficulties (Any-MCD) that included a range of cognitive disorders (e.g. AAMI, AACD, 
MND, CDR, OCD, CDR and MCI), which showed good stability across a 4 year period 
(Anstey et al., 2008). The current study will include the categories of MCI and Any-MCD.          
Interviews 
Interviewers received training in administering cognitive and physical measures. The 
majority of the interviews and assessments were conducted in the participant’s home. 
  
 
37 
 
However, interviews were sometimes conducted at the Australian National University, or at 
the participant’s workplace. 
 
General Method for the Current Study 
Study Participants  
This thesis reports longitudinal data collected from the full 60+ cohort at wave 1 
(baseline) and waves 2 and 3. When investigating progression to a cognitive disorder from 
wave 1 to wave 2, participants were excluded from the analysis if they had a wave 1 
(baseline) diagnosis of MCI or Any-MCD (see Figure 3.1-3.2). It was necessary to exclude 
these participants to ensure a baseline sample which was impairment free, and in order to 
investigate predictors of progression to impairment. A total of 83 cases with a baseline 
diagnosis of Any-MCD were excluded at Wave 1 which included 28 cases of MCI. A further 
10 cases were excluded due to a diagnosis of dementia across the three waves, with one case 
diagnosed at wave 1, one case diagnosed at wave 1 and 2 and eight cases diagnosed at wave 
3.  
When investigating progression to Any-MCD and MCI from wave 1 to wave 2, a total 
of 314 cases were excluded (see Figure 2.2-2.3) due to participants not meeting the criteria 
for the Health and Memory sub study, and sample attrition at each or both of waves 1 and 2. 
Within the 314 cases, a total of 294 cases did not complete the PATH interview at waves 1 
and 2, and 15 cases did not meet criteria for the Health and Memory sub study at wave 1 and 
did not complete the PATH interview at wave 2.  Overall, a total of 68 and 17 cases 
progressed to Any-MCD and MCI at wave 2, respectively (see Figure 2.2-2.3). When 
investigating progression to MCI from wave 1 to wave 2, a total of 51 cases which 
progressed to Any-MCD from wave 1 to 2 were excluded from the analyses to ensure the 
binary groups were specifically healthy/healthy versus healthy/MCI.  
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Cases with a baseline diagnosis (wave 1) of Any-MCD or MCI were also excluded for 
the analysis of progression to Any-MCD and MCI from wave 2 to wave 3 (see Figure 2.4-
2.5), while a further 60 cases were excluded due to a wave 2 diagnosis of Any-MCD and 
which consisted of 17 cases of MCI. As mentioned previously, it was essential to include a 
baseline sample free of cognitive impairment to investigate predictors of progression to 
cognitive disorders; therefore for the purpose of this specific analysis it was necessary that 
wave 2 was impairment free in order to investigate predictors of progression to cognitive 
impairment from wave 2 to 3.  As mentioned previously, a total of 10 cases were excluded 
due to a diagnosis of dementia across the three waves.  
A total of 571 cases were excluded when investigating Any-MCD and MCI at waves 
2 and 3 due to sample attrition represented in the form of absent cognitive assessment, 
inability to contact participants, participants had moved out of area or did not meet the 
criteria for the Health and Memory sub study,  at each or both waves. Within the 571 cases, a 
total of nine cases met criteria for the Health and Memory sub study at wave 2 and did not 
complete the PATH interview at wave 3; 232 cases did not meet the criteria for the Health 
and Memory sub study at wave 2 and did not complete the PATH interview at wave 3; 15 
cases completed the PATH interview but not the cognitive assessment at wave 2 and did not 
complete the PATH interview at wave 3, one case did not complete the PATH interview at 
waves 2 and 3; three cases did not complete the PATH interview at wave 2 and completed the 
health and memory sub study at wave 3; two cases did not complete the PATH interview at 
wave 2 and were not contactable, so that no cognitive data were collected at wave 3. As 
previously reported in this general method section, a total of 314 cases were excluded for the 
analysis of progression to Any-MCD at wave 2. Similarly, these cases were included in the 
571 cases excluded for the analysis of progression from wave 2 to wave 3. The 314 cases did 
not complete the PATH interview at wave 2, while 15 of these cases did not meet criteria for 
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the Health and Memory sub study at wave 3 and 294 cases did not complete the PATH 
interview at wave 3.  Overall, a total of 21 and 30 cases progressed to MCI and Any-MCD at 
wave 3, respectively (see Figure 2.4-2.5). 
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Figure 2.2 Flow of participants (+60 PATH Cohort) from Wave 1 to Wave 2 for Any-MCD 
Figure 2.3 Flow of participants (+60 PATH Cohort) from Wave 1 to Wave 2 for MCI 
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Figure 2.4 Flow of participants (+60 PATH Cohort) from Wave 2 to Wave 3 for Any-MCD 
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Figure 2.5 Flow of participants (+60 PATH Cohort) from Wave 2 to Wave 3 for MCI 
 
  
 
43 
 
In the study, participants who were lost to follow up, in comparison to participants 
who persisted across all of the waves, differed significantly on baseline scores of positive and 
negative affect, Mini-Mental Status Examination (MMSE), years of education (see Table 
2.1). A total of 16 cases were missing for baseline scores on the MMSE, which were imputed 
for the analyses (IBM SPSS, 2011; Schafer, & Graham, 2002). There were significant 
associations between groups (e.g. lost to follow up and not lost to follow up) on covariates 
including physical activity, heart disease, partner status, and consumption of anxiety and 
depression medication. Participants lost to follow up were also less likely to engage in 
physical activity, to report having heart disease, be prescribed medication for anxiety or 
depression and be in a relationship (see Table 2.1).  
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 Persisted to Wave 3 
(n = 1887) 
Lost to follow-up 
(n = 571) 
Statistica 
Age (M, SD) 
 
62.54 (1.51) 62.46 (1.51) t (2456) = -1.07, p =.287 
NA score (M, SD) 
 
13.75 (4.63) 14.38 (5.47) t (2440) = -2.73, p =.006 
PA score (M, SD) 
 
31.59 (7.16) 30.04 (7.75) t (2438) = -4.41, p = < .001 
MMSE score (M, SD) 
 
29.02 (1.60) 29.33 (1.11) t (2456) = 4.40, p = < .001 
Years of Educ (M, SD) 14.02 (2.69) 13.43 (2.90) t (2456) = -4.46, p = < .001 
    
Gender (N, %)    
Male 972 (51.5%) 306 (53.6%) 2 (1, n = 2458) = 0.68, p = .41 
Female 
 
915 (48.5%) 265 (46.4%)  
Employment (N, %)    
Employed 783 (41.5%) 224 (39.2%) 2 (1, n =2458) = 0.84, p =.36 
Not  Employed 
 
1104 (58.5%) 347 (60.8%)  
Physical activity (N, %)    
None/mild 917 (48.6%) 320 (56%) 2 (2, n =2458) = 10.98, p = .004 
Moderate 739 (39.2%) 200 (35.1%)  
Vigorous 
 
231 (12.2%) 51 (8.9%)  
Anxiety Medication (N,%)    
Yes 75 (4%) 52 (9.1%) 2 (1, n = 2458) = 22.53, p = <.001 
No 
 
1812 (96%) 519 (90.9%)  
Depression Medication    
Yes 82 (4.3%) 46 (8.1%) 2 (1, n = 2458) = 11.48, p = .001 
No 
 
1805 (95.7%) 525 (81.9%)  
Partner (N, %)    
Yes 1506 (79.8%) 418 (73.2%) 2 (1, n = 2458) = 10.86, p = .001 
No 
 
381 (20.2%) 153 (26.8%)  
Smoke (N, %)    
Yes 190 (10.1%) 72 (12.6%) 2 (1, n = 2458) = 2.71, p = .08 
No 
 
1697 (89.9%) 499 (87.4%)  
High blood pressure (N, %)    
Yes 1114 (59%) 220 (38.5%) 2 (1, n = 2458) = 0.98, p = .32 
No 
 
773 (41%) 351 (61.5%)  
Diabetes (N, %)    
Yes 134 (7.1%) 50 (8.8%) 2 (1, n = 2458) = 1.50, p = .22 
No 
 
1753 (92.9%) 521 (91.2%)  
Stroke (N, %)    
Yes 78 (4.1%) 32 (5.6%) 2 (1, n = 2458) = 1.89, p = .17 
No 
 
1809 (95.9%) 539 (94.4%)  
Heart disease (N, %)    
Yes 264 (14%) 105 (18.4%) 2 (1, n = 2458) = 6.31, p =.01 
No 1623 (86% 466 (81.6%)  
 
Table 2.1 
 
Baseline Characteristics of Sample Persisting to Wave 3 and Those Lost to Follow up 
Note. 
a
Means and SD shown for continuous variables. P values are 2 sided t-tests for continuous variables and 2 
for categorical variables. A chi square test for independence using Yates Continuity Criteria was used for all 
categorical variables apart from physical activity which used Pearson Chi Square. 
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Chapter 3.  Study One: Depressive Symptoms and Prediction of Progression to 
Cognitive Disorders in a Population Based Sample Aged 60+ 
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Depressive Symptoms and Predictors of Progression to Cognitive Disorders in a 
Population Based Sample +60 
Chapter 1 outlined the role of depression as a predictor of cognitive disorders, with 
research supporting evidence that depression, recurrent depression, the number of depressive 
symptoms and onset of depression (e.g. life stage) were associated with the development of 
cognitive impairment. Although there is a large amount of research supporting the role of 
depression in the context of cognitive disorders, to our knowledge few studies have 
investigated specific depressive symptoms as predictors of cognitive disorders, across various 
follow up assessments (Geerlings et al., 2000). As mentioned in Chapter 1, one study 
concluded that specific baseline depressive symptoms were predictive of AD at one follow up 
period, on average 3.2 years later, in a higher educated ( > 8 years) and older population ( age 
> 65 years) (Geerlings et al., 2000).  In this study depressive symptoms that predicted AD 
included a loss of appetite/weight, psychomotor agitation, suicidal ideation, depressed mood 
and subjective bradyphrenia (experiencing slowness in thinking) (Geerlings et al., 2000). 
Further analyses indicated that depressed mood and bradyphenia remained significant when 
adjusting for age, sex and subjective memory complaints (Geerlings et al., 2000). This study 
provides preliminary evidence for depressive symptoms as predictors of cognitive disorders, 
specifically AD. However further research is needed to ascertain whether collective 
depressive symptoms are predictive of cognitive disorders other than AD across more than 
one follow up assessment and in a general population.  
 Although there is limited research on depressive symptoms predicting the onset of 
cognitive disorders, other research suggests a relationship between certain depressive 
symptoms and cognition. These depressive symptoms are representative of part of the criteria 
for Major Depressive Disorder (MDD; APA, 2013). The next section will discuss the 
relationship between depressive symptoms and cognition, and potential implications for 
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research of depressive symptomology and cognitive impairment/decline.  
Depressive Symptoms, Cognition, and Cognitive Impairment/Decline 
The DSM-V (APA, 2013) outlines a range of depressive symptoms that are 
representative of the criteria for a diagnosis of MDD (see Chapter 1, Depression as a 
predictor of cognitive impairment/decline). The current thesis focuses specifically on the 
following symptoms which were available in the datasets on which the current research was 
based: sleep difficulties, depressed mood, psychomotor agitation/retardation, reduced 
pleasure or interest in activities, fatigue or loss of energy, weight loss, decreased/increased 
appetite, concentration difficulties, recurrent thoughts of death/suicide, and feeling worse in 
the morning. Depressive symptoms that were not available in the datasets were excluded, 
including feeling excessive worthlessness/guilt, reduced ability to think, and indecisiveness.   
Sleep difficulties  
Sleep disturbance is a common symptom of depression, evidenced by nearly 50-90% 
of individuals diagnosed with depression as having sleep difficulties (Tsuno, Besset, & 
Ritchie, 2010). This high rate highlights the importance of sleep as a depressive symptom, 
which is further supported by the inclusion of the assessment of sleep difficulties within 
psychometric measures of depression and as part of the DSM-V criteria for MDD represented 
through “insomnia and hypersomnia evident nearly every day” (APA, 2013; Koloski, Smith, 
& Pachana, 2008; Spitzer, Kroenke, & Williams, 1999). Sleep is integral to achieving a 
normal level of functioning, and is associated with cognitive performance. Previous literature 
indicates a positive correlation between quality of sleep and the recall of non-related words in 
a population of elderly adults aged 61-75 years (Mazzoni et al. 1999). Although the study is 
limited through the inclusion of an older age-group, the results suggest that an individual’s 
quality of sleep impacts upon verbal memory. Another study shows that chronic insomnia is 
associated with cognitive impairment, as indicated across tasks of memory span, attention 
48 
 
and executive function (Haimov, Hanuka, & Horowitz, 2008). Further findings suggest that 
when the amount of sleep per night is restricted, specifically by four and six hours, over a two 
week period, performance on cognitive tasks declines over a two week period (Van Dongen, 
Maislin, Mullington, & Dinges, 2003). Specifically, the researchers found that performance 
worsened on cognitive tasks of attention, working memory and cognitive throughput (Van 
Dongen et al. 2003). Overall, sleep difficulties are a fundamental symptom of depression and 
are associated with cognitive impairment and decline, evidenced by performance measured 
over time intervals and on a range of cognitive tasks. However future research is needed to 
investigate whether sleep difficulties predict the progression to cognitive disorders.  
Other research suggests that ageing is associated with an increased likelihood of sleep 
difficulties, which may confound the effects of depression. Past research indicates that ageing 
is associated with changes in sleep patterns (Crowley, 2011; Prinz, 2004).  Specifically, 
ageing directly affects daily sleep wake cycle, quantity and pattern of sleep stages, and 
wakefulness (Crowley, 2011; Prinz, 2004). This evidence suggests that ageing may confound 
the effects of depression, particularly when investigating sleep as a depressive symptom and 
progression to cognitive disorders within a relatively older population. Past research 
investigated this potential confounding effect, with one study researching ageing and changes 
in sleep in depressed and non-depressed individuals (Gillin et al., 1981). The findings from 
this study indicate that, relative to normal individuals and after adjusting for age, the 
depressed individuals exhibited an increased range of sleeping difficulties, for example, a 
reduction in sleep efficiency, increased early morning wake time and intermittent awake time 
(Gillin et al., 1981). Other research suggests that depression in comparison to age was the 
most significant predictor for excessive daytime sleepiness (Bixler et al., 2005), which is 
representative of hypersomnia (Ohayon, 2008). Further research found that ageing is not 
associated with self-reported sleep disturbances; instead other factors including; general 
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health, and mild/moderate/severe depressed mood are associated with reported sleep 
disturbances (Grandner et al., 2012).  Overall, past research suggests that sleep changes 
related to depression may be distinct from the ageing process, supporting further 
investigation of sleep difficulties as a depressive symptom in the context of cognitive 
disorders.  
Depressed mood and feeling worse in the morning 
In the DSM-V criterion for MDD, depressed mood is indicated through subjective 
reports of feeling sad, empty or hopeless (APA, 2013). Previous research supports a 
relationship between a sad mood and cognitive impairment. One study showed that induced 
sad mood affects memory for emotional words and facial emotional recognition (Chepnick, 
Farah, & Cornew, 2007), while other research found that a sad mood induced by music 
resulted in participants showing an increased recall of sad words on a delayed task and in 
autobiographical memory (Knight, Maines, & Robinson, 2002). Additional neuroimaging 
research supports an association between mood and cognition, with past findings showing an 
interaction between mood and cognition to be mediated by the Prefrontal Cortex (PFC) (Aoki 
et al., 2011; Mayberg et al., 1999).  
Various limitations are evident within the research on depressed/sad mood and 
cognition. Numerous studies induced a sad mood on a relatively healthy sample of 
participants (Chepnick et al., 2007; Knight et al., 2002; Mitchell & Phillips, 2007), which 
makes it difficult to generalize the results to individuals experiencing depression and who 
indicate the experience of a sad mood. Particularly, the severity or intensity of the ‘sad mood’ 
in a depressed individual versus a healthy individual would differ significantly. Furthermore, 
the studies include an ‘induced sad mood’ which may not be representative of a continuous 
sad mood experienced by individuals with the depressive symptom.  The past studies also 
included salient processing of emotional cognitive information (Chepnick et al., 2007; Knight 
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et al., 2002); however results may differ from processing non-emotional information. Despite 
these limitations the past research suggests a relationship between depressed/sad mood and 
cognition.  
The DSM-V diagnosis for MDD with melancholic features includes the criterion of 
depression regularly being worse in the mornings (APA, 2013).  When this symptom, in 
conjunction with other symptoms, is evident in the most severe stage of depression, a 
diagnosis of MDD with melancholic features is considered (APA, 2013). Therefore the 
symptom of “feeling worse in the morning” is often included within depressive measures 
(Goldberg, Bridges, Duncan-Jones, & Grayson, 1988). While there is a limited amount of 
research directly investigating the diurnal pattern of mood as a predictor of cognitive 
impairment, other related research suggests a possible relationship. As mentioned in Chapter 
1, a depressed mood in general is associated with cognitive impairment (Aoki et al., 2011; 
Chepnick et al., 2007; Knight et al., 2002; Mayberg et al., 1999; Mitchell & Phillips, 2007), 
and specifically repeated episodes of depression are predictive of dementia (Dotson et al., 
2010). As feeling worse in the morning is indicative of melancholia, it is hypothesised that 
the symptom of “feeling worse in the morning” may also be associated with cognitive 
impairment, for it includes a depressed mood and occurs on a regular basis, similarly to 
recurrent episodes of depression. However further research is needed to investigate this 
symptom in relation to progression to cognitive disorders.  
Psychomotor retardation or agitation 
Past research demonstrates the importance of psychomotor symptoms within 
depression, with evidence supporting psychomotor symptoms of retardation and agitation as 
independent constructs that may contribute significantly to diagnosis, prognosis and potential 
pathophysiology of depression (Sobin & Sackeim, 1997). Psychomotor retardation is 
observed through slowed speech and thinking, facial expression, speech lowered in volume, 
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inflection, amount, variety of content or muteness, eye movement, self-touching, posture, and 
speed and degree of movements (APA, 2013; Buyukdura, McClintock, & Croarkin, 2011). 
Past research shows that somatic and vegetative symptoms are related to a 10% risk in the 
chance of developing dementia (Gatz et al., 2005). However a limited number of studies exist 
supporting this finding or generalizing the results to other specific cognitive disorders.  
Further research highlights that individuals with depression display specific 
manifestations of psychomotor slowing, which may be associated with cognition.  Some of 
these psychomotor manifestations include poor eye movement and slowed motor reaction 
(Buyukdura et al., 2011; Sobin & Sackeim, 1997). Particularly, eye movement is fundamental 
to cognitive processes including visual search and reading of information (Liversedge & 
Findlay, 2000), while motor reaction is a combination of motor and cognitive processes 
(Sobin & Sackeim, 1997).  
Another psychomotor symptom of depression includes agitation (APA, 2013). 
Agitation is represented through the inability to stay still, pacing, hand wringing, or pulling 
and rubbing the skin, clothing or alternate objects (APA, 2013). Similar to psychomotor 
slowing and cognition, there is a limited amount of research investigating agitation and 
cognitive impairment/decline. To our knowledge, only one study, previously mentioned, 
found the depressive symptom of agitation to predict AD (Geerlings et al., 2000). However, 
based on the presentation of agitation as mentioned above, it is possible that agitated 
behaviours would result in distraction and impair cognitive ability, for example one’s ability 
to encode information successfully into memory. However, further investigation is needed to 
ascertain the relationship.  
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Reduced pleasure or interest in activities, fatigue or loss of energy and                     
loss of confidence 
Positive affect consists of a wide range of positive feelings including attentive, 
interested, alert, excited, enthusiastic, inspired, proud, determined, strong and active (Watson, 
Clarke, & Tellegen, 1988). These states are often impaired in individuals presenting with 
depression and are evident through a decreased pleasure/interest in activities or the 
experience of fatigue and loss of energy (APA, 2013; Nutt et al., 2007).  Past research on 
depression and cognitive impairment found an elevation in depressive symptoms and 
dominance of motivational symptoms, for example loss of energy and lack of interest, three 
years prior to incidence of AD (Berger et al., 1999), while other research found that reduced 
positive affect was a marginal risk factor for dementia with positive affect being represented 
through one item representative of loss of confidence including “I felt I was just as good as 
other people” (Gatz et al., 2005). Overall, the previous research suggests that symptoms of 
reduced interest in activities, fatigue or loss of energy and loss of confidence may be 
associated with the development of a cognitive disorder. However further research is needed 
to confirm this hypothesised relationship, particularly the symptom of fatigue associated with 
loss of energy. Further research is also required into a general population free of cognitive 
impairment, given that past research focused on participants in the preclinical stage of AD 
(Berger et al., 1999). 
The inability to experience pleasure, a common symptom of depression, is also 
referred to as anhedonia (Lemke, Puhl, Koethe, & Winkler, 2007). A past study included 
individuals diagnosed with co-morbid Major Depressive Disorder and Parkinson’s Disease 
(dPD) and further categorized them into three groups pending their presentation of depressive 
symptoms (e.g. depressed mood, apathy/anhedonia and both depressed mood and 
apathy/anhedonia) (Santangelo et al., 2009). The study found that individuals who met the 
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criteria for the apathy/anhedonia group scored significantly lower on cognitive tasks 
(Copying Task, Frontal Assessment Battery and Phonological Tasks) in comparison to 
individuals who fulfilled the criteria for the depressed mood (Santangelo et al., 2009). This 
finding suggests that anhedonia may be associated with cognition; however it is difficult to 
specify the relationship due to the combination of apathy and anhedonia.  
Further research suggests that emotional processing is impaired in individuals with 
cognitive disorders, which may indirectly effect their ability to experience pleasure. Past 
findings indicate that impaired emotional recognition of faces is associated with cognitive 
disorders specifically in MCI and AD (Drapeu, Gosselin, Gagnon, Peretz, & Lorrain, 2009; 
Spoletini et al., 2008).  A lot of the evidence supporting impaired emotional recognition is 
conducted on individuals who have received a diagnosis of a cognitive disorder or once the 
cognitive disorder has progressed. Therefore it is difficult to ascertain whether impaired 
emotional recognition is prodromal to cognitive impairment. However the finding that 
impaired emotional recognition is evident in pre-dementia syndromes such as MCI (Spoletini 
et al., 2007) could suggest a prodromal basis. If this is true, the presence of impaired 
emotional recognition could affect an individual’s ability to experience pleasure, thus 
indirectly leading to a symptom of depression, a syndrome that is a risk factor for cognitive 
impairment. However, as mentioned previously, there is a limited amount of research 
investigating this hypothesis or the specific symptoms of reduced pleasure, interest in 
activities, fatigue or loss of energy; therefore further research is needed.  
Poor concentration, suicidal ideation, weight loss and appetite 
Additional symptoms of depression include poor concentration, suicidal ideation and 
weight loss/poor appetite/overeating (APA, 2013). Past research on depression and cognitive 
impairment indicates that the depressive symptom of difficulties with concentration was 
dominant three years prior to a diagnosis of AD (Berger et al., 1999). This finding suggests 
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that difficulties with concentration may have a role in predicting AD itself, or are part of the 
prodromal phase, given that the study was performed on participants in the preclinical phase 
of AD. Furthermore, the participants were aged ≥ 75 years and in the preclinical phase of 
AD; therefore it is difficult to generalise these findings to a general population. A limited 
amount of research exists investigating difficulties with concentration, as a depressive 
symptom, for predicting cognitive impairment, which may be explicable by the view of this 
symptom as being prodromal to cognitive disorders. However concentration is a necessary 
component for cognitive performance, specifically of working memory (Lichtenberger, & 
Kaufman, 2012), suggesting that poor concentration, as a depressive symptom, may affect 
performance on cognition. Overall, this depressive symptom may predict cognitive 
impairment/decline; however this is a preliminary suggestion and additional research is 
required. 
 Recurrent thoughts of death and suicidal ideation are also symptomatic of depression 
(APA, 2013). To our knowledge there is limited research investigating the relationship 
between this specific depressive symptom and cognitive impairment, with one study, as 
previously discussed, finding suicidal ideation to be predictive of AD (Geerlings et al., 2000). 
Other research on suicidal ideation suggests that the depressive symptom is associated with 
cognitive inflexibility and the inability to problem solve (Dixon, Heppner & Anderson, 1991; 
Miranda, Gallagher, Bauchner, Vaysman, & Morroquin, 2011; Priester & Clum, 1993). 
Therefore the presence of cognitive inflexibility and inability to problem solve could impact 
upon the ability to function at a normal cognitive level, overall contributing to the rate at 
which an individual presents with cognitive difficulties. However more research is needed to 
support this hypothesis and establish whether this symptom is predictive of cognitive 
impairment/decline.   
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Weight loss and increase/loss of appetite are symptoms representative of depression 
(APA, 2013). To our knowledge, there is a limited amount of research investigating these 
symptoms within the context of depression and cognitive disorders, with a study finding loss 
of appetite and weight were predictive of AD (Geerlings et al., 2000). Other research has 
focused on weight loss/gain as a separate construct from depression and as prodromal to 
cognitive disorders, and with limited research on the direct effects of appetite not related to 
dieting. Past research also found a relationship between weight and the incidence of dementia 
(Fitzpatrick et al., 2009; Power et al., 2011; Stewart et al., 2005). Specifically, overweight 
men and men with a waist-to-hip ration ≥ 9 (indicative of obesity) had a lower hazard of 
dementia in comparison to men with a normal weight and waist-to-hip ratio ≤ 9 (Power et al., 
2011). However this study was limited to the investigation of a male population and adiposity 
within later life. In contrast, another study found that higher adiposity evident in mid-life 
increased the risk of developing dementia in later life (Fitzpatrick et al., 2009). Higher 
adiposity may be the result of an increased appetite, which could potentially impact upon 
weight gain and increase the risk of dementia. However further research is needed to 
ascertain this relationship between increased appetite and risk of cognitive disorders.  
Further research found that weight loss evident two to four years prior to a diagnosis 
of dementia was associated with the incidence of dementia (Stewart et al., 2005).  Poor 
appetite and hence limited caloric intake may directly impact on weight loss, and contribute 
to an increased incidence of dementia. However future research is needed to investigate this 
potential relationship between poor appetite and cognitive disorders.   
Overall, there is evidence to support a relationship between weight gain/loss and 
dementia, which is hypothesised to be affected by appetite. On the basis of past research it is 
difficult to ascertain the role of weight or appetite as a depressive symptom, in the context of 
predicting progression to cognitive disorders. This gap in the literature suggests that future 
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research is needed to investigate the potential association between these depressive symptoms 
and cognitive disorders.  
Summary of depressive symptoms 
Research supports that specific depressive symptoms are predictive of AD and 
dementia (Gatz et al., 2005; Geerlings et al., 2000; Fitzpatrick et al., 2009; Power et al., 2011; 
Stewart et al., 2005; Buyukdura et al., 2011; Chepnick et al., 2007; Haimov et al.,  2008; 
Knight et al., 2002; Liversedge, & Findlay, 2000; Mayber et al., 1999; Mazzoni et al. 1999; 
Santangelo et al., 2009; Van Dogen et al. 2003; Berger et al., 1999; Gatz et al., 2005). 
Specific depressive symptoms, including a loss of appetite/weight, psychomotor agitation, 
suicidal ideation, depressed mood, and bradyphrenia, are predictive of AD (Geerlings et al., 
2000). Furthermore only depressed mood and bradyphrenia remained significant predictors 
while adjusting for sex, age and subjective memory complaints (Geerlings et al., 2000). 
These findings are limited to a highly educated population and prediction of AD and no other 
cognitive disorders. The findings are also limited to one follow up assessment, on average 3.2 
years later, and the exclusion of other covariates apart from age, sex and subjective memory 
complaints.  Further research supports that somatic and vegetative symptoms representative 
of psychomotor retardation are associated with an increased risk of dementia (Gatz et al., 
2005). However this finding has not been replicated, nor has it been investigated in the 
context of alternate cognitive disorders. Other research suggests that weight is associated 
with dementia risk (Fitzpatrick et al., 2009; Power et al., 2011; Stewart et al., 2005),; and it is 
hypothesised that weight is directly impacted by increase/decrease of appetite, both of which 
are symptomatic of depression. However further research is needed to understand the role of 
increased/decreased appetite as symptoms of depression in the context of cognitive disorders. 
This is also true of the symptom of weight loss, which is well less understood as a symptom 
of depression in predicting specific cognitive disorders other than dementia.  
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Further literature supports the relationship between specific depressive symptoms and 
cognition. Individual symptoms, including sleep, depressed mood, psychomotor retardation, 
reduced pleasure/interest in activities and fatigue/loss of energy, are associated with cognition 
(Buyukdura et al., 2011; Chepnick et al., 2007; Haimov et al., 2008; Knight et al., 2002; 
Liversedge, & Findlay, 2000; Mayber et al., 1999; Mazzoni et al. 1999; Santangelo et al., 
2009; Van Dogen et al. 2003;). Limitations within these past studies include the use of 
outcome measures primarily based on performances across cognitive tasks (Chepnick et al., 
2007; Haimov et al., 2008; Knight et al., 2002; Mazzoni et al. 1999; Santangelo et al., 2009; 
Van Dogen et al. 2003). The use of these outcome measures makes it difficult to generalize 
these findings to whether symptoms are predictive of cognitive disorders.  
Other studies suggest that the level of positive affect experienced is associated with 
the presentation of depressive symptoms, including reduced pleasure/interest in activities and 
fatigue/loss of energy (APA, 2013; Nutt et al., 2007), while past research found that elevated 
mood states associated with positive affect are associated with incidence of AD, and that 
positive affect is a marginal risk for dementia at one follow up assessment period (Berger et 
al., 1999; Gatz et al., 2005). The limitations of these studies include the inability to generalise 
the findings to a normal population who develop other cognitive disorders (e.g. MCI), and 
that they use only a single follow up assessment, while the role of other depressive symptoms 
and cognition is less well understood, with a limited amount of research on symptoms that 
include poor concentration and suicidal ideation (Dixon, et al., 1991; Lichtenberger & 
Kaufman, 2012; Miranda et al., 2011; Priester & Clum, 1993).  
Overall, the research suggests preliminary evidence for certain depressive symptoms 
as predictors of AD. Other research supports that specific depressive symptoms are 
associated with cognition, evidenced by performance across cognitive tasks. Together the 
limitations of the past research indicate that further research is required to understand the role 
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of individual depressive symptoms as predictors of progression from normal ageing to 
cognitive disorders across various follow up assessments, while adjusting for additional 
covariates and demographic factors.  
The aim of the current study is to investigate whether specific depressive symptoms 
are predictive of progression to cognitive disorders (MCI and Any-MCD) from normal 
ageing across two follow assessments at wave 2 and wave 3. On the basis of previous 
findings (Berger et al., 1999; Gatz et al., 2005; Geerlings et al., 2000; Santangelo et al., 2009) 
it is hypothesised that depressive symptoms, including depressed mood and feeling worse in 
the morning, psychomotor agitation/retardation, loss of appetite/weight, suicidal ideation, 
reduced pleasure or interest in activities, fatigue and loss of energy, and loss of confidence, 
will predict progression to cognitive disorders. It is difficult to predict whether other 
symptoms of depression (e.g. reduced ability to concentration, sleep difficulties or increased 
appetite) will predict progression to cognitive disorders, due to the limited amount of research 
conducted in this area.  However, on the basis of Jack and colleagues (2010) model the 
“Dynamic Biomarkers of the Alzheimer’s Pathological Cascade” (see Chapter 1; page 19) it 
is suggested that significant neurological changes evident to the onset of cognitive 
impairment may result in a range of cognitive, emotional and behavioural depressive 
symptoms (e.g. reduced ability to concentration, sleep difficulties or increased appetite). 
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Method 
Data presented in this study are from the PATH project which has previously been 
described in detail (see Chapter 2, Method for PATH). This study focuses on cross sectional 
analyses and data collected from the 60+ cohort assessed at baseline, and followed up at 
waves 2 and 3. The sample used in the current study has previously been described in detail 
(see Chapter 2, Method for PATH & Chapter 3, General Method for the Current Study).  
Materials  
Assessment of Depressive Symptoms 
Brief Patient Health Questionnaire (BPHQ) 
The Brief Patient Health Questionnaire (BPHQ) is a self-report measure for mood and 
anxiety disorders and includes diagnostic validity (Spitzer et al., 1999; see Appendix C). The 
BPHQ was originally developed from The Primary Care Evaluation of Mental Disorders 
(Prime-MD), which is a screening instrument for mental health disorders (Spitzer et al., 
1999). In addition to items measuring anxiety, the BPHQ consists of nine items measuring 
depression that will be used for purpose of the current analyses.  
The nine items represent a range of depressive symptoms, including depressed mood, 
anhedonia, appetite change, sleep disturbance, psychomotor agitation or retardation, loss of 
energy, diminished concentration and suicidal thoughts/attempts (Cannon et al., 2007). 
Participants must self-report how often they have been bothered by the symptom over the 
past two weeks. Individuals are scored 0-3 points according to their answer on a 4 point scale 
ranging from; “not at all,” “several days,” “more than half the days,” and “nearly every day” 
(Spitzer, et al., 1999). Overall scores range from 0-27 points with higher scores indicative of 
a potential DSM-IV diagnosis for depression (Spitzer, Williams, Kroenke, Hornyak, & 
McMurray, 2000).  
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Past research supports BPHQ as a valid and reliable measure of depression, with 
much of this evidence gathered from research conducted on the Patient Health Question 9 
item questionnaire (PHQ-9) which is representative of the depression measurement in the 
BPHQ. A past systematic review indicates the PHQ-9 is a well validated measure with 
superior sensitivity and specificity for the detection and monitoring of depression (Kroenke, 
Spitzer, Williams, & Lowe, 2010). Specific literature analysed within the review indicates 
that the PHQ-9 performs in the same manner across sex and age groups, while the PHQ-9 
showed increased internal consistency across a range of cognitive levels (Kroenke et al., 
2010). Further research supports the summed score for the PHQ-9 as a valid and reliable 
measure for screening depression in elderly individuals, specifically aged > 59 (Lamers et al., 
2008). However this study was limited to elderly patients who were currently chronically ill.  
Goldberg Anxiety and Depression Scale (GADS) 
The Goldberg Anxiety and Depression Scale (GADS) is a self-report measure of 
anxiety and depression, which is widely used within community studies and for clinical 
samples (Goldberg et al., 1988; Koloski et al., 2008; see Appendix D). The GADS consists of 
a total of 18 items with nine items measuring anxiety and nine items measuring depression. 
The nine items measuring depression were used for the present analyses. The nine items 
represent symptoms of depression, including anhedonia, loss of energy, loss of confidence, 
hopelessness, weight loss/poor appetite, disrupted sleep, psychomotor slowing, and feeling 
worse in the morning (Goldberg et al., 1988). Participants must report if they have recently 
felt these symptoms and record their answer as yes/no. Scores range from 0 to 9 with higher 
scores indicating the presence of depressive symptoms.   
Other research supports the implementation of the GADS as a measure of depression. 
One study investigating the effect of age on depression included the GADS as a measure of 
psychological distress (Jorm et al., 2005). The findings from this study suggest that the 
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GADS had a weak factorial invariance between the age groups of 20-24, 40-44 and 60-64, 
supporting the implementation of this measurement across a wide age range (Jorm et al., 
2005). This finding is consistent with previous research which implemented the GADS to 
predict change in depressive symptomology across a population sample 18-79 years old 
(Christensen et al., 1999; Henderson et al., 1998), further supporting the implementation of 
this measure across a wide age range. Overall, these findings support the implementation of 
the GADS in the current study, which assessed participants at baseline who were 60-64 years 
old. 
Assessment of Demographics and Covariates  
Participants were questioned by an interviewer at the PATH interview on their total 
years of education, employment status and marital status. Employment status was recorded 
and categorized as: employed full-time/employed part-time, looking for full-time 
work/employed part time/unemployed and looking for work/not in the labour force, while 
marital status was categorized as married/de facto/separated/divorced/widowed/never 
married.  For the purpose of the present analyses employment was collapsed into a binary 
variable: employed whether full-time or part-time (employed full time/employed part-time, 
looking for full-time work/employed part-time) and not employed (unemployed and looking 
for work/not in the labor force).  Marital status was collapsed into a binary variable called 
partner status and comprised the categories partnered (married/defacto) and not partnered 
(separated/divorced/widowed/never married).  
Lifestyle factors were assessed at the interview. Throughout the interview high blood 
pressure was measured twice by implementing the Omron M4 blood pressure monitor, from 
which diastolic and systolic pressures were averaged (Jorm, Anstey, Christensen, & Rodgers, 
2004). A value of ≥ 85mm Hg represented diastolic hypertension, while ≥ 140 mm Hg was 
indicative of systolic hypertension (Barrett-Connor, & Palinkas, 1994). Based on these values 
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a binary variable titled high blood pressure was created (yes/no). Stroke, diabetes, heart 
disease, antidepressants and anxiety medication consumption, and current smoking status, 
were self-reported and recorded as a binary variable (yes/no). Participants were assessed for 
physical activity based on the UK Whitehall II Study assessment and were coded into 
none/mild (< .05 hours per week), moderate (0.5 -1.49 hours per week) and vigorous (> 1.49 
hours per week) categories (Stafford, Hemingway, Stansfield, Brunner, & Marmot, 1998).  
Sample Size 
Sample size was predetermined by the original aims of the larger cohort study 
(Anstey et al., 2012). The sample size was sufficient to allow for investigation of risk and 
protective factors and interactions among risk factors. The sample size was based on 
participation rate in the PATH study recruited in the first wave (N =2551). Participants were 
allocated to one of two categories for analyses based on their progression to a diagnosis of 
cognitive impairment at specific time points at wave 2 and wave 3 (i.e. healthy/healthy or 
healthy/cognitive impairment). Participants were allocated to the healthy/healthy group if 
they remained stable across waves and free of cognitive impairment from wave 1 to 2 or 
wave 2 to 3.   
When investigating progression to MCI from wave 1 to 2, the healthy/healthy group 
consisted of 2076 participants and the healthy/MCI group consisted of 17 participants. When 
analysing Any-MCD from wave 1 to 2, the healthy/healthy group consisted of 2076 
participants and the healthy/Any-MCD group included 68 participants (see Figures 2.2-2.3). 
When investigating MCI from wave 2 to 3 the healthy/healthy consisted of 1797 and the 
healthy/MCI group included 21 participants; and when analysing Any-MCD from wave 2 to 
3, 1797 participants were allocated to the healthy/healthy group and 30 participants to the 
healthy/Any-MCD group (see Figures 2.4.-2.5).  
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Statistical Analysis 
SPSS version 22 was used to perform the analysis. A Generalized Linear Model 
(GZLM) using binary logistic regression was implemented to investigate items of the BPHQ 
and GADS as predictors of progression to a binary group diagnostic membership (e.g. 
healthy/healthy, and healthy/Any-MCD or healthy/MCI), while controlling for demographics 
and covariates. A GLZM, binary logistic regression model is an applicable method of 
analyses for data that include a dependent variable with a binary outcome that is not normally 
distributed (Garson, 2013). Therefore, based on the nature of the current research question, 
investigating prediction to a binary outcome (healthy/MCI or healthy/Any-MCD) with a non-
normal distribution, this model was considered applicable for the present analyses.  
Predictor variables included individual BPHQ and GADS items, which were entered 
individually into the GLZM model.  For the purpose of the current analyses the BPHQ items 
were collapsed into a binary variable (no/yes) to indicate the presence of a depressive 
symptom. Endorsement of “not at all” was coded as having no depressive symptom, while the 
presence of a depressive symptom was indicative of endorsement of “several days,” “more 
than half of the day,” or “nearly every day”. Other demographics/covariates were adjusted 
for, and included education, physical activity, employment status, depression and anxiety 
medication, partner status, current smoking status, high blood pressure, diabetes, stroke and 
heart disease. A series of hierarchical models was tested. In Model 1, the 10 GADS items and 
9 BPHQ items were entered separately to analyse prediction to Any-MCD/MCI from wave 1 
to 2 and wave 2 to 3. Items that significantly predicted progression to Any-MCD/MCI in 
Model 1 were analysed in Model 2 and entered separately while adjusting for gender and 
education. Items that were significant in Model 2 were entered into Model 3 individually 
while adjusting for all other covariates (physical activity, employment, depression and 
anxiety medication, partner status, current smoking status, high blood pressure, diabetes, 
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stroke and heart disease). Age was excluded from all the models due to the narrow aged 
cohort included in the current analyses. Results in model 1 are displayed in tables while 
results from model 2 and 3 are discussed in text within the results section. A Pearson product-
moment correlation coefficient indicated a small negative correlation between gender and 
education (r = -.16, n = 2551, p < .001). The association between covariates in model 3 was 
analysed using the Phi Coefficient, with results indicating small to large effects between 
specific variables (see Appendix E).  
There is no assumption for the distribution of the predictor or dependent variables in 
binary logistic regression (Pallant, 2011); therefore it was not necessary to investigate 
normality (e.g. skewness/kurtosis). The maximum number of predictors entered within a 
model across the waves was 11, which was relatively small compared to the overall sample 
size (N = 1827 to 2514), and therefore did not violate an assumption of binary logistic 
regression (Pallant, 2011). Similarly, the assumption of Multicollinearity was not violated, 
with analysis indicating that the tolerance values for the predictors in the model were not     
< .10 (Pallant, 2011).  
Data Screening 
The data were screened for accuracy of input and plausibility of frequencies, which 
indicated that both were satisfactory. A missing values analysis indicated a range of three to 
eight cases missing for each of the following covariates: employment, depression and anxiety 
medication, partner status, current smoking status, diabetes, stroke and heart disease. Past 
research recommends imputing missing values rather than deleting cases to retain the full 
sample size and avoid loss of power (Schafer & Green, 2002). Imputation is also 
recommended for cases that are missing at random (IBM, SPSS, 2011; Schafer & Green, 
2002). Therefore imputation in the form of substituting the most common answer (yes/no) 
was implemented to deal with the current missing cases. The most common answer, i.e. “no” 
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was imputed for missing cases for depression and anxiety medication, smoking status, 
diabetes, stroke and heart disease, while the most common answer including “unemployed” 
was imputed for employment and “married/de facto” for partner status.   
Further missing values analysis indicated 302, 128 and 64 missing cases for the 
covariates/demographics of physical activity, years of education and high blood pressure, 
respectively.  Imputation using an Expectation Maximization (EM) method was implemented 
to deal with the missing data for physical activity, years of education and high blood 
pressure.  
A Missing Values Analysis indicated that 9 to 12 cases were missing across each item 
of the BPHQ and GADS. The cases appeared missing at random, therefore imputation using 
EM methods was considered the appropriate method for dealing with these cases (IBM SPSS, 
2011; Schafer, & Graham, 2002). Distribution of the variables was examined, which 
indicated a total of 4-17 cases as outliers for each BPHQ items and 7-15 cases as outliers for 
6 items on the GADS (items 11-15 & 18). However, based on the robustness of the study’s 
large sample size, the cases were included in the present analyses.  
As mentioned previously (see Chapter 3, General Method), a total of 314 cases were 
excluded for the analysis of progression to Any-MCD from wave 1 to 2, while 571 cases 
were excluded from the analysis of progression to Any-MCD from wave 2 to 3. Due to the 
necessity of including the outcome variable of Any-MCD and MCI for the specific research 
question under investigation, cases of missing outcome data were excluded from the analysis 
by implementing the case pairwise option.  
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Results 
Description of Participants  
A total of 1818 to 2144 participants were included in the current analyses (see Figures 
2.2-2.5). Table 3.1 presents demographic and covariate information for participants belonging 
to a diagnostic category within each analysis (e.g. Wave 1 to 2 MCI model) across the three 
waves (e.g. healthy/healthy versus healthy/cognitive disorder). Figures 3.1-3.6 show the 
differences in the prevalence of depressive symptoms (GADS & BPHQ) between the 
diagnostic groups (e.g. healthy/healthy and healthy/cognitive disorder) across the waves (e.g. 
wave 1 to 2 and wave 2 to 3). Participants in the diagnostic groups healthy/MCI and 
healthy/Any-MCD from waves 2 to 3 did not endorse any of the nine BPHQ items at 
baseline, therefore a comparison between diagnostic groups (e.g. healthy/healthy and 
healthy/cognitive disorder) was not included for BPHQ items from wave 2 to 3 for the MCI 
and Any-MCD model. 
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 Gender 
 
Age Years of 
education 
Partner 
Status 
   
 F/M M (SD) M (SD) Yes/No    
        
Wave 1 to 2 
 
       
MCI model        
Healthy/healthy 1020/1056 62.53(.03) 14.10(.60) 1636/440    
Healthy/MCI 7/10 61.76(.37) 12.76(.62) 14/3    
        
Any-MCD 
model 
       
Healthy/healthy 1020/1056 62.53(.03) 14.10(.06) 1636/440    
Healthy/Any-
MCD 
30/38 62.44(.19) 12.99(.27) 62/6    
        
Wave 2 to 3 
 
       
MCI model        
Healthy/healthy 881/916 62.51(.04) 14.22(.06) 1421/376    
Healthy/MCI 8/13 62.57(.36) 12.81(.71) 21/0    
        
Any-MCD 
model 
       
Healthy/healthy 881/916 62.51(.04) 14.22(.06) 1421/376    
Healthy/Any-
MCD 
 
13/18 62.53(.31) 13.03(.57) 30/0    
Table 3.1 
 
Demographics and Partner Status for Diagnostic Categories across the Waves 
 
Note. MCI = Mild Cognitive Impairment; Any-MCD = Any Mild Cognitive 
Disorder; Partner status Yes = married, partnered or defacto and No = separated, 
divorced, widowed or never married.  
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Figure 4.3  
 
Percentage of sample endorsing depressive items on the GADS for wave 1 to 2 the Any-MCD 
model 
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Figure 3.1. Percentage of Sample Endorsing Depressive Items on the GADS for Wave 1 to 2  
in the MCI Model; Healthy/healthy n = 2076, Healthy/MCI n = 17 
Figure 3.2. Percentage of Sample Endorsing Depressive Items on the GADS for Wave 1 to 2 in  
the Any-MCD Model; Healthy/healthy n = 2076, Healthy/Any-MCD n = 68 
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Figure 3.3. Percentage of Sample Endorsing Depressive Items on the GADS for Wave 2 to 3  
in the MCI Model; Healthy/healthy n = 1797, Healthy/MCI n = 21 
 
 
 
 
0
10
20
30
40
50
60
70
80
90
En
d
o
rs
e
d
 it
e
m
s 
(%
) 
Healthy/healthy
Healthy/MCI
 
Figure 3.4. Percentage of Sample Endorsing Depressive Items on the GADS for Wave 2 to 3  
in the Any-MCD Model; Healthy/healthy n = 1797, Healthy/Any-MCD n = 30 
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Figure 3.5. Percentage of Sample Endorsing Depressive Items on the BPHQ for Wave 1 to 2  
in the MCI Model; Healthy/healthy n = 2480, Healthy/MCI n = 34 
Figure 3.6. Percentage of Sample Endorsing Depressive Items on the BPHQ for Wave 1 to 2 
 in the Any-MCD Model; Healthy/healthy n = 2079, Healthy/Any-MCD n = 68 
 
 
0
10
20
30
40
50
60
70
80
90
100
En
d
o
rs
e
d
 it
e
m
s 
(%
) 
Healthy/Healthy
Healthy/MCI
 
0
10
20
30
40
50
60
70
80
90
En
d
o
rs
e
d
 it
e
m
s 
(%
) 
Healthy/Healthy
Healthy/Any-MCD
  
 
71 
 
Overall depression scores were calculated from depressive items on the GADS & 
BPHQ recorded at baseline. See Table 3.2 for the overall scores for participants belonging to 
a diagnostic category (e.g. healthy/healthy and healthy/cognitive disorder) within each 
analysis across the three waves (e.g. MCI model, Wave 1 to 2). A series of independent t-
tests were performed, as part of descriptive statistics, to analyse the differences in overall 
depressive scores from BPHQ and GADS items between groups (e.g. healthy/healthy and 
healthy/cognitive disorder) within each analysis across waves 1 to 2 and 2 to 3 (see Table 
4.2). The overall BPHQ depression score was not analysed between groups at wave 2 to 3 
due to no participants in the healthy/MCI or healthy/Any-MCD groups endorsing “yes” on 
BPHQ items at baseline. There were significant differences between overall depressive 
GADS scores for the diagnostic groups in the MCI and Any-MCD model from wave 1 to 2,  
and from wave 2 to 3   (p < .05). There were significant differences between overall BPHQ 
depression scores for the diagnostic groups in the MCI and Any-MCD models from wave 1 
to 2 (p < .001).   
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 Table 3.2 
 
Baseline Overall Depression Scores for GADS and BPHQ and T-tests Results Comparing  
Scores between Diagnostic Groups within the Models across Waves 1, 2 and 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Overall depression 
score on GADS
a 
   Overall 
Depression Score 
on BPHQ
b 
   
 M (SD) t df p M (SD) t df p 
Wave 1 to 2         
         
MCI model
g         
Healthy/healthy 1.27 (1.53) -2.59
* 
2091 .010 10.59 (2.20) -4.52
*
 2091 <.001 
Healthy/MCI
c 
2.24 (1.72)    13 (.00)    
         
Any-MCD
h
 
model 
        
Healthy/healthy 1.27 (1.53) -5.65
*
 2142 <.001 10.59 (2.20) -9.25
*
 2142 <001 
Healthy/Any-
MCD
d 
2.34 (1.71)    13.06 (0.86)    
         
Wave 2 to 3         
         
MCI model
i         
Healthy/healthy 1.37 (1.58) 2.43
*
 1816 .014 - - - - 
Healthy/MCI
e 
0.52 (0.75)        
         
Any-MCD
j
 
model 
        
Healthy/healthy 1.37 (1.58) 3.12
* 
1825 .002 - - - - 
Healthy/Any-
MCD
f 
0.47 (0.68)        
 
Note. p = two tailed  
a
Overall GADS scores range 0-9 
b
Overall BPHQ scores range 9-36  
c-f
Results for t, df and p values are the same as the healthy/healthy diagnostic category within each  model comparing 
overall GADS depression scores 
g
Sample size across both GADS and BPHQ scores was the same. Healthy/healthy = 2076 and healthy/MCI = 17 
h
Sample size across both GADS and BPHQ scores was the same. Healthy/healthy = 2076 and healthy/Any-MCD = 68 
i
Sample size for the GADS; Healthy/healthy = 1797 and healthy/MCI = 21 
j
Sample size for the GADS; Healthy/healthy = 1797 and healthy/Any-MCD = 30 
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Goldberg Items and Progression to MCI from Wave 1 to 2 
Table 3.3 presents the results for items of the GADS entered separately into the model 
as a predictor of progression to MCI at wave 2. Items 13 and 15 were excluded from the 
analysis due to participants in the healthy/MCI category not endorsing “yes” for these items 
(see Figure 4.1).  Item 10 “lacking energy” and item 12 “lost confidence” were significant (p 
< .05). Items 11 “lost interest,” and 14 “difficulties concentrating” were significant (p < .01). 
Items 16 “waking early,” 17 “felt slowed up” and 18 “felt worse in the morning” were not 
significant (p > .05).   
 
Table 3.3 
 
GADS Items as Predictors of Progression to MCI from Wave 1 to 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
GADS Items   Model 1   
 B SE OR 95% CI p 
10. Lacking energy 1.20
*
 0.49 3.33 [1.28, 8.69] .014 
11. Lost interest 1.58
** 
0.58 4.84 [0.56, 1.07] .006 
12. Lost confidence 1.43
*
 0.64 4.19 [1.19, 14.82] .026 
13. Felt hopeless - - - - - 
14. Difficulties 
concentrating 
1.70
**
 0.50 5.48 [2.07, 14.54] .001 
15. Lost weight - - - - - 
16. Waking early -0.44 0.51 0.64 [0.24, 1.74] .386 
17. Felt slowed up
 
0.68
 
0.30 0.01 [0.73, 5.39] .180 
18. Felt worse in the 
morning 
0.86 0.58 2.37 [0.77, 7.31] .135 
 
Note.
 *
p < .05, 
**
p < .01. 
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Lacking energy  
Item 10, which is representative of “have you been lacking energy” (OR = 3.33; 95% 
CI 1.28-8.69; p = .014) was a significant predictor of progression to MCI. This finding 
suggests that when participants answered “yes” for lacking energy, the odds of progressing to 
MCI increase by a factor of 3.33. In the second model, Item 10 was non-significant when 
controlling for gender and age (p > .05).   Gender and education were also non-significant (p 
> .05).  
Lost interest 
Item 11, which is representative of “have you lost interest in things” (OR = 4.84; 95% 
CI 0.56-1.07; p = .006), was a significant predictor of progression to MCI. This result 
indicates that when participants endorsed “yes” for losing interest the odds of progressing to 
MCI at wave 2 increase by a factor of 4.84. When adjusting for education and gender in the 
second model, item 11 was non-significant (p > .05).  Gender and education were also non-
significant (p > .05).  
Lost Confidence 
Item 12, which is representative of “have you lost confidence in yourself” (OR = 
4.19; 95% CI 1.19-14.82; p = .026), was a significant predictor of progression to MCI. This 
result indicates that when a participant endorsed “yes” for losing energy the odds of 
progressing to MCI at wave 2 increased by a factor of 4.19. When adjusting for gender and 
education in Model 2, item 12 did not remain significant (p > .05). Gender and education 
were also non-significant (p > .05).  
Difficulties concentrating 
Item 14, which is representative of “have you had difficulty concentrating” (OR = 
5.48; 95% CI 2.07-14.54; p = .001), was a significant predictor of progression to MCI. This 
finding suggests that when participants answered “yes” for having difficulties concentrating, 
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the odds of progressing to MCI increase by a factor of 5.48. In the second model, item 14 was 
non-significant (p > .05) when controlling for gender and education, which were also non-
significant (p > .05).   
Goldberg Items and Progression to Any-MCD from Wave 1 to 2 
Table 3.4 presents the results for items of the GADS entered separately into the model 
as predictors of progression to Any-MCD from wave 1 to 2. Item 15 was excluded from the 
analyses due to participants in the healthy/Any-MCD group not endorsing “yes” to this item 
at baseline. Items 13 “felt hopeless” and 16 “waking early” were non-significant (p > .05). 
Item 10 “lacking energy,” item 11 “lost interest,” item 14 “difficulties concentrating” and 
item 17 “felt slowed up” were significant predictors of progression to MCI (p < .001). Item 
12 “lost confidence” and item 18 “felt worse in the morning” were also significant predictors 
of progression to MCI (p < .01).  
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Table 3.4 
 
GADS Items as Predictors of Progression to Any-MCD from Wave 1 to 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lacking energy 
Item 10, which is representative of “have you been lacking in energy” (OR = 4.48; 
95% CI 2.75-7.30; p = .000), was a significant predictor of progression to Any-MCD. This 
finding indicates that when participants endorsed lacking energy, the odds of progressing to 
Any-MCD at wave 2 increase by a factor of 1.50. In the second model, item 10 (OR = 4.68; 
95% CI 2.86-7.65; p < .001) remained a significant predictor of for progression to Any-
MCD, while controlling for education and gender. Within this model, gender was significant 
(OR = 1.91; CI 1.13-3.19; p = .014), suggesting the odds of males progressing to Any-MCD 
increase by a factor of 1.91. Education was non-significant (p > .05) and there were no 
significant interaction effects for gender and item 10 (p > .05).  
GADS Items   Model 1   
 B SE OR 95% CI p 
10. Lacking energy 1.50
**
 0.25 4.48 [2.75, 7.30] <.001 
11. Lost interest 1.41
**
 0.32 4.08 [2.21, 7.55] <.001 
12. Lost confidence 1.22
*
 0.36 3.37 [1.67, 6.79] .001 
13. Felt hopeless 0.28 0.60 1.32 [0.41, 4.31] .643 
14. Difficulties 
concentrating 
1.18
**
 0.26 3.26 [1.90, 5.60] <.001 
15. Lost weight -
 
- - - -
 
16. Waking early -0.13 0.25 0.88 [0.54, 1.43] .596 
17. Felt slowed up
 
1.05
**
 0.25 2.87 [1.76, 4.68] <.001 
18. Felt worse in 
the morning 
0.86
*
 0.29 2.37 [1.33, 4.21] .003 
 
Note.
 **
p < .001. 
*
p < .01. 
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In model 3, item 10 was significant (OR = 4.58; 95% CI 2.73-7.65; p = <.001) when 
adjusting for all other covariates including: employment, physical activity, anxiety and 
depression medication, partner status, smoking, high blood pressure, diabetes, stroke and 
heart disease. The finding suggests that when participants reported “yes” for lacking energy 
the odds of progressing to Any-MCD increase by a factor of 4.58, when adjusting for other 
variables in the model. In the model, partner status (OR = 3.01; 95% CI 1.28-7.07; p = .012) 
was a significant predictor of Any-MCD at wave 2. This finding suggests that when 
participants endorsed having a partner (married/defacto) the odds of progressing to Any-
MCD increase by a factor of 3.01. Item 10 (OR = 4.70; 95% CI 2.88-7.68; p = <.001) and 
partner status (OR = 3.13; 95% CI 1.34-7.33; p = .008) remained significant predictors of 
Any-MCD when all non-significant covariates were removed from the model including: 
employment, physical activity, anxiety and depression medication, smoking, high blood 
pressure, diabetes, stroke and heart disease    
Lost interest 
Item 11, which is representative of “have you lost interest in things” (OR = 4.08; 95% 
CI 2.21-7.55; p < .001), was a significant predictor of progression to Any-MCD. This finding 
indicates that when participants endorsed losing interest, the odds of progressing to Any-
MCD at wave 2 increase by a factor of 4.08. In the second model, item 11 (OR = 3.91; 95% 
CI 2.11-7.26; p < .001) remained significant when adjusting for gender and age . In the 
model, gender and education (p > .05) were non-significant.  
In model 3, item 11 was significant (OR = 4.71; 95% CI 2.45-9.06; p <.001) when 
adjusting for all other covariates including: employment, physical activity, anxiety and 
depression medication, partner status, smoking, high blood pressure, diabetes, stroke and 
heart disease. The finding suggests that when participants reported “yes” for losing interest in 
things the odds of progressing to Any-MCD increase by a factor of 4.71, when adjusting for 
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other variables in the model. In the model, partner status (OR = 3.17; 95% CI 1.34-7.51; p = 
.009) was a significant predictor of Any-MCD at wave 2. This finding suggests that when 
participants endorsed having a partner (married/defacto) the odds of progressing to Any-
MCD increase by a factor of 3.17. Item 11 (OR = 4.72; 95% CI 2.53-8.82; p < .001) and 
partner status (OR = 3.28; 95% CI 1.39-7.70; p = .007) remained significant predictors of 
Any-MCD when all non-significant covariates were removed from the model including: 
employment, physical activity, anxiety and depression medication, smoking, high blood 
pressure, diabetes, stroke and heart disease    
Lost confidence 
Item 12, which is representative of “have you lost confidence in yourself” (OR = 3.37, 
95% CI 1.67-6.79; p = .001), was a significant predictor of progression to Any-MCD. This 
finding indicates that when participants endorsed losing confidence the odds of progressing to 
Any-MCD at wave 2 increase by a factor of 3.37. In the second model, item 12 remained 
significant (OR = 3.45; 95% CI 1.71-6.99; p = .001) when adjusting for gender and 
education. Within the model, gender was significant (OR = 1.75; 95% CI 1.05-2.03; p = .031) 
suggesting that for males the odds of progressing to Any-MCD increase by a factor of 1.75. 
Education was non-significant (p > .05) and there were no significant interaction effects for 
gender and item 12 (p > .05).  
In model 3, item 12 was significant (OR = 3.33; 95% CI 1.59-6.98; p = .001) when 
adjusting for all other covariates including: employment, physical activity, anxiety and 
depression medication, partner status, smoking, high blood pressure, diabetes, stroke and 
heart disease. The finding suggests that when participants reported “yes” for losing 
confidence the odds of progressing to Any-MCD increase by a factor of 3.33, when adjusting 
for other variables in the model. In the model, partner status (OR = 2.91; 95% CI 1.24-6.84; p 
= .014) was a significant predictor of Any-MCD at wave 2. This finding suggests that when 
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participants endorsed having a partner (married/defacto) the odds of progressing to Any-
MCD increase by a factor of 2.91.  
Difficulties concentrating 
Item 14, which is representative of “have you had difficulty concentrating” (OR = 
3.26; 95% CI 1.90-5.60; p < .001), was a significant predictor of progression to Any-MCD. 
This finding indicates that when participants endorsed difficulties with concentration the odds 
of progressing to Any-MCD at wave 2 increase by a factor of 3.26. In the second model, item 
14 remained significant (OR = 3.23; 95% CI 1.03-2.86; p < .001) when adjusting for gender 
and education. Within the model, gender was significant (OR = 1.72; 95% CI 1.03-2.86; p = 
.038) suggesting the odds of males progressing to Any-MCD increase by a factor of 1.72. 
Education was non-significant (p > .05) and there were no significant interaction effects for 
gender and item 14 (p > .05).    
In model 3, item 14 was significant (OR = 3.20; 95% CI 1.82-5.63; p < .001) when 
adjusting for all other covariates including: employment, physical activity, anxiety and 
depression medication, partner status, smoking, high blood pressure, diabetes, stroke and 
heart disease. The finding suggests that when participants reported “yes” for difficulties 
concentrating the odds of progressing to Any-MCD increase by a factor of 3.20, when 
adjusting for other variables in the model. In the model, partner status (OR = 2.82; 95% CI 
1.20-6.61; p = .017) was a significant predictor of Any-MCD at wave 2. This finding 
suggests that when participants endorsed having a partner (married/defacto) the odds of 
progressing to Any-MCD increase by a factor of 1.20.  
Felt slowed up 
Item 17, which is representative of “have you felt slowed up” (OR = 2.87; 95% CI 
1.76-4.68; p < .001), was a significant predictor of progression to Any-MCD. This finding 
indicates that when participants endorsed feeling slower the odds of progressing to Any-
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MCD at wave 2 increase by a factor of 2.87. In the second model, item 17 (OR = 2.85; 95% 
CI 1.74-4.66; p < .001) remained a significant predictor of progression to Any-MCD, while 
controlling for gender and education. Within the model, gender (OR = .1.71; 95% CI 1.03-
2.84; p = .039) was significant, suggesting the odds of males progressing to Any-MCD 
increase by a factor of 1.71. Education was non-significant (p > .05) and there were no 
significant interaction effects for gender and item 17 (p > .05).  
In model 3, item 17 was significant (OR = 2.78; 95% CI 1.67-4.62; p = .000) when 
adjusting for all other covariates including: employment, physical activity, anxiety and 
depression medication, partner status, smoking, high blood pressure, diabetes, stroke and 
heart disease. The finding suggests that when participants reported “yes” for feeling slower 
the odds of progressing to Any-MCD increase by a factor of 2.78, when adjusting for other 
variables in the model. In the model, partner status (OR = 2.86; 95% CI 1.22-6.73; p = .016) 
was a significant predictor of Any-MCD at wave 2. This finding suggests that when 
participants endorsed having a partner (married/defacto) the odds of progressing to Any-
MCD increase by a factor of 2.86.  
Felt worse in the morning  
Item 18, which is representative of “have you tended to feel worse in the mornings” 
(OR = 2.37; 95% CI 1.33-4.21; p = .003), was a significant predictor of progression to Any-
MCD. The results indicate that when participants endorsed feeling worse in the morning the 
odds of progressing to Any-MCD at wave 2 increase by a factor of 2.37. In the second model, 
item 18 (OR = 2.43; 95% CI 1.36-4.35; p = .003) remained a significant predictor of 
progression to Any-MCD, while adjusting for gender and education. In the model, gender 
(OR = 1.77; 95% CI 1.06-2.94; p = .029) was significant, suggesting the odds of males 
progressing to Any-MCD increase by 1.77. Education was non-significant (p > .05) and there 
were no significant interaction effects for gender and item 18 (p > .05).  
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In model 3, item 18 was significant (OR = 2.47; 95% CI 1.36-4.48; p = .003) when 
adjusting for all other covariates including: employment, physical activity, anxiety and 
depression medication, partner status, smoking, high blood pressure, diabetes, stroke and 
heart disease. The finding suggests that when participants reported “yes” for feeling worse in 
the morning the odds of progressing to Any-MCD increase by a factor of 2.47, when 
adjusting for other variables in the model. In the model, partner status (OR = 2.86; 95% CI 
1.22-6.71; p = .016) was a significant predictor of Any-MCD at wave 2. This finding 
suggests that when participants endorsed having a partner (married/defacto) the odds of 
progressing to Any-MCD increase by a factor of 2.86.  
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Goldberg Items and Progression to MCI from Wave 2 to 3 
Table 3.5 presents the results for items of the GADS entered separately into the model 
as predictors of progression to MCI at wave 3. All items were non-significant (p > .05). Items 
11-13 and 15 were excluded from the analyses due to participants in the healthy/MCI group 
not endorsing “yes” on the specific items at baseline.  
  
Table 3.5  
 
GADS Items as Predictors of Progression to MCI from Wave 2 to 3  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
GAD Items   Model 1   
 B SE OR 95% CI p 
10. Lacking energy -1.85 1.02 0.16 [0.02, 1.22] .07 
11. Lost interest - - - - - 
12. Lost confidence - - - - - 
13. Felt hopeless - - - - - 
14. Difficulties 
concentrating 
1.05
 
1.03 0.35 [0.05, 2.62] .31 
15. Lost weight - - - - - 
16. Waking early 0.21 0.44 1.24 [0.53, 2.93] .63 
17. Felt slowed up
 
-1.83 1.03 0.16 [0.02, 1.20] .07 
18. Felt worse in 
the morning 
-1.06 1.03 0.35 [0.05, 2.59] .30 
  Note. **p < .01. 
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Goldberg Items and Progression to Any-MCD from wave 2 to 3 
Table 3.6 presents the results for each item of the GADS entered separately into the 
model as a predictor of progression to Any-MCD at wave 3. Items 11-13 and 15 were 
excluded from the analyses due to participants in the healthy/Any-MCD not endorsing “yes” 
on the specific items at baseline. Items 14, 16 and 18 were non-significant (p > .05). Item 10 
“lacking energy” and item 17 “felt slowed up” were significant (see Table 3.6). However the 
findings suggest when participants endorsed “yes” to lacking energy, the odds of progressing 
to Any-MCD decrease by a factor of 0.02 (OR = 0.02; CI 95% 0.02-0.03; p = < .001). While 
other results suggest that when participants endorsed “yes” to felt slowed up the odds of 
progressing to Any-MCD decrease by a factor of 0.23 (OR = 4.35; CI 95% 0.05-0.97; p = 
.045). 
Table 3.6  
 
GADS Items as Predictors of Progression to Any-MCD from Wave 2 to 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GAD Items   Model 1   
 B SE OR 95% CI p 
10. Lacking energy 
**
 -2.19
 
0.19 0.02 [0.02, 0.03] <.001 
11. Lost interest - - - - - 
12. Lost confidence -
 
- - - - 
13. Felt hopeless - - - - - 
14. Difficulties        
concentrating 
-1.42
 
1.02 0.24 [0.03, 1.78] .163 
15. Lost weight - - - - - 
16. Waking early -0.73 0.40 1.48 [0.22, 1.06] .069 
17. Felt slowed up 
* 
-1.47 0.73 0.23 [0.05, 0.97] .045 
18. Felt worse in the 
morning 
-1.43 1.02 0.24 [0.32, 1.76] .160 
 
Note. 
*
p < .05. 
**
p < .001.  
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Overall Depression Score on the GADS as a Predictor of Progression to MCI and Any-
MCD 
Overall depression score from the GADS was entered as a predictor of progression to 
MCI and MCD across the waves in separate models. Overall depression score (OR 1.33; 95% 
CI 1.06-0.12; p = .012) was a significant predictor of progression to MCI at wave 2. This 
finding suggests that, for every one point increase on overall depressive score, the odds of 
progressing to MCI increase by a factor of 1.33. Overall depression score (OR = 1.37; 95% 
CI 1.22-1.53; p = < .001) was a significant predictor of progression to Any-MCD at wave 2. 
This result indicates that, for every one point increase on overall depressive score, the odds of 
progressing to Any-MCD increase by a factor of 1.19. Overall depressive score was 
significant  for Any-MCD (OR = .48; 95% CI 0.29-0.77; p = .003) at wave 3, however the 
results suggest that for every one point decrease on overall depressive score, the odds of 
progressing to Any-MCD increase by a factor of .48. Overall depression score was not 
significant for predicting MCI at wave 3 (p > .05).  
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BPHQ Items as Predictors of Progression to MCI across Waves 1 to 2 and Waves 2 to 3  
As mentioned previously, the participants in the healthy/MCI group at wave 2 to 3 did 
not endorse “yes” for 9 of the BPHQ items at baseline therefore an analyses for this specific 
time point was unable to be completed. Table 3.7 presents the results for items of the BPHQ 
entered separately into the model as predictors of progression to MCI at wave 2. Items A. 
“little interest or pleasure,” B. “feeling down depressed or hopeless,” D. “feeling tired or 
having little energy,” F. “feeling bad about yourself” and G. “Trouble concentrating” were all 
significant predictors of progression to MCI at wave 2 (p < .001). All other items were non-
significant (p > .05).   
Table 3.7 
 
BPHQ Items as Predictors of Progression to MCI from Wave 1 to 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BPHQ Items   Model 1   
 B SE OR 95% CI p 
a. Little interest/pleasure 
 
1.49
* 
0.51 4.44 [1.63, 12.13] .004 
b. Felt down, depressed or 
hopeless 
 
1.98
** 
0.35 7.23 [2.76, 18.86] <.001 
c. Trouble falling/staying 
asleep or sleeping too 
much 
 
0.31 0.50 1.37 [0.52, 3.61] .528 
d. Felt tired/little energy 
 
2.39
* 
0.75 10.95 [2.50, 48.00] .002 
e. Poor appetite or 
overeating 
 
0.79 0.64 2.20 [0.63, 7.74] .218 
f. Feeling bad about self 1.77* 0.51 5.85 [2.14, 16.01] .001 
g. Trouble concentrating 
 
2.05** 0.49 7.78 [2.97, 20.36] <.001 
h. Moving/speaking 
slowly or being 
fidgety/restless 
 
1.42 0.76 4.13 [0.92, 18.41] .063 
i. Thoughts you would be 
better off dead or hurting 
self 
1.52 1.05 4.57 [0.59, 35.67] .147
 
 
Note.
 *
p < .01, 
**
p < .001. 
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Little interest or pleasure 
Item A, which is representative of “little interest or pleasure in doing things” (OR = 
4.44, 95% CI 1.63-12.13, p = .004), was a significant predictor of progression to MCI at 
wave 2. This finding indicates that when participants endorsed “yes” to experiencing little 
interest or pleasure in doing things the odds of progressing to MCI at wave 2 increase by a 
factor of 4.44.  
In the second model, item A (OR = 4.42, 95% CI 1.62-12.08, p < .001) remained a 
significant predictor for progression to MCI, while controlling for gender and education. This 
finding suggests that when participants answered “yes” on this item the odds of progressing 
to MCI at wave 2 increase by a factor of 4.42, while controlling for other factors in the 
model. Within the model gender and education were non-significant (p > .05).  
In model 3, item A. remained significant (OR = 4.36, 95% CI 1.54-12.36, p = .006) 
when adjusting for all other covariates (employment, physical activity, anxiety and 
depression medication, partner status, smoking, high blood pressure, diabetes, stroke and 
heart disease). This finding suggests that when participants reported “yes” for little interest or 
pleasure in doing things, the odds of progressing to MCI increase by a factor of 4.36, while 
adjusting for other variables in the model.  All covariates were non-significant (p > .05).   
Feeling down, depressed or hopeless 
Item B, which is representative of “feeling down, depressed or hopeless” (OR = 7.23, 
95% CI 2.76-18.86, p < .001), was a significant predictor of progression to MCI at wave 2. 
This finding indicates that when participants endorsed “yes” to feeling down, depressed or 
hopeless, the odds of progressing to MCI at wave 2 increase by a factor of 7.23.  
In the second model, item A (OR = 7.23, 95% CI 2.77-18.92, p < .001) remained a 
significant predictor for progression to MCI, while controlling for gender and education. This 
finding suggests that when participants answered “yes” on this item the odds of progressing 
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to MCI at wave 2 increase by a factor of 7.23, while controlling for other factors in the 
model. Within the model gender and education were non-significant (p > .05).  
In model 3, item A. remained significant (OR = 7.32, 95% CI 2.71-19.84, p < .001) 
when adjusting for all other covariates (employment, physical activity, anxiety and 
depression medication, partner status, smoking, high blood pressure, diabetes, stroke and 
heart disease). This finding suggests that when participants reported “yes” for feeling down, 
depressed or hopeless, the odds of progressing to MCI increase by a factor of 7.32, while 
adjusting for other variables in the model. All covariates were non-significant (p > .05).   
Feeling tired or having little energy 
Item D, which is representative of “feeling tired or having little energy” (OR = 10.95, 
95% CI 2.50-48.00, p = .002), was a significant predictor of progression to MCI at wave 2. 
This finding indicates that when participants endorsed “yes” to feeling tired or having little 
energy the odds of progressing to MCI at wave 2 increase by a factor of 10.95.  
In the second model, item D (OR = 11.08, 95% CI 2.52-48.63, p = .001) remained a 
significant predictor for progression to MCI, while controlling for gender and education. This 
finding suggests that when participants answered “yes” on this item the odds of progressing 
to MCI at wave 2 increase by a factor of 11.08, while controlling for other factors in the 
model. Within the model gender and education were non-significant (p > .05).  
In model 3, item D. remained significant (OR = 10.78, 95% CI 2.43-47.86, p = .002) 
when adjusting for all other covariates (employment, physical activity, anxiety and 
depression medication, partner status, smoking, high blood pressure, diabetes, stroke and 
heart disease). This finding suggests that when participants reported “yes” for feeling tired or 
having little energy, the odds of progressing to MCI increase by a factor of 10.78, while 
adjusting for other variables in the model. All covariates were non-significant (p > .05).  
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Feeling bad about yourself 
Item F, which is representative of “feeling bad about yourself –or that you are a 
failure or have let yourself or family down” (OR = 5.85, 95% CI 2.14-16.01, p = .001), was a 
significant predictor of progression to MCI at wave 2. This finding indicates that when 
participants endorsed “yes” to feeling bad about yourself –or that you are a failure or have let 
yourself or family down the odds of progressing to MCI at wave 2 increase by a factor of 
5.85.  
In the second model, item F (OR = 5.83, 95% CI 2.13-15.97, p = .001) remained a 
significant predictor for progression to MCI, while controlling for gender and education. This 
finding suggests that when participants answered “yes” on this item the odds of progressing 
to MCI at wave 2 increase by a factor of 5.83, while controlling for other factors in the 
model. Within the model gender and education were non-significant (p > .05).  
In model 3, item F., remained significant (OR = 5.69, 95% CI 1.97-16.42, p = .001) 
when adjusting for all other covariates (employment, physical activity, anxiety and 
depression medication, partner status, smoking, high blood pressure, diabetes, stroke and 
heart disease). This finding suggests that when participants reported “yes” for “feeling bad 
about yourself or that you are a failure or have let yourself or family down,” the odds of 
progressing to MCI increase by a factor of 5.69, while adjusting for other variables in the 
model. All covariates were non-significant (p > .05).   
Trouble concentrating 
Item G, which is representative of “Trouble concentrating on things, such as reading 
the newspaper or watching television” (OR = 7.78, 95% CI 2.97-20.36, p < .001), was a 
significant predictor of progression to MCI at wave 2. This finding indicates that when 
participants endorsed “yes” to trouble concentrating on things, such as reading the newspaper 
or watching television the odds of progressing to MCI at wave 2 increase by a factor of 7.78.  
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In the second model, item G (OR = 7.73, 95% CI 2.94-20.33, p < .001) remained a 
significant predictor for progression to MCI, while controlling for gender and education. This 
finding suggests that when participants answered “yes” on this item the odds of progressing 
to MCI at wave 2 increase by a factor of 7.73, while controlling for other factors in the 
model. Within the model gender and education were non-significant (p > .05).  
In model 3, item G. remained significant (OR = 7.21, 95% CI 2.64-19.66, p = < .001) 
when adjusting for all other covariates (employment, physical activity, anxiety and 
depression medication, partner status, smoking, high blood pressure, diabetes, stroke and 
heart disease). This finding suggests that when participants reported “yes” for trouble 
concentrating on things, such as reading the newspaper or watching television, the odds of 
progressing to MCI increase by a factor of 7.21, while adjusting for other variables in the 
model. All covariates were non-significant (p > .05).   
BPHQ Items as Predictors of Progression to Any-MCD across Waves 1 to 2 and Waves 2 to 
3  
Similarly, participants in the healthy/Any-MCD group from wave 2 to 3 did not 
endorse “yes” for the 9 BPHQ items therefore analyses was unable to be performed for the 
specific time point. Table 3.8 presents the results for items of the BPHQ entered separately 
into the model as predictors of progression to Any-MCD at wave 2. Items A. “little interest or 
pleasure,” B. “feeling down depressed or hopeless,” D. “feeling tired or having little energy,” 
E. “poor appetite or overeating,” F. “feeling bad about yourself” and G. “Trouble 
concentrating” were all significant predictors of progression to Any-MCD at wave 2              
(p < .01). All other items were non-significant (p > .05).   
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Table 3.8 
 
BPHQ Items as Predictors of Progression to Any-MCD from Wave 1 to 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Little interest or pleasure 
Item A, which is representative of “little interest or pleasure in doing things” (OR = 
26.47, 95% CI 14.87-47.14, p < .001), was a significant predictor of progression to Any-
MCD at wave 2. This finding indicates that when participants endorsed “yes” to experiencing 
little interest or pleasure in doing things, the odds of progressing to Any-MCD at wave 2 
increase by a factor of 26.47.  
BPHQ Items 
 
  Model 1   
 B SE OR 95% CI p 
a. Little 
interest/pleasure
 
 
3.28
** 
0.29 26.47 [14.87, 47.14] <.001 
b. Felt down, 
depressed or hopeless 
 
2.28
** 
0.26 9.74 [5.90, 16.08] <.001 
c. Trouble 
falling/staying asleep 
or sleeping too much 
 
0.13 0.26 1.14 [0.69, 1.87] .619 
d. Felt tired/little 
energy
 
 
2.39
** 
0.38 10.95 [5.21, 23.01] <.001 
e. Poor appetite or 
overeating 
 
0.98* 0.31 2.67 [1.45, 4.89] .002 
f. Feeling bad about 
self 
1.27
** 
0.29 3.58 [2.02, 6.32] <.001 
g. Trouble 
concentrating 
 
1.36
** 
0.27 3.91 [2.29, 6.66] <.001 
h. Moving/speaking 
slowly or being 
fidgety/restless 
 
0.36 0.60 1.43 [0.44, 4.66] .555 
i. Thoughts you would 
be better off dead or 
hurting self 
0.80 0.74 2.22 [0.52, 9.50] .284 
 
Note.
 *
p < .01, 
**
p < .001. 
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In the second model, item A (OR = 26.66, 95% CI 14.94-47.58, p < .001) remained a 
significant predictor for progression to Any-MCD, while controlling for gender and 
education. This finding suggests that when participants answered “yes” on this item the odds 
of progressing to Any-MCD at wave 2 increase by a factor of 26.66, while controlling for 
other factors in the model. In the model gender was significant (OR =1.77; 95% CI 1.04-3.04; 
p = .036) which suggests the odds of males progressing to Any-MCD increase by 1.77. There 
were no significant interaction effects for gender and item A (p > .05). Within the model 
education was non-significant (p > .05).  
In model 3, item A. remained significant (OR = 30.56, 95% CI 16.94-55.11, p < .001) 
when adjusting for all other covariates (employment, physical activity, anxiety and 
depression medication, partner status, smoking, high blood pressure, diabetes, stroke and 
heart disease). This finding suggests that when participants reported “yes” for little interest or 
pleasure in doing things, the odds of progressing to Any-MCD increase by a factor of 30.56, 
while adjusting for other variables in the model.  All covariates were non-significant (p > .05) 
except for partner status which was significant (OR = 3.45; 95% CI 1.41-8.44, p = .007).  
This finding suggests when participants endorsed having a partner (married/defacto) the odds 
of progressing to Any-MCD increase by 3.45. There were no significant interaction effects 
for item A and partner status (p > .05).  
Feeling down, depressed or hopeless 
Item B, which is representative of “feeling down, depressed or hopeless” (OR = 9.74, 
95% CI 5.90-16.08, p < .001), was a significant predictor of progression to Any-MCD at 
wave 2. This finding indicates that when participants endorsed “yes” to feeling down, 
depressed or hopeless the odds of progressing to Any-MCD at wave 2 increase by a factor of 
9.74.  
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In the second model, item B (OR = 9.88, 95% CI 5.97-16.35, p < .001) remained a 
significant predictor for progression to Any-MCD, while controlling for gender and 
education. This finding suggests that when participants answered “yes” on this item the odds 
of progressing to Any-MCD at wave 2 increase by a factor of 9.88, while controlling for 
other factors in the model. Within the model gender and education were non-significant (p > 
.05).  
In model 3, item B. remained significant (OR = 10.59, 95% CI 6.32-17.75, p < .001) 
when adjusting for all other covariates (employment, physical activity, anxiety and 
depression medication, partner status, smoking, high blood pressure, diabetes, stroke and 
heart disease). This finding suggests that when participants reported “yes” for feeling down, 
depressed or hopeless, the odds of progressing to Any-MCD increase by a factor of 10.59, 
while adjusting for other variables in the model. All covariates were non-significant (p > .05) 
except for partner status which was significant (OR = 3.20; 95% CI 1.34-7.61, p = .009).  
This finding suggests when participants endorsed having a partner (married/defacto) the odds 
of progressing to Any-MCD increase by 3.20. There were no significant interaction effects 
for item B and partner status (p > .05).  
Feeling tired or having little energy 
Item D, which is representative of “feeling tired or having little energy” (OR = 10.95, 
95% CI 5.21-23.01, p < .001), was a significant predictor of progression to Any-MCD at 
wave 2. This finding indicates that when participants endorsed “yes” to feeling tired or 
having little energy the odds of progressing to MCI at wave 2 increase by a factor of 10.95.  
In the second model, item D (OR = 11.37, 95% CI 5.41-23.95, p < .001) remained a 
significant predictor for progression to Any-MCD, while controlling for gender and 
education. This finding suggests that when participants answered “yes” on this item the odds 
of progressing to Any-MCD at wave 2 increase by a factor of 11.37, while controlling for 
  
 
93 
 
other factors in the model. Within the model gender and education were non-significant (p > 
.05).  
In model 3, item D. remained significant (OR = 11.15, 95% CI 5.27-23.60, p < .001) 
when adjusting for all other covariates (employment, physical activity, anxiety and 
depression medication, partner status, smoking, high blood pressure, diabetes, stroke and 
heart disease). This finding suggests that when participants reported “yes” for feeling tired or 
having little energy, the odds of progressing to MCI increase by a factor of 11.15, while 
adjusting for other variables in the model. All covariates were non-significant (p > .05) 
except for partner status which was significant (OR = 3.02; 95% CI 1.28-7.13, p = .012).  
This finding suggests when participants endorsed having a partner (married/defacto) the odds 
of progressing to Any-MCD increase by 3.02. There were no significant interaction effects 
for item D and partner status (p > .05.)  
Poor appetite or overeating  
Item E, which is representative of “poor appetite or overeating” (OR = 2.67, 95% CI 
1.45-4.89, p = .002), was a significant predictor of progression to Any-MCD at wave 2. This 
finding indicates that when participants endorsed “yes” to poor appetite or overeating the 
odds of progressing to Any-MCD at wave 2 increase by a factor of 2.67.  
In the second model, item E (OR = 2.84, 95% CI 1.54-5.24, p = .001) remained a 
significant predictor for progression to Any-MCD, while controlling for gender and 
education. This finding suggests that when participants answered “yes” on this item the odds 
of progressing to Any-MCD at wave 2 increase by a factor of 2.84, while controlling for 
other factors in the model. In the model gender was significant (OR =1.80; 95% CI 1.08-3.01; 
p = .024) which suggests the odds of males progressing to Any-MCD increase by 1.80. There 
were no significant interaction effects for gender and item E (p > .05). Within the model 
education was non-significant (p > .05).  
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In model 3, item E., remained significant (OR = 2.71, 95% CI 1.44-5.08, p = .002) 
when adjusting for all other covariates (employment, physical activity, anxiety and 
depression medication, partner status, smoking, high blood pressure, diabetes, stroke and 
heart disease). This finding suggests that when participants reported “yes” for poor appetite 
or overeating, the odds of progressing to Any-MCD increase by a factor of 2.71, while 
adjusting for other variables in the model.  All covariates were non-significant (p > .05) 
except for partner status which was significant (OR = 2.86; 95% CI 1.22-6.70, p = .016).  
This finding suggests when participants endorsed having a partner (married/defacto) the odds 
of progressing to Any-MCD increase by 2.86. There were no significant interaction effects 
for item E and partner status (p > .05).  
Feeling bad about yourself 
Item F, which is representative of “feeling bad about yourself –or that you are a 
failure or have let yourself or family down” (OR = 3.58, 95% CI 2.02-6.32, p < .001), was a 
significant predictor of progression to Any-MCD at wave 2. This finding indicates that when 
participants endorsed “yes” to feeling bad about yourself –or that you are a failure or have let 
yourself or family down the odds of progressing to Any-MCD at wave 2 increase by a factor 
of 3.58.  
In the second model, item F (OR = 3.56, 95% CI 1.99-6.23, p < .001) remained a 
significant predictor for progression to Any-MCD, while controlling for gender and 
education. This finding suggests that when participants answered “yes” on this item the odds 
of progressing to Any-MCD at wave 2 increase by a factor of 3.56, while controlling for 
other factors in the model. Within the model gender and education were non-significant (p > 
.05).  
In model 3, item F., remained significant (OR = 3.81, 95% CI 2.11-6.87, p < .001), 
was a significant predictor of progression to Any-MCD at wave 2. This finding indicates that 
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when participants endorsed “yes” to “feeling bad about yourself –or that you are a failure or 
have let yourself or family down” the odds of progressing to Any-MCD at wave 2 increase by 
a factor of 3.81. All covariates were non-significant (p > .05) except for partner status which 
was significant (OR = 2.92; 95% CI 1.24-6.86, p = .014).  This finding suggests when 
participants endorsed having a partner (married/defacto) the odds of progressing to Any-
MCD increase by 2.92. There were no significant interaction effects for item F and partner 
status (p > .05)  
Trouble Concentrating 
Item G, which is representative of “trouble concentrating on thing, such as reading the 
newspaper or watching television” (OR = (OR = 3.91, 95% CI 2.29-6.66, p = < .001), was a 
significant predictor of progression to Any-MCD at wave 2. This finding suggests that when 
participants endorsed “yes” to trouble concentrating on things, such as reading the newspaper 
or watching the television the odds of progressing to Any-MCD at wave 2 increase by a 
factor of 3.91.  
In the second model, item G (OR = 3.86, 95% CI 2.26-6.60, p < .001) remained a 
significant predictor for progression to Any-MCD, while controlling for gender and 
education. This finding suggests that when participants answered “yes” on this item the odds 
of progressing to Any-MCD at wave 2 increase by a factor of 3.86, while controlling for 
other factors in the model. Within the model gender and education were non-significant (p > 
.05).  
In model 3, item G., remained significant (OR = 3.91, 95% CI 2.25-6.81, p <.001) 
when adjusting for all other covariates (employment, physical activity, anxiety and 
depression medication, partner status, smoking, high blood pressure, diabetes, stroke and 
heart disease). This finding suggests that when participants reported “yes” for trouble 
concentrating on things, such as reading the newspaper or watching television, the odds of 
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progressing to Any-MCD increase by a factor of 3.91, while adjusting for other variables in 
the model. All covariates were non-significant (p > .05) except for partner status which was 
significant (OR = 2.73; 95% CI 1.16-6.41, p = .021).  This finding suggests when participants 
endorsed having a partner (married/defacto) the odds of progressing to Any-MCD increase by 
2.73. There were no significant interaction effects for item G and partner status (p > .05). 
Overall BPHQ Depression Score as a Predictor of Progression to MCI and Any-MCD 
Overall depression score from the BPHQ was entered as a predictor of progression to 
MCI and MCD across the waves in separate models. Overall depression score were a 
significant predictor of progression to Any-MCD (OR =1.30, 95% CI 1.21-1.38, p < .001) 
and  MCI (OR = 1.26, 95% CI 1.13-1.41, p < .001) across waves 1 to 2.  
Summary of Depressive Symptoms Predictive of Progression to MCI and Any-MCD 
Overall, the results indicate that specific depressive symptoms are predictive of 
progression to MCI or Any-MCD specifically from waves 1 to 2. Depressive symptoms from 
the GADS that were predictive of progression to a cognitive disorder included: lacking 
energy, lost interest, lost confidence, difficulties concentrating, felt slowed up, felt worse in 
the morning, while depressive symptoms from the BPHQ included: feeling little 
interest/pleasure, feeling down, depressed or hopeless, tired and little energy, poor appetite or 
overeating, feeling bad about self, and trouble concentrating. See Table 3.9 for a summary of 
the depressive symptoms and progression time points to MCI or Any-MCD.  
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 Wave progression Progression to Any-MCD or 
MCI 
GADS items 
 
  
Lacking energy
1
 Waves 1-2 MCI 
Any-MCD 
 
Lost interest
1
 
 
Waves 1-2 MCI 
Any-MCD 
 
Lost confidence 
1
 Waves 1-2 MCI 
Any-MCD 
 
Difficulties concentrating 
1
 Waves 1-2 MCI 
Any-MCD 
 
Felt slowed up 
1
 
 
Waves 1-2 Any-MCD 
 
Felt worse in the morning
1
 Waves 1-2 Any-MCD 
 
   
BPHQ items 
 
  
Little interest or pleasure in doing 
things
1,2 
 
Waves 1-2 
 
MCI 
Any-MCD 
Feeling down, depressed or 
hopeless
1,2 
 
Waves 1-2 
 
MCI 
Any-MCD 
Feeling tired or having little 
energy
1,2
  
 
Waves 1-2 MCI 
Any-MCD 
Poor appetite or overeating
1 
 
Waves 1-2 Any-MCD 
Feeling bad about yourself
1,2 
Waves 1-2 MCI 
Any-MCD 
 
Trouble concentrating
1,2 
Waves 1-2 MCI 
Any-MCD 
   
   
 
 
 
 
  
1 
 In the Any-MCD model the depressive symptoms remained significant when adjusting in Model 2 for gender 
and education and in Model 3 for all other covariates covariates  including employment, physical activity, 
anxiety and depression medication, partner status, smoking, high blood pressure, diabetes, stroke and heart 
disease. 
2
In the MCI model the depressive symptoms remained significant when adjusting in Model 2 for gender and 
education and in Model 3 for all other covariates covariates  including employment, physical activity, anxiety 
and depression medication, partner status, smoking, high blood pressure, diabetes, stroke and heart disease. 
 
 
 
Table 3.9 
 
Summary of Depressive Symptoms from the GADS and BPHQ which were Predictive of 
Progression to Any-MCD and MCI 
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Discussion 
This study found that specific depressive symptoms were significant predictors of 
progression to MCI or Any-MCD across specific time points, with particular symptoms 
reaching significance across two depressive measures and when adjusting for demographics 
and covariates. The significant depressive symptoms included: lacking energy, lost interest, 
lost confidence, difficulties concentrating, felt slowed up, felt worse in the morning, little 
interest or pleasure in doing things, feeling down, depressed or hopeless, feeling tired or 
having little energy, poor appetite or overeating, and feeling bad about yourself. Depressive 
symptoms from the GADS (e.g. lacking energy, lost interest, lost confidence, difficulties 
concentrating, felt slowed up and felt worse in the morning) remained significant when 
analysing progression to Any-MCD from wave 1 to 2 and adjusting for demographics and 
other lifestyle, heart disease and medication covariates. However specific depressive 
symptoms from the GADS (e.g. lacking energy, lost interest, lost confidence and difficulties 
concentrating) did not remain significant when analysing progression to MCI from wave 1 to 
2 and adjusting for covariates and lifestyle, heart disease and medication demographics. This 
finding suggests demographics and covariates may have an important role for mediating the 
relationship between depressive symptoms and progression to MCI which should be 
considered for future research.  Demographics and covariates were also significant, 
specifically participants who were male or endorsed having a partner (e.g. defacto/married) 
had an increased odds of progressing to cognitive impairment. These findings are contrary to 
previous research which suggests there is no strong consensus on gender as a predictor of 
cognitive impairment (Peterson et al., 2014). However supports recent research indicating 
higher incidence rates of MCI in men (Roberts et al., 2012). Our findings also show that a 
higher number of men progressed to cognitive impairment. This outcome may be a result of 
women’s longevity and attrition within the sample, with the resulting number of male 
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participants affecting the current findings.  Our research also suggested that participants who 
endorsed having a partner/defacto were more likely to progress to cognitive impairment 
which is dissimilar from past findings which suggest marriage is a protective factor against 
progression to cognitive impairment (Fratiglioni, & Wang, 2007). Similarly, there were 
higher numbers of participants who endorsed having a partner which may have impacted the 
current findings. Overall, further research is needed to understand the role of partner status 
and gender in predicting cognitive impairment.  
Depressive symptoms from the BPHQ (e.g. little interest/pleasure in doing things, 
feeling down, depressed or hopeless, feeling tired or having little energy, poor appetite or 
overeating, feeling bad about yourself and trouble concentrating) remained significant when 
analysing progression to MCI and Any-MCD from wave 1 to 2 and adjusting for 
demographics and lifestyle, heart disease and medication covariates. Specific depressive 
symptoms were significant and cross validated between 2 depressive measures when 
analysing progression to MCI and Any-MCD from wave 1 to 2. Cross validation was evident 
for the GADS item “loss of interest” and the BPHQ item of “little interest/pleasure,” which 
were significant predictors of progression to Any-MCD and MCI at wave 2. The symptom of 
“trouble concentrating” on the BPHQ and “difficulties concentrating” on the GADS were 
significant predictors of Any-MCD and MCI at wave 2. While the GADS item “lacking 
energy” and BPHQ item “feeling tired or having little energy” were both significant 
predictors of cognitive impairment at wave 2.  
Our finding of specific depressive symptoms as predictive of cognitive impairment 
(e.g. MCI or Any-MCD) is partially consistent with past hypotheses explaining the 
relationship between depression and dementia (Jorm, 2001). In particular, our finding of 
difficulties concentrating as predictive of progression to cognitive disorders may support the 
hypothesis that cognitive deficits associated with depression cumulate with those of dementia 
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to increase the threshold for developing a diagnosis (Jorm, 2001). Overall, this hypothesis 
may explain why participants who endorsed difficulties with concentration, when assessed 
for depression, were more likely to progress to a diagnosed cognitive disorder across waves. 
However our other results suggest that mood related depressive symptoms also predicted 
progression to cognitive disorders (e.g. lacking energy, lost interest, lost confidence, felt 
slowed up, felt worse in the morning, little interest or pleasure in doing things, feeling down, 
depressed or hopeless, feeling tired or having little energy, poor appetite or overeating, and 
feeling bad about yourself). This finding may support another hypothesis which suggests 
depression is associated with glucortocoid hypersecretion, leading to neuronal death in the 
hippocampus that can result in memory deficits and dementia (Jorm, 2001) therefore the 
presence of specific depressive symptoms or a cluster of symptoms may result in 
neurological changes and cognitive impairment. Furthermore, our finding that a range of 
cognitive, emotional and behavioural depressive symptoms are endorsed at baseline and 
predictors of cognitive impairment may support Jack and colleagues (2010) model which 
states various neurological changes occur prior to cognitive impairment.  
Overall, our findings partially confirm our hypothesis of specific depressive 
symptoms as predictors of progression to cognitive disorders. However, other hypothesised 
symptoms including psychomotor agitation, loss of weight and suicidal ideation did not 
significantly predict progression to a cognitive disorder. Other symptoms which we could not 
predict whether there would be a relationship with cognitive impairment based on limited 
past research, were significant (e.g. difficulties concentrating and increased appetite). 
However sleep difficulties was non-significant for predicting progression to Any-MCD or 
MCI at wave 2. Our findings that specific symptoms remained significant when adjusting for 
demographics and lifestyle, heart disease and medication covariates and/or were cross 
validated between 2 depressive measures suggests certain depressive symptoms were stronger 
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predictors than other symptoms which were non-significant or failed to remain significant 
across models when adjusting for demographics or covariates and between depressive 
measures. The following section will discuss these findings in relation to past research, the 
limitations and strengths of the current study and implications for the future research.  
Lacking energy and feeling tired and progression to MCI and Any-MCD from 
Wave 1 to 2 
The GADS item “have you been lacking energy” and the BPHQ item “feeling tired or 
little energy” significantly predicted progression to MCI and Any-MCD. When analysing 
progression to MCI, the GADS item, “have you been lacking energy” did not remain 
significant when adjusting for gender and education which suggests a strong effect of these 
two demographic factors. However when analysing progression to Any-MCD, the GADS 
item “have you been lacking energy” remained significant when adjusting for demographics 
and lifestyle, heart disease and medcation covariates, suggesting this symptom was a strong 
predictor of cognitive impairment. Similarly, the BPHQ item “feeling tired or little energy” 
was significant when analysing progression to MCI and Any-MCD and remained significant 
when adjusting for demographics and lifestyle, heart disease and medication covariates, 
which suggests this symptom is a strong predictor of progression to cognitive impairment.  
This symptom is represented in the DSM-V criterion for MDD as fatigue or loss of 
energy nearly every day (APA, 2013), while low positive affect is characterised by the 
presence of lethargy in conjunction with other feelings (Watson et al., 1988). Our findings of 
“lacking in energy” and “feeling tired or little energy” as significant predictors is consistent 
with past research indicating the depressive symptom of “loss of energy” was elevated 3 
years prior to the incidence of AD (Berger et al., 1999). Our result extends on this past study 
by indicating that loss of energy/feeling tired is predictive of progression to Any-MCD in a 
baseline sample with no cognitive impairment. While our finding that this specific depressive 
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symptom was significant across 2 measures from wave 1 to 2 suggests a strong relationship 
between reduced energy and feeling tired and progression to cognitive impairment. 
Lost interest or pleasure in doing things and progression to MCI and Any-MCD 
from Wave 1 to 2 
The GADS item representative of “lost interest in things” and the BPHQ item “little 
interest or pleasure in doing things” were significant predictors of progression to MCI and 
Any-MCD. When analysing progression to MCI, the GADS item, “lost interest in things” did 
not remain significant when adjusting for gender and education which suggests a strong 
effect of these two demographic factors. However when analysing progression to Any-MCD 
the GADS item “lost interest in things” remained significant when adjusting for 
demographics and lifestyle, heart and disease and medication covariates, suggesting this 
symptom was a strong predictor of cognitive impairment. Similarly, the BPHQ item “little 
interest of pleasure in doing things” was a significant predictor of progression to MCI and 
Any-MCD and remained significant when adjusting for demographics and covariates, which  
suggests this symptom is a strong predictor of progression to cognitive impairment.  
The GADS item “lost interest in things” and BPHQ item “little interest or pleasure in 
doing things” are representative of the depressive symptom “reduced pleasure or interest in 
activities” (APA, 2013). Past research suggests that positive affect encompasses a wide range 
of positive mood states (e.g. interest) which are directly related to the presentation of this 
symptom of depression (APA, 2013; Nutt et al., 2007). Furthermore, past research found that 
mood states associated with positive affect, for example “a loss of interest”, was an elevated 
symptom evident 3 years prior to a diagnosis of AD (Berger et al., 1999).  Our result supports 
this past finding and demonstrates this symptom is a strong predictor of cognitive impairment 
as it remained significant when adjusting for demographics and covariates and was cross 
validated between two depressive measures at a specific time point.   
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Difficulties concentrating and progression to MCI and Any-MCD from Wave 1 
to 2 
The GADS item “have you had difficulty concentrating” and the BPHQ item “trouble 
concentrating on things, such as reading the newspaper or watching TV” were significant 
predictors of progression to MCI and Any-MCD. The GADS item did not remain significant 
when analysing progression to MCI while adjusting for demographics, suggesting a strong 
effect of these variables. The GADS item remained significant when analysing progression to 
Any-MCD and adjusting for demographics and lifestyle, heart disease and medication 
variables. The BPHQ item “trouble concentrating on things, such as reading the newspaper or 
watching TV” was a significant predictor of progression to MCI and Any-MCD and when 
adjusting for demographics, lifestyle and medication covariates.  
The two items are part of the DSM-V MDD criterion of diminished ability to think or 
concentrate, or indecisiveness nearly every day (APA, 2013). The current finding that 
difficulties concentrating remained significant when adjusting for demographics and all other 
covariates and that the symptom was cross-validated and significant across two measures, 
suggests the strength of this symptom as a predictor of progression to cognitive impairment. 
However the GADS item did not remain a significant predictor of progression to MCI when 
adjusting for demographics which suggests gender and education have a strong effect.  
The current finding extends on limited research investigating this depressive symptom 
as a predictor of cognitive impairment, with only one study showing that concentration was 
not a significant predictor of AD (Geelings et al., 2000). However it remains difficult to 
ascertain whether this symptom is specific to depression or merely prodromal to cognitive 
impairment. Our study addressed this inherent limitation by excluding baseline participants 
with cognitive impairment to investigate this symptom as an independent predictor of a 
cognitive disorder. Overall, our results highlight the necessity to consider this symptom as a 
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potential risk factor for cognitive disorders and the need for future studies to further 
investigate this potential relationship.  
Lost Confidence, Depressed Mood, Psychomotor Slowing, Felt Worse in the 
Morning, and Poor Appetite or Overeating and Progression to MCI and Any-MCD 
from Wave 1 to 2 
Lost confidence 
The GADS item “have you lost confidence in yourself” was a significant predictor of 
progression to MCI and Any-MCD. The item did not remain a significant predictor of MCI 
when adjusting for demographics which suggests a strong effect of gender and education in 
mediating the relationship between loss of confidence and cognitive impairment. The item 
remained a significant predictor for Any-MCD when adjusting for demographics and 
lifestyle, heart disease and medication covariates which suggests this depressive symptom is 
a strong predictor of cognitive impairment.  
The symptom of “lost confidence” is not specifically outlined in the criteria for MDD 
(APA, 2013). However past research shows that self-confidence is a positive mood state 
included within the construct of positive affect, a construct which is often impaired in 
individuals with depression (Nutt et al., 2007). This finding is consistent with past research 
suggesting that reduced positive affect is a marginal risk factor for dementia, which was 
endorsed through one of four depressive items on the CES-D including “I felt that I was just 
as good as other people” (Gatz et al., 2005). However our research identifies “loss confidence 
in yourself” as a separate symptom which predicted cognitive impairment. Furthermore it is 
important to consider that the symptom of loss of confidence reached significance 
concurrently with difficulties concentrating within the same time period (e.g. from wave 1 to 
2 for MCI and Any-MCD). Endorsement of loss of confidence may be a consequence of 
experiencing difficulties concentrating and individuals becoming increasingly aware of this 
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symptom. However this consideration is beyond the scope of this discussion and should be 
considered for future research. Overall, the results suggest that loss of confidence is a strong 
predictor of progression to cognitive impairment, suggesting that it should be considered in 
future research.  
Depressed mood 
The BPHQ item “feeling down, depressed or hopeless,” was a significant predictor of 
progression to MCI and Any-MCD. This item did not remain a significant predictor of MCI 
when adjusting for demographics, supporting the strong effect of theses variables in 
moderating this relationship. However this item remained a significant predictor of Any-
MCD when adjusting for lifestyle, heart disease and medication covariates, suggesting this 
symptom is a strong predictor of Any-MCD. This item is representative of the DSM-V 
criterion for MDD that a depressed mood is indicated through subjective reports of feeling 
sad, empty or hopeless (APA, 2013). Past findings have been limited to inducing a sad mood 
within participants to demonstrate the effect on performance across cognitive tasks (Chepnick 
et al., 2007; Knight et al., 2002). However our result extends previous findings by indicating 
subjective self-reports of depressive symptoms, specifically “feeling down, depressed or 
hopeless,” is associated with progression to cognitive impairment and subsequent diagnosis. 
Overall, additional research is required to replicate the current findings and investigate the 
association between depressed mood as a predictor of cognitive impairment.  
 Psychomotor slowing  
The GADS item “have you felt slowed up” was a significant predictor of progression 
to Any-MCD and remained significant when adjusting for demographics and covariates, 
suggesting a strong relationship between this symptom and cognitive impairment. This item 
is representative of the depressive symptom psychomotor retardation (APA, 2013). 
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Overall, the evidence that psychomotor slowing is predictive of progression to 
cognitive disorders is consistent with one study which found that psychomotor slowing, 
representative though somatic and vegative symptoms, increased the risk of dementia (Gatz 
et al., 2005). Our finding also supports past cognitive studies which suggest that cognitive 
functions impaired through psychomotor slowing including eye movement and motor 
reaction are necessary for normal cognitive function (Buyukdura et al., 2011; Liversedge & 
Findlay, 2000; Sobin & Sackeim, 1997). It is suggested that people who endorsed 
psychomotor slowing may have shown gradual impairment across cognitive functions (e.g. 
eye movement and motor reaction), leading to increased progression to a diagnosis of 
cognitive disorder.  
Although the GADS item for psychomotor slowing reached significance, the BPHQ 
item which concurrently assesses psychomotor slowing and agitation (e.g. “moving or 
speaking so slowly that other people have noticed? Or the opposite –being so fidgety or 
restless that you have been moving around a lot more than usual”) was not a significant 
predictor for cognitive impairment. This finding suggests psychomotor slowing and agitation 
may need to be assessed as separate constructs for future research. The Hamilton Depression 
Rating Scale (HDRS) is one of the most widely implemented scales to assess depression 
severity (Williams, 2001). The 17 item scale is used to quantify information obtained from an 
interview (Hamilton, 1960). The scale consists of two items that assess psychomotor agitation 
and retardation as separate constructs (Hamilton, 1960). Future research would benefit from 
the inclusion of depressive measures, for example the HDRS to assess psychomotor agitation 
and slowing.  
Felt worse in the morning 
The GADS item “have you tended to feel worse in the morning” was a significant 
predictor of progression to Any-MCD and remained significant when adjusting for 
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demographics and covariates, supporting a strong relationship between this symptom and 
cognitive impairment. This item is representative of the criterion for MDD with melancholic 
features including that depression is regularly worse in the morning (APA, 2013). Previous 
research has been limited to investigating depressed mood, recurrent episodes of depressed 
mood (Aoki et al., 2011; Chepnick et al., 2007; Dotson et al., 2010; Knight et al., 2002; 
Mayberg et al., 1999; Mitchell & Phillips, 2007) and progression to cognitive impairment. To 
our knowledge there is minimal research that has found the diurnal pattern of mood as a 
predictor of cognitive impairment therefore our findings suggest this symptom may have an 
important role in predicting progression to cognitive impairment and needs to be investigated 
further in future research.  
Poor appetite or overeating  
The BPHQ item “poor appetite or overeating” was a significant predictor of Any-
MCD and remained significant when adjusting for demographics and covariates, suggesting a 
strong relationship between the two variables. Increased or decreased appetite is a symptom 
representative of depression (APA, 2013). Our findings support past research suggesting a 
loss of appetite or weight predicts cognitive impairment and that higher adiposity predicts 
cognitive impairment (Fitzpatrick et al., 2009; Geerlings et al., 2000). Specifically, a loss of 
weight or higher adiposity may be associated with reduced or increased appetite, respectively. 
Our finding supports that appetite changes within the context of depression predicts 
progression to cognitive impairment. However, the GADS item “have you lost weight (due to 
poor appetite)” did not reach significance which leads to the question of whether participants 
who endorsed the BPHQ item were indicating overeating instead of poor appetite. It is 
suggested that alternate measures assessing increased and reduced appetite as separate 
constructs may further the limitations of the current findings. Other depressive measures may 
be useful to implement for future research, for example the Beck Depression Inventory II 
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(BDI-II), which is a 21 item self-report measure including the separate assessment of 
decreased and increased appetite (Beck, Steer, & Brown, 1996). 
Non-significant Symptoms of Sleep Difficulties, Psychomotor Agitation, Suicidal 
Ideation and Loss of Weight and progression to MCI and Any-MCD from Wave 1 to 2 
Symptoms of sleep difficulties, psychomotor agitation, suicidal ideation, and loss of 
weight were not significant predictors of progression to MCI or Any-MCD. The finding that 
sleep difficulties did not reach significance is surprising, given that this symptom is a primary 
presenting concern for depression and is associated with cognitive performance (APA, 2013; 
Haimov et al., 2008; Mazzoni et al., 1999; Van Dogen et al., 2003).  However our study 
found that, across two measures of depression, sleep difficulties did not predict progression to 
cognitive disorders. 
Psychomotor agitation was not a significant predictor of progression to cognitive 
impairment which is inconsistent with past findings of this symptom significantly predicting 
AD (Geerlings et al., 2000). However out finding supports past research suggesting that 
psychomotor agitation and slowing are separate constructs (Sobin & Sackeim, 1997), 
particularly because psychomotor slowing was a significant predictor of cognitive 
impairment within the current study.  Suicidal ideation was not a significant predictor of 
progression to cognitive impairment. This finding is consistent with the limited amount of 
previous findings supporting a relationship between the two variables with only one past 
study finding a relationship between suicidal ideation and cognitive impairment (Geerling et 
al., 2000). The symptom of weight loss due to poor appetite was not a significant predictor of 
cognitive impairment. This finding was inconsistent with previous research supporting a 
relationship between weight loss and dementia (Geerlings et al., 2000; Stewart et al., 2005) 
and our current finding that reduced/increased appetite was a significant predictor of 
progression to cognitive impairment which it is hypothesized would impact upon weight. 
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However, out data suggested that no participants in the healthy/MCI and healthy/Any-MCD 
groups endorsed “yes” for this symptom at baseline, which suggests this symptom may not be 
a predominant depressive symptom evident at baseline and/or that this symptom alone is not 
predictive of cognitive impairment. Overall, further research is needed to address whether 
weight loss is a predictor of progression to cognitive impairment.  
GADS Depressive Symptoms and Progression to MCI and Any-MCD from 
Wave 2 to 3  
GADS items including lacking energy, difficulties concentrating, waking early, felt 
slowed up and felt worse in the morning were not significant predictors of progression to 
MCI. The finding that “difficulties concentrating” was non-significant is inconsistent with 
our results that concentration issues predicted progression to MCI and Any-MCD from wave 
1 to 2. However this result is consistent with one past study indicating concentration 
difficulties was a not a significant predictor of AD (Geerlings et al., 2000). Other symptoms 
of “lacking energy,” “waking early,” “felt slowed up” and “felt worse in the morning” were 
not significant. This finding was inconsistent with our previous results, specifically lacking 
energy, psychomotor slowing and felt worse in the morning, which were significant 
predictors of cognitive impairment from wave 1 to 2.  Other items including “lost interest,” 
“lost confidence,” “felt hopeless,” and “lost weight” were excluded from the analyses due to 
participants in the healthy/MCI group not endorsing “yes” on these items at baseline. This 
outcome leads to questions including: are depressive symptoms evident 8 years prior to 
progression to cognitive impairment and do depressive symptoms change overtime therefore 
is it necessary to assess the trajectory of depressive symptoms in conjunction with 
progression to cognitive impairment across time and between closer time intervals? Overall, 
these questions suggest further research is needed to assess whether depressive symptoms at 
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baseline can predict progression to cognitive impairment at later time intervals, for example 8 
years later. 
The GADS items “lacking energy” and “felt slowed up” were significant from wave 2 
to 3. However the results were intriguing suggesting that endorsing “yes” to these items 
decreased the likelihood of progressing to Any-MCD from wave 2 to 3. Overall these 
findings suggest further research is needed.  
Study Limitations and Strengths 
Type 1 error rates were not investigated within the current study. The decision to 
exclude type 1 error rates was on the basis that previous authors suggest controlling for this 
error effects the interpretation of result (Johnson et al., 2000; Ottenbacher, 1998; Rothman, 
1990). A further limitation within the study was the inclusion of the BPHQ, which assessed 
symptoms concurrently within one item, for example psychomotor agitation and retardation. 
This resulted in difficulties ascertaining whether slowing or agitation, as distinct constructs, 
are predictive of progression to cognitive disorders. This issue may have been avoided with 
the implementation of an alternate depressive measure in conjunction with an interview, for 
example the HDRS (Hamilton, 1960). However it is important to note that the HDRS does 
not include part of the DSM-V MDD criterion for increase/decrease in appetite. Similarly, the 
BPHQ assessed increased and decreased appetite concurrently, making it difficult to 
disentangle the two symptoms. The BDI-II may have been useful to overcome this limitation, 
through the measurement’s separate assessment of increased and decreased appetite (Beck et 
al., 1996). However the BDI-II does not include the DSM-V MDD symptom of psychomotor 
slowing. Overall, a review of other depressive measures (e.g. HDRS and BDI-II) highlights 
the lack of consistency between DSM-V criteria for MDD and items on depressive 
assessments. This limitation suggests a need for the development of self-report measures of 
depression that represent the criteria for MDD, with each symptom assessed separately.   
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Another limitation included the implementation of the GADS, which assessed 
symptoms as “occurring recently” and does not reflect the DSM criteria for MDD, which 
outline symptoms that have been present in the past 2 weeks (APA, 2013). The GADS also 
excluded the symptom of weight gain; therefore it is not representative of all depressive 
symptoms. Furthermore, the BPHQ and GADS are measurements inherently associated with 
self-report bias. However, given the size of our sample, the implementation of the GADS and 
BPHQ was convenient and time effective. Another limitation is the exclusion from these 
depressive measures of DSM-V MDD symptoms, particularly of feeling excessive 
worthlessness and guilt, and reduced ability to think/indecisiveness, while other general study 
limitations include sample attrition and the exclusion of participants across the waves which 
may have resulted in sample bias.  
An additional limitation was that participants in the healthy/cognitive impairment 
groups from wave 2 to 3 did not endorse “yes” on BPHQ items or specific GADS items at 
baseline therefore we were unable to complete an analysis of depressive symptoms as 
predictors of progression to cognitive impairment for this specific time point or compare 
results across two time intervals (e.g. from wave 1 to 2 and wave 2 to 3). This issue raises 
questions as to whether depressive symptoms assessed at baseline are able to predict 
progression at later time intervals and whether it would be beneficial to assess depressive 
symptoms as predictors of cognitive impairment within a closer time interval, for example 
assess depressive symptoms at wave 2 for progression of cognitive impairment from wave 2 
to 3. Furthermore, depressive symptoms may change over time therefore it may be beneficial 
to reassess depressive symptoms not only at baseline but also wave 2. Overall, these issues 
should be considered for future research.  
The strengths of this study included the implementation of two measurements of 
depression. This allowed for cross validation between results on one item/depressive 
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symptom across the BPHQ and GADS. Depressive symptoms/items (e.g. difficulties 
concentrating, lacking energy or feeling tired and lost interest or pleasure in doing things) 
that reached significance across the two measures suggest a stronger relationship of 
progression to cognitive disorders. This study also investigated progression to a range of 
cognitive disorders including MCI and Any-MCD, which extends previous research limited 
to investigating risk of AD (Geerlings et al., 2000). Other strengths of this general study 
include the large 60+ population-based community sample, high retention of the sample, a 
narrow age range that enables avoidance of cohort effects, a detailed assessment and clinical 
diagnosis of cognitive impairment, and the collection of data across three time points with 
eight years of follow-up.  
These data suggest that specific depressive symptoms significantly predict 
progression to cognitive disorders from wave 1 to 2. Symptoms include: lacking 
energy/feeling tired, lost interest or pleasure in doing things, lost confidence, difficulties 
concentrating, psychomotor slowing, feeling worse in the morning, feeling down, depressed 
or hopeless, poor appetite/overeating and feeling bad about oneself. All of the BPHQ 
symptoms remained significant when adjusting for demographics and covariates when 
analysing progression to Any-MCD and MCI. While all of the BPHQ items remained 
significant when adjusting for demographics and covariates when analysing progression to 
Any-MCD, however did not remain significant when analysing progression to MCI.  A total 
of 3 symptoms were cross validated between two measures at a specific time point (e.g. wave 
1 to 2) and include: difficulties concentrating, lacking energy/feeling tired and loss of 
interest/pleasure in doing things. The finding of depressive symptoms that remained 
significant when adjusting for demographics and covariates and were cross validated between 
the GADS and BPHQ suggests a strong association for the following symptoms and 
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cognitive impairment: difficulties concentrating, lacking energy/feeling tired and loss of 
interest/pleasure in doing things. 
Future Research and Clinical Implications 
The present findings provide important considerations for future research within the 
field and to develop our understanding of the role of depression in cognitive impairment. The 
current research suggests specific baseline depressive symptoms are predictive of progression 
to cognitive disorders from wave 1 to 2. However further research is needed to investigate 
whether the effect of depressive symptoms on progression to cognitive differs between time 
points (i.e. 4 versus 8 years) and for distinct cognitive disorders. It will also be important to 
investigate why specific symptoms on the GADS “felt slowed up” and “felt worse in the 
morning” were only significant for progression to Any-MCD and not MCI from wave 1 to 2 
and why specific GADS items (i.e. lacking energy, lost interest, lost confidence and 
difficulties concentrating) do not remain significant predictors of progression to cognitive 
impairment when adjusting for gender and education.  
Other directions for future research include the implementation of alternate forms of 
depressive assessments at more than one time point. This would allow researchers to 
investigate the trajectory of identified depressive symptoms (e.g. stability) and resulting 
changes in diagnoses of cognitive disorders. Alternate self-report depression measures should 
be considered to ensure that all DSM-V MDD symptoms are assessed and as separate 
constructs. On the basis of past psychometrics discussed (BDI-II and HDRS), future research 
should look towards developing one depressive measure which assesses all depression 
symptoms and as separate constructs. Furthermore, other research should aim to include a 
two stage screening process which includes an initial depressive checklist/psychometric 
measure after which individuals who endorse symptoms are subject to a more thorough 
interview to assess specific depressive symptoms.  
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Additional research is needed prior to conclusions being drawn about the clinical 
implications of the current study. However further research could provide important clinical 
implications in the future including potentially monitoring of specific depressive symptoms 
for individuals and health professionals in individuals aged 60 years and over, and who are 
potentially at risk of developing a cognitive disorder. This could also lead to appropriate 
assessment and screening of depressive symptoms in the at risk population which may result 
in appropriate detection and referral for earlier prevention or delay of the onset of cognitive 
disorders.  However, these clinical implications are preliminary and as previously mentioned 
more research is needed prior to establishing the clinical benefits.  
In summary, the current research supports the role of specific depressive symptoms in 
cognitive impairment. Future research needs to investigate this relationship further, including 
alternate depressive measures at more than one time, analyzing the role of depressive 
symptoms as predictors across more than one time period and using a two stage-sampling 
design to assess depression. Additional research will increase our understanding of depressive 
symptoms as predictors of cognitive impairment and will contribute to knowledge within the 
field.  
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Chapter 4.  Study Two: Affect and Prediction of Progression to Cognitive Disorders in 
a Population Based Sample Aged 60+ 
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Affect and Prediction of Progression to Cognitive Disorders in a Population Based 
Sample Aged 60+ 
Chapter 1 outlined that a vast amount of research supports depression as a risk factor 
for the development of cognitive disorders.  Positive and negative affect are important to 
consider in this research context, particularly because they are central to depressive disorders 
(APA, 2013; Nutt et al., 2007). Positive affect encompasses a wide range of positive feelings 
including attentive, interested, alert, excited, enthusiastic, inspired, proud, determined, strong 
and active (Watson et al., 1988). In contrast, negative affect represents various negative 
feelings including distressed, upset, hostile, irritable, scared, afraid, ashamed, guilty, nervous 
and jittery  (Watson et al., 1988).  
To our knowledge, a limited number of studies have investigated negative affect as a 
predictor of cognitive disorders, while few studies have specifically investigated positive 
affect as predictive of cognitive disorders. Generally, the objective of past studies has been to 
investigate the relationship between depression and the incidence/onset of AD or Dementia 
(Berger et al., 1999; Gatz et al., 2005). Therefore these studies have included a broad measure 
of depression with a minimal number of items assessing mood states representative of 
positive affect. A past study found that depression was a significant predictor for dementia 
and AD, using total cut off scores from the Centre for Epidemiological Studies Depression 
Scale (CES-D; Gatz et al., 2005). The CES-D is a self-report measure consisting of 20 items 
measuring depression and includes four items which are representative of positive affect 
(Radloff, 1977). Items representative of positive affect comprise: “I felt that I was just as 
good as other people”, “I felt hopeful about the future”, “I was happy”, and “I enjoyed life” 
(Radloff, 1977). Further results from this study suggest that a lack of positive affect was a 
marginal risk factor for dementia (Gatz et al., 2005). Another study found an elevation in 
depressive symptoms three years prior to a diagnosis of AD, with symptoms predominantly 
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being motivation related, for example, loss of energy and lack of interest (Berger et al., 
1999). These symptoms are also representative of feelings encompassed within positive affect 
(Watson et al., 1988). Findings from this study were drawn from the implementation of the 
Comprehensive Psychopathological Rating Scale (CPRS) to question and observe depressive 
symptoms, only few of which were specifically related to positive affect, in addition to 
measuring other psychotic and sleep disturbance symptoms (Berger et al., 1999). However 
this study was limited to investigating participants in the preclinical phase of AD and aged 75 
years and older, making it difficult to generalise these findings to the general population.   
Further evidence supports an association of negative and positive affect with 
performance across cognitive domains. Past research indicates that affect is associated with 
cognitive domains that are often impaired in cognitive disorders, including: working memory, 
episodic memory, visuo-spatial awareness and attention (Gagnon & Belleville, 2011; 
Saunders & Summers, 2011; Taler & Phillips, 2008). One study supports the relationship of 
positive affect and working memory (Carpenter, Peters, Vastfjall, & Isen, 2013). In this study 
a total of 46 participants aged 63-85 years were recruited from a community sample, with 
findings indicating participants who were assigned to a positive feeling condition, in 
comparison to a neutral feeling condition, performed better across tasks of working memory, 
for example recalling letters (Carpenter et al., 2013). These findings are supported by 
neuropsychological theory which proposes that positive affect is associated with increased 
dopamine release into the prefrontal cortex, which facilitates working memory (Ashby, Isen, 
& Turken, 1999). In other research, participants’ positive mood elicited by music resulted in 
broadened visual spatial processing, further supporting the role of positive affect in cognition 
(Rowe, Hirsh, & Anderson, 2007). However, this study consisted of a sample of 24 university 
students (Rowe et al., 2007). In contrast, other studies support the role of negative affect and 
cognition, particularly high rates of negative affect at baseline, in predicting cognitive decline 
118 
 
(Christodoulou et al., 2009). However, this finding was specific to a study investigating 38 
participants who were diagnosed with relapsing remitting or secondary progressive Multiple 
Sclerosis (MS), making it difficult to generalise these findings to other populations.  Other 
research indicates that increased negative affect is associated with narrower focus on an 
attentional blink program, though this study included a sample of 68 university students 
(Maclean, Arnell, & Busseri, 2010).  
Other longitudinal research suggests that positive affect has an important role in 
cognitive function. Dolcos and colleagues (2012) investigated functional markers (i.e. 
positive affect) associated with changes in cognitive status. The study consisted of 294 
participants assessed across two waves and assigned to one of two cognitive status groups 
including NIC (not impaired controls) and MCI (mild cognitive impairment). The results 
show that higher scores on positive affect predict a decreased risk of cognitive decline in the 
stable NIC-NIC and MCI-MCI groups (Dolcos et al., 2012). Furthermore, higher scores of 
positive affect predict cognitive improvement in the unstable MCI-NCI group.  
Psychological theories also suggest mechanisms for the influence of affect on 
cognition. Particular theories of affect congruence state that affect has a role in cognition 
through two mechanisms including inferential and memory processes (Schwarz, 1990). The 
Inferential Model posits that when individuals are performing a task they may ask “how do I 
feel about this?”, and through questioning they may mistake previous feelings to the target as 
a result, suggesting that overall the individual incorrectly processes information (Schwarz, 
1990). The Affect Priming Model specifies that affect is central to individual’s cognitive 
representations of the world (Bower, 1981). This model suggests that affect immediately 
primes associated memories and ideas when an individual is doing a cognitive task that 
utilities memory based information (Bower, 1981).  
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An additional theory is that affect influences how people think, particularly that 
positive affect influences assimilative, schema based processing style (Bless & Fieldler, 
2006). Assimilation is referred to as a process in which processing is guided by knowledge 
structures, therefore producing top-down deductive thinking (Bless & Fieldler, 2006). In 
contrast, negative affect is associated with accommodative, externally focused thinking, 
which refers to focusing on the external world/information and using inductive bottom up 
thinking (Bless & Fieldler, 2006).   
Positive affect may also impact on cognition through indirectly increasing behaviours 
or lifestyle factors that enhance mental and physical wellbeing and are protective for 
cognitive decline. Protective factors, including engagement in social activities, daily and high 
levels of physical activity, are all associated with lower risks of developing dementia 
(Buchman et al., 2012; Laurin et al., 2001; Wang et al., 2002). Social engagement and 
physical activities require mental activity and provide a sense of meaning/social role 
(Hillman, Erickson, & Kramer, 2008; Wang et al., 2002), which may contribute to these 
factors being protective against cognitive decline. Furthermore, engagement in social 
interaction and/or physical activity may result in feelings of accomplishment and an 
improved mood, which is particularly important given that depression (e.g. depressed mood) 
increases the risk of cognitive decline/impairment (Diniz et al., 2013; Gao et al., 2013). It is 
hypothesised that an individual’s initial engagement in social activities and physical activity 
would require some degree of interest, enthusiasm and energy, which are all associated with 
positive affect (Watson et al., 1988). This notion is supported by findings which suggest that 
positive affect is positively related to evaluation of interaction quality, the number of social 
interactions and the amount of time spent in social interactions (Berry & Hansen, 1996), 
while other research indicates that higher scores of positive affect (i.e. interest, excitement, 
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enthusiasm and alertness) are associated with increased levels of habitual physical activity 
(Pasco, et al., 2011).   
Overall, the past research and theories support an association between positive and 
negative affect and areas of cognition, which are evident in cognitive decline/impairment. 
Furthermore, there is some evidence to support the role of positive affect in predicting 
specific cognitive disorders and to suggest that it provides a protective factor against 
cognitive decline, while the role of negative affect is less understood. However it is evident 
that more research is required to understand the specific role of positive and negative affect in 
predicting cognitive disorders.   
The aim of the current research is to further investigate positive and negative affect as 
predictors of progression to Any-MCD/MCI from normal ageing. This aim will be 
investigated in conjunction with implementing a specific affect measure, the Positive and 
Negative Affect Scale (PANAS), and with measuring progression to cognitive impairment at 
follow up assessments at waves 2 and 3. It is hypothesised that low positive affect will 
predict progression to Any-MCD/MCI. Due to the lack of past research on negative affect 
and prediction of progression to cognitive impairment/decline, we cannot predict whether 
negative affect will predict progression to Any-MCD/MCI. However, based on the past 
findings of the relationship between negative affect and cognition and research on depression 
and dementia (Barnes et al., 2012; Diniz et al., 2013; Dotson et al., 2010; Gao et al., 2013), it 
is predicted that there may be an association between the two constructs.  
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Method 
Data presented in this study are from the PATH project, which has previously been 
described in detail (see Chapter 2, Method for PATH). This study focuses on analyses of 
longitudinal data collected from the 60+ cohort assessed at baseline, and followed up at 
waves 2 and 3. The sample used in the current study has previously been described in detail 
(see Chapter 2, Method for PATH and Chapter 3, General Method for the Current Study).  
Materials 
Assessment of affect  
The PANAS is a reliable measure of mood, which includes scales that are highly 
internally consistent, and largely uncorrelated (Watson, et al., 1988; see Appendix E). The 
PANAS is a self-report measure consisting of 20 items. Half of the items assess negative 
affect and the other half assess positive affect. The 20 items consist of words that describe 
different emotions. Participants are required to rate the extent to which the word represents 
how they feel at the present moment/over the past week. Participants rate their answer on a 5 
point scale ranging from very slightly/not at all to extremely.  
Previous research supports the implementation of the PANAS within non-clinical 
samples (Crawford & Henry, 2004). One study found the PANAS to have adequate validity 
in measuring positive and negative affect (Crawford & Henry, 2004), while the PANAS was 
found to be a reliable measure with Cronbach’s  0.89 for the positive affect scale and 0.85 
for the negative affect scale (Crawford & Henry, 2004). Overall, past research supports the 
PANAS as an appropriate measure of affect for the current study (Crawford & Henry, 2004; 
Watson et al., 1988). However, past research on the psychometric properties of the PANAS is 
limited to non-clinical samples (Crawford & Henry, 2004), and additional research on the 
psychometric properties of the PANAS is needed within clinical populations. This limitation 
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is particularly relevant to the current study, which includes a clinical sample of individuals 
diagnosed with cognitive disorders, and suggests that further research is needed in this area.  
Assessment of demographics and covariates 
The following demographics and covariates were included: gender, years of 
education, employment and marital status, high blood pressure, stroke, diabetes, heart 
disease, antidepressant medication, anxiety medication, smoking status, and number of hours 
of physical activity. A detailed description of each covariate is included in Study 1 (see 
Chapter 4;  Method).  
Sample size 
Sample size was predetermined by the original aims of the larger cohort study 
(Anstey et al., 2012). The sample size was sufficient to allow for investigation of risk and 
protective factors and interactions among risk factors.  
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Statistical Analyses 
SPSS version 22 was used to perform the analyses. A Generalized Linear Model 
(GZLM), using binary logistic regression, was implemented to investigate whether affect was 
a significant predictor of progression to a binary group membership (e.g. healthy/healthy, and 
healthy/Any-MCD or healthy/MCI), while adjusting for demographics and covariates. As 
previously reported in Study 1, the GLZM model was selected based on its suitability for 
analysing a dependent variable with a binary outcome and non-normal distribution (Garson, 
2013).  
Within the analyses the predictor covariates included baseline measurements of 
overall positive and negative affect scores (PANAS), while the controlled demographics 
included baseline assessment of gender and education. The analyses included 8 Generalised 
Linear Models that predicted progression to Any-MCD and MCI. Further models adjusting 
for other covariates (i.e. employment, physical activity, depression and anxiety medication, 
partner status, current smoking status, high blood pressure, diabetes, stroke and heart disease) 
were not included due to non-significant findings in the previous models when affect was 
entered separately and/or when adjusting for education and gender. In the Model 1 positive or 
negative affect predictors were entered separately and in Model 2, positive or negative affect 
predictors were entered separately while adjusting for gender and education. The covariate 
age was excluded from all the models due to the narrow age of the cohort. An additional 
measure of verbal intelligence, Spot The Word (STW), was included to adjust for premorbid 
IQ.  
As previously mentioned, the binary logistic regression does not assume that the 
dependent variable is normally distributed. Furthermore, it does not assume the distribution 
of the predictor variables (Pallant, 2011). Therefore it was not necessary to analyse the 
variables for normality (e.g. skewness/kurtosis).  The maximum number of predictors entered 
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within a model was 3, which was relatively small in comparison to the sample size (N = 
2500); therefore an assumption of logistic regression was not violated (Pallant, 2011). 
Similarly, another assumption was not violated, with analysis revealing no high 
intercorrelations between the predictor variables (positive and negative affect scores and 
demographics/covariates) indicated by tolerance values not being < .10 (Pallant, 2011).  
Data Screening  
The data were screened for accuracy of input and plausibility of frequencies, which 
indicated that both were satisfactory. The number of missing cases for the 
demographics/covariates (education, physical activity, employment, depression and anxiety 
medication, partner status, current smoking status, high blood pressure, diabetes, stroke and 
heart disease) and outcome variables (Any-MCD and MCI) was reported previously (see 
Chapter 3, General Method for the Current Study and Chapter 4, Statistical Analysis). As 
previously reported, the missing cases were dealt with by substitution of the most common 
answer, imputation using the EM method and the case pairwise option. A total of 66 cases 
were missing for STW, which as mentioned previously is a measure of verbal intelligence 
and was included in the exploratory analysis. Imputation using the EM method was 
implemented to deal with missing data for STW.   
Additional analysis indicated that 18 cases and 16 cases were missing for positive and 
negative affect, respectively. However the cases with missing values for positive and negative 
affect did not have sufficient outcome data for inclusion in the current analyses; therefore the 
‘exclude case pairwise’ option was selected to deal with missing data. The case pairwise 
option allows for the exclusion of cases on the basis of missing data required for a specific 
analysis (Pallant, 2011). 
The distribution of the continuous variables was examined and indicated 15 outliers 
for positive affect and 30 outliers for negative affect. However, the number of outliers was 
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small in comparison to the large sample size included in the current research, which is robust; 
therefore the outliers were included in the current analyses.  
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Results 
Description of Participants  
Participants were allocated to the healthy/healthy group if they remained stable across 
waves and were free of cognitive impairment from wave 1 to 2 and wave 2 to 3.  When 
investigating progression to MCI from wave 1 to 2, the healthy/healthy group consisted of 
2076 participants and the healthy/MCI group consisted of 17 participants. When analysing 
Any-MCD from wave 1 to 2, the healthy/healthy group consisted of 2076 participants and the 
healthy/Any-MCD group included 68 participants. When investigating progression to MCI 
from wave 2 to 3 the healthy/healthy consisted of 1797 and the healthy/MCI group included 
21 participants; and when analysing Any-MCD from wave 2 to 3, a total of 1797 participants 
were allocated to the healthy/healthy group and 30 participants to the healthy/Any-MCD 
group.  
See Table 2.1 in Chapter 2 for demographic and characteristics (gender, age and years 
of education and partner status). Table 4.1 presents baseline affect scores for participants 
belonging to a diagnostic category (e.g. healthy/healthy versus healthy/cognitive disorder) 
within each analysis (e.g. Wave 1 to 2 MCI model) across the three waves. A series of 
independent-samples t-tests were conducted to compare negative and positive affect scores 
between groups (e.g. healthy/healthy and healthy/cognitive disorder) within the four models 
across wave 1 to 2 and wave 2 to 3 (see Table 4.2).  There were no significant differences in 
negative or positive affect scores for the diagnostic groups across the MCI and Any-MCD 
models across all the waves.  
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Note. NA = negative affect; PA = positive affect
 
 
Table 4.1 
 
Baseline Affect Scores for Diagnostic Categories across the Waves 
 Overall NA score Overall PA score 
 M (SD) M (SD) 
   
Wave 1 to 2 
 
  
MCI model   
Healthy/healthy 13.88(4.82) 31.42(7.26) 
Healthy/MCI 15.06(4.75) 31.06(6.60) 
   
Any-MCD model   
Healthy/healthy 13.88(4.82) 31.42(7.26) 
Healthy/Any-MCD 13.68(4.30) 30.85(7.51) 
   
Wave 2 to 3 
 
  
MCI model   
Healthy/healthy 13.73(4.63) 31.62(7.13) 
Healthy/MCI 14.38(4.83) 32.29(9.83) 
   
Any-MCD model   
Healthy/healthy 13.73(4.63) 31.62(7.13) 
Healthy/Any-MCD 
 
15.13(4.96) 30.87(9.16) 
 
Note. MCI = Mild Cognitive Impairment; Any-MCD = Any Mild Cognitive Disorder 
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Table 4.2 
 
T-test Results Comparing Affect Scores between Diagnostic Categories within Models 
across Waves 
          
 PA score     NA score    
 M (SD) t df p  M (SD) t df p 
Wave 1 to 2          
MCI model          
Healthy/healthy 31.42 (7.26) 0.20 2080 .84  13.88 (4.82) -1.00 2082 .32 
Healthy/MCI
a 
31.06 (6.60)     15.06 (4.75)    
          
Any-MCD model           
Healthy/healthy 31.42 (7.26) 0.63
 
2131 .53  13.88 (4.82) 0.35 2133 .73 
Healthy/Any-
MCD
b 
30.85 (7.51)     13.31 (3.74)    
          
Wave 2 to 3          
MCI model          
Healthy/healthy 31.62 (7.13) -0.42 1809 .67  13.73 (4.63) -0.64 1811 .52 
Healthy/MCI
c 
32.29 (9.83)     13.38 (4.82)    
          
Any-MCD model          
Healthy/healthy 31.62 (7.13) 0.57 1818 .56  13.73 (4.63) -1.65 1820 .10 
Healthy/Any-
MCD
d
 
 
30.87 (9.16)     15.13 (4.96)    
 
Note. NA = negative affect; PA = positive affect; p = P-values are 2 tailed.
 
a-d 
Results for t, df and p value are the same as healthy/healthy diagnostic category within each model comparing 
positive or negative affect scores. 
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Positive Affect and Progression to Any-MCD/MCI from Wave 1 to 2 Any-MCD 
PA was not a significant predictor of progression to Any-MCD at wave 2 (p > .05). 
PA remained non-significant when adjusting for gender and education (p > .05). However 
gender was significant (OR = 1.70; 95% CI 1.02-2.82; p = .04), suggesting that for males the 
odds of progressing to Any-MCD increase by a factor of 1.70. There was no significant 
interaction effect for gender and PA (p > .05).  
MCI 
PA was not a significant predictor of progression to MCI from wave 1 to 2 (p > .05). 
PA was not significant for predicting progression to MCI, when adjusting for gender and 
education which were also non-significant (p > .05).  
Positive Affect and Progression to Any-MCD/MCI from Wave 2 to Wave 3  
Any-MCD 
 PA was not a significant predictor of progression to Any-MCD from wave 2 to 3 (p > 
.05). PA was not significant when adjusting for gender and education (p > .05). Gender and 
education were also non-significant (p > .05).   
MCI 
 PA was not a significant predictor of progression to MCI from wave 2 to 3 (p > .05).  
PA remained non-significant when adjusting for gender and education (p > .05). Education 
was non-significant (p > .05) however gender was significant (OR = 3.56, 95% CI 1.28-9.87, 
p = .02) suggesting that for males the odds of progressing to MCI increases by a factor of 
3.56. There was no significant interaction effect for gender and PA (p > .05).  
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Negative Affect and Progression to Any-MCD/MCI from Wave 1 to Wave 2  
Any-MCD 
Negative affect (NA) did not significantly predict progression to Any-MCD from 
wave 1 to 2 (p > .05). NA remained non-significant when adjusting for gender and education 
(p > .05). Education was non-significant (p > .05) however gender was significant (OR = 
1.71, 95% CI 1.03-0.38, p = .03). This result suggests that for males the odds of progressing 
to MCI increase by a factor of 1.71. There was no significant interaction effect for gender and 
NA (p > .05).   
MCI 
NA was not a significant predictor of progression to MCI and remained non-
significant when adjusting for gender and education (p >. 05). Gender and education were not 
significant (p > .05).  
Negative Affect and Progression to Any-MCD/MCI from Wave 2 to Wave 3 
Any-MCD 
 NA was not a significant predictor for progression to Any-MCD and remained non-
significant when adjusting for education and gender (p > .05). Education and gender were not 
significant (p > .05).   
MCI 
 NA was not a significant predictor of progression to MCI and remained non-
significant when adjusting for education and gender. Education was significant (OR = 0.86, 
95% CI 0.74-0.99, p = .04) suggesting that for every additional year of education the odds of 
progressing to MCI decreased by 14%. There was no significant interaction effect between 
education and NA (p > .05). Gender was significant (OR = 3.53, 95% CI 1.28-9.77, p = .02), 
suggesting that for males the odds of progressing to MCI increase by a factor of 3.53. There 
was no significant interaction effect between gender and NA (p > .05).  
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Exploratory analysis was implemented using a GLZM binary regression. The analysis 
investigated affect as a predictor of progression to MCI/Any-MCD from wave 1 to 2 and 
wave 2 to 3, while adjusting for verbal intelligence. Overall scores from STW were used as a 
measure of verbal intelligence (Baddeley, Emslie, & Nimmo-Smith, 1993).  Results showed 
that positive and negative affect remained non-significant for progression to MCI or Any-
MCD at all time points, across the other waves when adjusting for STW scores (p > .05).  
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Discussion 
Positive affect was not significant for predicting progression to MCI or Any-MCD 
across waves 1 to 2 and waves 2 to 3. Positive affect also remained non-significant when 
adjusting for demographics of education and gender. Negative affect was not significant for 
predicting progression to MCI or Any-MCD across waves 1 to 2 and waves 2 to 3 and 
remained non-significant when adjusting for demographics. A further analysis adjusting for 
other lifestyle, heart disease, and medication covariates was not completed due to non-
significant results in models 1 and 2. Our results do not support our hypothesis that low 
positive affect would predict progression to cognitive impairment and is discussed further in 
relation to past research in the section below.  
Our findings that positive and negative affect were non-significant predictors of 
progression to cognitive impairment is inconsistent with past research supporting the 
relationship between affect and cognitive impairment (Berger et al., 1999; Carpenters et al., 
2013; Gatz et al., 2005; Rowe et al., 2007). However past research has primarily focused on 
depression and cognitive impairment therefore has not included a specific measure of affect 
or has induced affect within experimental groups to test performance on cognitive tasks 
(Berger et al., 1999; Carpenters et al., 2013; Gatz et al., 2005; Rowe et al., 2007). Therefore it 
is difficult to generalise the past findings to our current study based on the differences in 
methodology, specifically that our study included a specific assessment of affect, a 
population based sample and diagnoses of cognitive disorders.  
Another study which found a significant relationship between negative affect and 
cognitive decline using the PANAS as a measurement of affect was limited to participants 
with a diagnosis of MS (Christodoulou et al., 2009). This finding by Christodoulou and 
colleagues (2009) in conjunction with our non-significant results for negative affect as a 
predictor of progression to cognitive impairment highlights whether the PANAS reliably 
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assesses affect across different clinical populations or if another measurement of affect needs 
to be considered. Indeed, one of the few past studies which found higher scores on positive 
affect predicted a decrease in the risk of cognitive decline included an alternate assessment of 
affect called the Bradburn Affect Balance Scale (Bradburn, 1969; Dolcos et al., 2012). 
However it is important to note these findings were limited to positive affect and did not 
include negative affect. A comparison of the two measurements of affect, indicates the 
PANAS (Watson, et al., 1988) includes instructions which specifically ask the individual to 
indicate the extent to which you feel this way right now or over the past week, which may 
impact the reliability of the answers across participants who may answer according to current 
feelings or how they felt during the past week. In comparison the Bradburn Affect Balance 
Scale (Bradburn, 1969) instructs the participant to answer based on how they felt over the 
past few weeks. Overall, this issue suggests that further research should investigate negative 
and positive affect as predictors of cognitive impairment and include alternate measures of 
affect.  
Our findings also indicate demographics including education and gender were 
significant for predicting progression to Any-MCD or MCI at specific time points. This 
finding indicates that males were more likely to progress to Any-MCD and MCI and reflects 
past research supporting higher incidences of MCI in male populations (Roberts et al., 2012).  
Our finding that increased years of education decrease progression to MCI, supports previous 
research that higher levels of education reduces the risk for MCI (Sattler et al., 2012). 
Overall, these findings suggest gender and education have an important role in predicting 
cognitive impairment and need to be considered for future research.  
As previously mentioned one limitation within our study was the inclusion of the 
PANAS for the current population and that it is a self-report measure therefore may result in 
participants underreporting their symptoms. Other issues include the occurrence of sample 
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attrition across the three waves which resulted in the exclusion of participants from the 
current analyses. An inherent problem arising from the exclusion of participants is sample 
bias, which may have impacted upon our overall findings. The current study may have been 
strengthened by seeking cross-validation of self-report scores, and the collection of affect 
scores from more than one time point (e.g. baseline and wave 2) to assess whether affect 
remained constant or changed across time and continued to be non-significant or became a 
significant predictor of progression to cognitive disorders.  However current study strengths 
included the inclusion of a large 60+ population based community sample, a detailed 
assessment and clinical diagnosis of cognitive impairment, and the collection of data across 
three time points and an 8 year period. 
Overall, the results from the current study indicate that positive and negative affect 
are not significant predictors of progression to Any-MCD or MCI. Demographics of 
education and gender were significant of Any-MCD or MCI at specific time points. Further 
research is needed including alternate measures of affect with cross validation of these scores 
using assessments or interview, the assessment of affect at more than one time point and the 
inclusion of adjusting for lifestyle, heart disease and medication covariates. Overall, 
additional research will develop our understanding of the role of affect in cognitive 
impairment and contribute to the research field.    
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5. General Discussion 
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This chapter discusses the main findings of Study 1 and 2 and their theoretical implications. 
The results are discussed collectively, limitations of the current research and directions for 
future research and clinical implications are considered.  
Study 1: Depressive Symptoms as Predictors of Progression to Cognitive Disorders 
The findings from Study 1 partially fulfill the hypothesis that depressive symptoms 
predict progression to cognitive disorders. As predicted, symptoms of lacking energy/feeling 
tired, lost interest/little pleasure in doing things, loss of confidence, psychomotor slowing, 
feeling worse in the morning, feeling down, depressed or hopeless, loss/increase of appetite, 
and feeling bad about oneself were predictive of progression to MCI and/or Any-MCD from 
wave 1 to 2. In contrast to our hypothesis, difficulties concentrating and increased appetite 
were significant predictors of progression to Any-MCD and/or MCI from wave 1 to 2. 
Psychomotor agitation and suicidal ideation were not significant predictors which is 
inconsistent with our hypothesis.  
The BPHQ items (e.g. little interest/pleasure, feeling down, depressed or hopeless, 
feeling tired/little energy, feeling bad about oneself and difficulties concentrating) remained 
significant when adjusting for demographics and covariates and analysing progression to 
Any-MCD and MCI. However the BPHQ item “poor appetite or overeating” was a 
significant predictor for Any-MCD only, and remained significant when adjusting for 
demographics and covariates. This finding suggests this symptom was a predictor for a range 
of cognitive disorders and not MCI alone. This result may be associated with the stability of 
Any-MCD diagnoses across time in comparison to MCI and highlights the importance of 
analysing the two diagnostic categories simultaneously.  
 The GADS items (lacking energy, lost interest, lost confidence, difficulties 
concentrating, felt slowed up and felt worse in the morning) remained significant when 
adjusting for demographics and covariates and analysing progression to Any-MCD. However 
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the GADS items (e.g. lacking energy, lost interest, lost confidence and difficulties 
concentrating) did not remain significant when analysing progression to MCI and adjusting 
for gender and education. This finding suggests that gender and education moderated this 
relationship between depressive symptoms and MCI. Other GADS items which were 
significant predictors of Any-MCD from wave 1 to 2 including “felt slowed up in the 
morning” and “felt worse in the morning” did not reach significance for MCI from wave 1 to 
2. As mentioned previously this finding may be a result of the stability of Any-MCD 
diagnoses across time in comparison to MCI alone and reinforces analysing the two 
diagnostic categories concurrently. 
Symptoms of lacking energy/feeling tired, little interest or pleasure in doing things, 
and difficulties concentrating were more significant predictors of progression to cognitive 
impairment than other depressive symptoms. The three symptoms remained significant when 
adjusting for demographics and covariates and analysing progression to Any-MCD and were 
cross validated by two depressive measures (e.g. the symptoms on the GADS and the BPHQ 
reached significance when analysing progression to Any-MCD and MCI in Model 1).  
Overall, our findings extend previous research by indicating that specific depressive 
symptoms are predictive of progression to MCI and Any-MCD at one time point and that 
specific symptoms which remained significant and were cross validated between two 
measures were stronger predictors than other symptoms (Barnes et al., 2012; Gatz et al., 
2005; Geerlings et al., 2000; Diniz et al., 2013, Dotson et al., 2012, Ravaglia et al., 2008, 
Rosenberg et al., 2010, Yaffe et al., 1999). Our findings support previous literature, 
specifically, the hypothesis that depression is associated with significant cognitive deficits 
that may cumulate with those caused by the dementing disease to bring forward a diagnosis 
of dementia and the “reserve threshold theory” (Butters et al., 2008; Jorm, 2001). Our finding 
that concentration difficulties were a stronger predictor of progression to cognitive disorders 
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in comparison to other depressive symptoms may have reflected the accumulation of this 
symptom with other symptoms (e.g. associated with cognitive impairment) and resulted in an 
earlier diagnosis/progression to MCI and Any-MCD. While our finding that other mood-
related and behavioural depressive symptoms were predictive of progression to cognitive 
impairment may reflect the hypothesis that depression is associated with neural damage 
resulting in memory deficit and dementia (Jorm, 2001). This raises the question of whether 
individual depressive symptoms or a cluster of specific symptoms are the result of neural 
damage, however this is beyond the scope of review in this thesis and should be considered in 
future.  
Our finding that specific depressive symptoms are predictive of progression to 
cognitive disorders may have implications for past literature, specifically, the hypothesis that 
depression is prodromal to cognitive impairment (Jorm, 2001). Our finding that specific 
symptoms are predictive of progression could suggest that individuals presenting with 
specific symptoms of depression progress to a clear diagnosis of a cognitive disorder. 
However, our study focused on depressive symptoms as independent risk factors rather than 
prodromal features; therefore it is difficult to ascertain this distinction. Future research should 
consider whether distinct depressive symptoms are prodromal to cognitive disorders.  
The present results also indicate that a range of depressive symptoms (i.e. 
behavioural, mood and cognitive) were significant predictors of progression to cognitive 
disorders. This finding may reflect previous literature which outlines a specific cascade of 
biomarkers (physiological, biochemical and anatomical) that precede the onset of AD (Jack et 
al., 2010). Specifically, the range of significant depressive symptoms in the current research 
may reflect the substantial neurological changes occurring prior to the onset of cognitive 
impairment.  
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Study 2: Positive and Negative Affect and Progression to Cognitive Disorders  
Our findings from Study 2 indicate positive and negative affect did not significantly 
predict progression to cognitive impairment. Our findings are inconsistent with our 
hypothesis that low scores on positive affect would predict progression to cognitive 
impairment. Our results are also inconsistent with psychological theories and past research 
supporting a relationship between affect and cognition/cognitive impairment (Berger et al., 
1999; Bower, 1981; Bless & Tieldler, 2000; Carpenters et al., 2013; Gatz et al., 2005; Rowe 
et al., 2007; Schwarz, 1990). However past research has been limited to studies investigating 
depression and cognitive impairment therefore no specific affect measure was implemented 
or affect was induced within experimental groups and performance assessed on cognitive 
tasks (Berger et al., 1999; Carpenters et al., 2013; Gatz et al., 2005; Rowe et al., 2007). Our 
results are also inconsistent with other studies which included the PANAS and Bradburn 
Affect Balance Scale as measures of affect and support a relationship between affect and 
cognitive impairment (Christodoulou et al., 2009; Dolcos et al., 2012). It is hypothesized in 
the current study the PANAS did not tap into positive or negative affect well enough to 
identify these constructs therefore alternate measures of affect should be considered in future 
research.   
Positive Affect, Depressive Symptoms and Progression to Cognitive Disorders 
The findings in Study 1 support the relationship between depression and cognitive 
disorders however our results in Study 2 were not significant therefore do not support past 
research (Diniz et al., 2013; Gao et al., 2013).  The overall findings from the two studies are 
intriguing given that many of the significant symptoms in Study 1 were reflective of positive 
and negative affect. Specifically, symptoms of lacking energy, lost interest/pleasure, and loss 
of confidence are associated with positive affect (Watson et al., 1988). While symptoms of 
feeling down, depressed or hopeless and feeling bad about oneself represent emotional states 
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of negative affect (Watson et al., 2004). The discrepancy in our findings between the two 
studies, reinforces whether the PANAS tapped into positive and negative affect well enough 
to identify these constructs within a clinical population. To our knowledge there is a limited 
amount of research on the psychometric properties of the PANAS within a clinical sample, 
with studies restricted to non-clinical samples (Crawford & Henry, 2004), which may have 
impacted upon the current research.    
Limitations and Future Directions 
Limitations 
Limitations of the two studies have been discussed in depth previously in Study 1 and 
2 (see Chapters 4 and 5, Discussion). As previously stated, limitations in Study 1 included 
depressive measures which did not measure depressive symptoms separately, assessed 
depressive symptoms that occurred “recently,” excluded specific depressive symptoms, and 
included inherent self-report bias. Additional issues included the exclusion of analysis of 
BPHQ items as predictors of progression to cognitive disorders from wave 2 to 3 due to 
participants not endorsing items at baseline. Other limitations of Study 2 include the 
implementation of the PANAS as a measure of affect and questions about the extent to which 
it taps into constructs of positive and negative affect. Other limitations associated with 
PANAS include its apparent limited implementation within clinical populations (Crawford & 
Henry, 2004), the short time period it measures and choice to report feelings based on 2 
options (i.e. present moment/past week) and associated self-report bias. 
General limitations of the two studies include the decision to include only one 
baseline assessment of affect and depression. Changes may have occurred in depression and 
affect across time; therefore it is important to consider this trajectory and the effect upon 
cognitive impairment. As well, the small number of participants in the diagnostic categories, 
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(Any-MCD or MCI) in comparison to the large number of participants in the healthy 
categories, may have impacted upon the power within the analyses for the studies.   
Future directions 
Directions for future research include the inclusion of different measures of 
depression and affect across more than one time point to measure the trajectory of these 
constructs in relation to cognitive changes/diagnosis of cognitive disorders. It is also 
suggested that research include a two stage screening process during which individuals 
complete a depressive checklist/psychometric measure, after which individuals who endorse 
symptoms are assessed thoroughly through interview about these symptoms.  
To our knowledge this is the first study to investigate affect and depressive symptoms 
as predictors of progression to cognitive disorders across two time points. Other research is 
needed within this area to replicate and extend our current findings. Future research needs to 
investigate whether the symptoms that were stronger predictors than other symptoms (i.e. lost 
interest/pleasure, difficulties concentrating and lacking energy/feeling tired) collectively 
predict progression to cognitive disorders, while other clusters of significant depressive 
symptoms should also be investigated as predictors of progression to cognitive disorders.  
Another important point to consider from the present findings is that symptoms of positive 
and negative affect were significant on depressive measures but not specific affect measures 
(i.e. lacking energy, loss of confidence/interest, feeling bad about oneself and feeling down, 
depressed or hopeless). Future research should include a different measure of affect in 
conjunction with depressive measures to analyse whether affect and depressive symptoms 
reach concurrent significance for predicting cognitive impairment.  
Clinical Implications 
The results of the current research highlight the importance of further research in this 
field if we are to develop methods of monitoring specific depressive symptoms in individuals 
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aged 60 years and over and who are potentially at risk of developing a cognitive disorder. 
Continued research into the specific role of depressive symptoms may have clinical 
implications for health professionals to monitor clusters of depressive symptoms that may 
make it more likely for an individual to develop a cognitive disorder. It may also highlight 
the importance of not waiting for a clinical diagnosis of depression in order to screen for 
potential risk factors of cognitive impairment. Overall the current findings in conjunction 
with future research may result in the implementation of appropriate depressive measures in 
conjunction with interviewing of individuals aged 60 and over to screen for the presence of 
depressive symptoms. Earlier identification of these predictors may result in facilitating 
prompt intervention (medication or psychological treatment) which may target the depression 
and prevent or delay the course of progression to a cognitive disorder. However, the current 
clinical implications are preliminary and further research is required to increase our 
knowledge prior to the application of these findings within clinical settings. 
Conclusion 
Dementia is a significant health problem within Australia, with the rates of diagnosis 
predicted to increase in conjunction with associated medical costs within our ageing 
population (Access Economics, 2003; Australian Institute of Health and Welfare, 2012). Due 
to the widespread burden of this disease, much of the focus has turned to methods of risk 
reduction of dementia. The results of the current research suggest the importance of 
considering specific depressive symptoms in predicting progression to pre-clinical dementia 
syndromes including Any-MCD and MCI.  While additional research is needed to establish 
the role of affect in predicting progression to cognitive impairment. It is hoped that further 
research into the field will lead to a greater understanding of specific depressive symptoms 
and affect as predictors of progression to cognitive disorders, and in turn may have long-term 
clinical implications for the intervention and prevention/delay of cognitive disorders in 
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individuals aged 60 years and over. Overall, further research into this topic will help to 
manage the increasing problem of dementia within Australia by identifying possible risk 
factors, and lead to appropriate identification and reduction of onset of cognitive disorders to 
help the ageing population and associated burden of costs within Australia.   
 
 
 
  
144 
 
References  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
145 
 
Access Economics (2003). The dementia epidemic: Economic impact and positive solutions 
for Australia. Report for Alzheimer's Australia. Retrieved from: 
https://fightdementia.org.au/research-and-publications/reports-and-
publications/access-economics-reports 
 
Amado-Boccara, I., Gougoulis, N., Poirier Littre, M.F., Galinowski, A., & Loo, H. (1995). 
Effects of antidepressants on cognitive functions: A review. Neuroscience and 
Biobehavioural Reviews, 19(3), 479-493. Retrieved from 
http://www.journals.elsevier.com/neuroscience-and-biobehavioral-reviews/ 
 
Anstey, K.J., Dear, K., Christensen, H., & Jorm, A.F. ( 2005). Biomarkers, health, lifestyle, 
and demographic variables as correlates of reaction time performance in early, middle 
and late adulthood. . The Quarterly Journal of Experimental Psychology: A human 
experimental psychology, 58(1), 5-21.  
Retrieved from http://www.tandfonline.com/loi/pqja20 
 
Anstey, K. J., Cherbuin, N., Christensen, H., Burns, R., Reglade-Meslin, C., Salim, A., 
Kumar, R., Jorm, A.F., & Sachdev, P. (2008). Follow-up of Mild Cognitive 
Impairment and related disorders over four years in adults in their sixties: The PATH 
Through Life Study. Dementia and Geraitric Cognitive Disorders, 26, 226-233. doi: 
10.1159/000154646 
 
 
 
 
146 
 
Anstey, K. J., Burns, R.A., Birrell, C.L., Steel, D., Kiely, K.M., & Luszcz, M.A. (2010).  
Estimates of probable dementia prevalence from population-based surveys compared 
with dementia prevelance estimates based on meta-analyses. BMC Neurology, 62(10), 
1-12. Retrieved from http://www.biomedcentral.com/1471-2377/10/62 
 
Anstey, K.J., Christensen, H., Butterworth, P., Easteal, S., Mackinnon, A., Jacomb, T., 
Maxwell, K., Rodgers, B., Windsor, T., Cherbuin, N., & Jorm, A.F. (2012). Cohort 
Profile: The PATH through life project. International Journal of Epidemiology, 41, 
951-960. doi: 10.1093/ije/dyr025 
 
Anstey, K.J., Cherbuin, N., Eramudugolla, R., Sargent-Cox, K., Easteal, S., Kumar,  
 R., & Sachdev, P. (2013). Characterizing mild cognitive disorders in the  
 young-old over 8 years: Prevalence, estimated incidence, stability of diagnosis,  
 and impact on IADLs. Alzheimer’s & Dementia, 9, 640-648  
 doi: 10.1016/j.jalz.2012.11.013 
 
Ashby, F. G., Turken, A.U., & Isen, A.M. (1999). A neuropsychological theory of positive 
affect and it's influence on cognition. Psychological Review, 106, 529-550.  
doi: 10.1037/0033-295X.106.3.529 
 
 
American Psychiatric Association. (2012). DSM-5: The future of psychiatric diagnosis.   
Retrieved 14th November 2012, from http://www.dsm5.org/Pages/Default.aspx 
 
American Psychiatric Association. (2013). Diagnostic and statistical manual of mental 
disorders (5th ed.). Arlington, VA. 
 
  
 
147 
 
Australian Institute of Health and Welfare 2012. Dementia in Australia. Cat. no. AGE 70. 
Canberra: AIHW. Retreived from: http://www.aihw.gov.au/publication-
detail/?id=10737422958 
 
Baddeley, A., Emslie, H., & Nimmo-Smith, I. (1993). The Spot-the-Word test: A robust 
estimate of verbal intelligence based on lexical decision. British Journal of Clinical 
Psychology, 32, 55-65. doi: 10.1111/j.2044-8260.1993.tb01027.x 
 
Bankole, Cloniger, Roache, Bordnick, & Ruiz (2000). Age of onset as a discriminator  
between alcoholic subtypes in a treatment seeking outpatient population. The 
American Journal of Addictions, 9, 17-27.  
Retrieved from: http://www.ncbi.nlm.nih.gov/pubmed/10914290 
 
Barnes, D. E., Alexopoulos, G.S., Lopez, O.L., Williamson, J.D., & Yaffe, K. (2006).  
Depressive symptoms, vascular disease, and mild cognitive impairment. Archives of 
General Psychiatry, 63, 273-280. Retrieved from http://archpsych.jamanetwork/com/ 
 
Barnes, D.E., Yaffe, K., Byers, A.L., McCormick, M., Schafer, C., Whitmer, R.A. (2012).  
Midlife vs late-life depressive symptoms and risk of dementia: Differential effects for 
Alzheimer’s Disease and Vascular Dementia. Archives of General Psychiatry, 69, 
493-498. Retrieved from http://archpsych.jamanetwork/com/ 
 
Barrett-Connor, E., & Palinkas, L.A. . (1994). Low blood pressure and depression in older 
men: A population based study. British Medical Journal 308, 446-449. doi: 
http://dx.doi.org/10.1136/bmj.308.6926.446 
148 
 
Beck, A.T., Steer, R.A., Brown, G.K. (1996). Beck Depression Inventory Manual (2
nd
 ed).  
San Antonio: Psychological corporation.  
 
Berger, A. K., Fratiglioni, L., Forsell, Y., Winblad, B., & Backman, L. (1999). The 
occurrence of depressive symptoms in the preclinical phase of AD: A population 
based study. Neurology, 53(9), 1998-2002. Retreived from http://www.neurology.org/ 
 
 
Berry, D.S., & Hansen, J.S (1996). Positive affect, negative affect and social interaction. 
Journal of Personality and Social Psychology, 71, 796-809. Retrieved from 
http://psycnet.apa.org/index.cfm?fa=buy.optionToBuy&id=1996-06401-014 
 
Billioti de Gage, S., Begaud, B., Bazin, F., Verdoux, H., Dartigues, J.F., Peres, K., Kurth, T., 
& Pariente, A. (2012). Benzodiazepine use and risk of dementia: Prospective 
population based study. BMJ, 345, 1-12. doi: 10.1136/bmj.e6231 
 
Bixler, E.O., Vgontzas, A.N., LIn, H.M., Calhoun, S.L., Vela-Bueno, A., Kales, A. (2005). 
Excessive daytime sleepiness in a general population sample: The role of sleep apnea, 
age, obesity, diabetes and depression. The Journal of Endocrinology and Metabolism, 
90, 4510-4515. doi: 10.1210/jc.2005-0035 
 
Bless, H., & Fiedler, K. (2006). Mood and the regulation of information processing. In J.P 
Forgas (Eds.), Affect in social cognition and behaviour. New York: Psychology Press.  
 
 
  
 
149 
 
Borkowski, J., Benton, A.L., & Spreen, O. (1967). Word fluency and brain damage. 
Neuropsychologia, 5, 135-140.  
doi: http://dx.doi.org/10.1016/0028-3932(67)90015-2 
 
Borod, J. C., Goodglass, H., &, & Kaplan, E. (1980). Normative data on the Boston Naming 
Test. Journal of Clinical Neuropsychology, 2, 209-216. doi: 
10.1080/01688638008403793 
 
Bower, G.H. (1981). Mood and memory. American Psychologist, 36, 129-148. Retreived 
from http://www.apa.org/pubs/journals/amp/ 
 
Bradburn, N.M. (1969). The structure of psychological well-being. Chicago: Aldine.   
 
Bryan, J., & Tiggemann, M. (2001). The effect of weight-loss dieting on cognitive  
performance and psychological well-being in overweight women. Appetite, 36, 147-
156. doi: http://dx.doi.org/10.1006/appe.2000.0389 
 
Butters, M. A., Young, J.B., Lopez, O., Aizenstein, H.J., Mulstant, B.H., Reynolds, C.F., 
DeKosky, S.T., & Becker, J.T. (2008). Pathways linking late-life depression to 
persistent cognitive impairment. Dialogues in Clinical Neuroscience, 10(3), 345-357. 
Retrieved from http://www.dialogues-cns.org/ 
 
Cannon, D. S., Tiffany, S.T., Coon, H., Scholand, M.B., McMahon, W.M., & Leppert, M.F. 
(2007). The PHQ-9 as a brief assessment of lifetime major depression. Psychological 
Assessment, 19, 247-251. doi: 10.1037/1040-3590.19.2.247.  
150 
 
Carpenter, S. M., Peters, E., Vastfjall, D., & Isen, A.M. (2013). Positive feelings facilitate 
working memory and complex decision making among older adults. Cognition and 
Emotion, 27, 184-192. doi: 10.1080/02699931.2012.698251 
 
Castren, E., & Hen, R. (2013). Neuronal placisticy and antidepressant actions. Trends in 
Neuroscience, 36, 259-267. doi: 10.1016/j.tins.2012.12.010 
 
Cerejeira, J., Lagarto, L., & Mukaetova-Ladinska, E.B. (2012). Behavioral and psychological 
symptoms of dementia. Frontiers in Neurology, 3, doi: 10.3389/fneur.2012.00073   
 
Chen, P., Ganguli, M., Mulsant, B.H., & DeKosky, S.T. (1999). The temporal relationship 
between depressive symptoms and dementia. Archives of General Psychiatry, 56, 
261-266. doi: 10.1001/archpsyc.56.3.261. 
 
Chepnick, L. G., Cornew, L.A., & Farah, M.J. (2007). The influence of sad mood on 
cognition. Emotion, 7, 802-811. doi: 10.1037/1528-3542.7.4.802 
 
Cherbuin, N., & Anstey, K.J. (2012). The mediterranean diet is not related to cognitive 
change in a large prospective investigation: The PATH Through Life Study. American 
Journal of Geriatric Psychiatry, 20, 635-639. doi: 
http://dx.doi.org/10.1097/JGP.0b013e31823032a9 
 
  
  
 
151 
 
Christ, S. L., Lee, D.J., Flemming, L.E., LeBlanc, W.G., Arheart, K.L., Chung-Bridges, K., 
Caban, A.J., & McCollister, K.E. (2007). Employment and occupation effects on 
depressive symptoms in older americans: Does working past age 65 protect against 
depression? The Journals of Gerentology Series B: Psychological sciences and social 
sciences, 62(6), S399-S403. Retrieved from 
http://www.psychsocgerentology.oxfordjournals.org/ 
 
Christensen, H., Jorm, A.F., Mackinnon, A.J., Korten, A.E., Jacomb, P.A., Henderson, A.S., 
& Rodgers, B. (1999). Age differences in depression and anxiety symptoms: A 
structural equation modelling analysis of data from a general population sample. 
Psychological Medicine, 29, 325-339. Retrieved from 
http://journals.cambridge.org/action/displayJournal?jid=PSM 
 
Christodoulou, C., Melville, P., Scherl, W.F, Macallister, W.S., Abensur, R.L., Troxell, R.M., 
& Krupp, L.B. (2009). Negative affect predicts subsequent cognitive change in 
multiple sclerosis. Journal of International Neuropsychological Society, 15, 53-61. 
doi: 10.1017/S135561770809005X 
 
Crook, T., Bartus, R.T., Ferris, S.H., Whitehouse, P., Cohen, G.D., & Gershon, S. (1986). 
Age-associated memory impairment: Proposed diagnostic criteria and measures of 
clinical change-report of a nationale institute of mental health work group. 
Developmental Neuropsychology, 2, 261-276. doi: 10.1080/87565648609540348 
 
Crowley, K. (2011). Sleep and sleep disorders in older adults. Neuropsychology Review, 21, 
41-53. doi: 10.1007/s11065-010-9154-6 
152 
 
D'Anci, K. E., Watts, K.L., Kanarek, R.B., & Taylor, H.A. (2009). Low-carbohydrate weight-
loss diets. Effects on cognition and mood. Appetite, 52, 96-103. doi: 
http://dx.doi.org/10.1016/j.appet.2008.08.009 
 
Dartigues, J.F., Gagnon, M., Letenneur, L., Barberger-Gateau, P., Commenges, D., Evaldre, 
M., & Salamon, R. (1992). Principal lifetime occupation and cognitive impairment in 
a french elderly cohort (Paquid). American Journal of Epidemiology, 135, 981-988. 
Retrieved from: http://aje.oxfordjournals.org/ 
 
Delis, D. C., Kramer, J.H., & Kaplan, E.F. (1987). California Verbal Learning Test. San 
Antonio: Harcourt Brace, Psychological Corporation. 
 
Diniz, B.S., Butters, M.A., Albert, S.M., Dew, M.A., & Reynolds, C.F. (2013). Late  
life depression and risk of vascular dementia and Alzheimer’s disease: systematic 
review and meta-analysis of community based cohort studies. The British Journal of 
Psychiatry, 202, 329-335. doi: 10.1192/bjp.bp.112.118307 
 
Dixon, W.A., Heppner, P.P., & Anderson, W.P. (1991). Problem solving  
appraisal, stress, hopelessness and suicide ideation in a college population. Journal of 
Counselling Psychology, 38, 51-56. doi: 10.1037/0022-0167.38.1.51   
 
Dolcos, S., MacDonald, S.W.S., Braslavsky, A., Camicioli, R., & Dixon, R.A. (2012). Mild  
cognitive impairment is associated with selected functional markers: Integrating 
concurrent, longitudinal and stability effects. Neuropsychology, 26, 209-223.       
doi: 10.1037/a0026760 
 
  
 
153 
 
Dooley, D., Prause, J., & Ham-Rowbottom, K.A,. (2000). Underemployment and depression: 
Longitudinal relationships. Journal of Health and Social Behaviour, 41(4), 421-436. 
Retrieved from http://www.jstor.org/stable/2676295 
 
Dotson, V. M., Beydoun, M.A., & Zonderman, A.B. (2010). Recurrent depressive symptoms 
and the incidence of dementia and mild cognitive impairment. Neurology, 75, 27-34. 
doi: 10.1212/WNL.0b013e3181e62124 
 
Drapeau, J., Gosselin, N., Gagnon, L., Peretz, I., Lorrain, D. (2009). Emotional recognition 
from face, voice, and music in dementia of the Alzheimer type. Annals of the New 
York Academy of Sciences 1169, 342-345. doi: 10.1111/j.1749-6632.2009.04768.x 
 
Etgen, T., Sander, D., Bickel, H., & Forstl, H. (2011). Mild Cognitive Impairment and  
Dementia: The importance of modifiable risk factors. Deutsches Arzteblatt 
International, 108, 743-750. doi: 10.3238/arztebl.2011.0743 
 
Fitzpatrick, A., Kuller, L.H., Lopez, O.L., Dieher, P., O'Meara, E.S., Longstreth, W.T., & 
Luchsinger, J.A. (2009). Midlife and late-life obesity and the risk of dementia. JAMA 
Neurology, 66, 336-342.  Retrieved from 
http://archneur.jamanetwork.com/journal.aspx 
 
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975). Mini Mental State: A practical 
method for grading the cognitive state of patients for the clinicans. Journal of 
Psychiatric Research, 12, 189-198.  
Retrieved from: http://www.journals.elsevier.com/journal-of-psychiatric-research/  
 
154 
 
Fuhrer, R., Dufouil, C., & Dartigues, J.F. (2003). Exploring sex differences in the 
relationship between depressive symptoms and dementia incidence: Prospective 
results from the PAQUID study Journal of the American Geraitrics Society, 51(8), 
1055-1063. Retreived from http://www.americangeriatrics.org/ 
 
Gagnon, L. G., & Belleville, S. (2011). Working memory in mild cognitive impairment and 
Alzheimer’s disease: Contribution of forgetting and predictive value of complex span 
tasks. Neuropsychology, 25, 226-236. doi: 10.1037/a0020919 
 
Gallacher, J., Elwood, P., Pickering, J., Bayer, A., Fish, M., & Ben-Shlomo, Y. (2012). 
Benzodiazepine use and risk of dementia: Evidence from the Caerphilly Prospective 
Study (CaPS). Journal of Epidemiology and Community Health, 66, 869-873. doi: 
10.1136/jech-2011-200314 
 
Gao, Y., Huang, C., Zhao, K., Ma, L., Qiu, X., Zhang, L., Xiu, Y., Chen, L., Lu, W., Huang, 
C., Tang, Y., &  Xiao, Q. (2013). Depression as a risk factor for dementia and mild 
cognitive impairment: a meta analysis of longitudinal studies International Journal of 
Geriatric Psychiatry, 28, 441-449. doi: 10.1002/gps.3845  
 
Garson, G. D. (2013). Generalized linear models/generalized estimating equations. North 
Carolina, United States of America: Statistical Publishing Associates. 
 
Gatz, J. L., Tyas, S.L., St. John, P., & Montgomery, P. (2005). Do depressive symptoms 
predict Alzheimer's Disease and Dementia? The Journals of Gerontology, 60A,      
744-747. doi: 10.1093/gerona/60.6.744  
  
 
155 
 
Geerlings, M. I., Bouter, L.M., Schoevers, R., Beekman, A.T.F., Jonker, C., Deeg, D.J.H., 
Van Tilburg, W., Ader, H.J., & Schmand, B. (2000). Depression and risk of cognitive 
decline and Alzheimer's disease: Results of two prospective community based studies 
in the Netherlands. The British Journal of Psychiatry, 176, 568-575. doi: 
10.1192/bjp.176.6.568 
 
Geerlings, M.I., Schmand, B., Braam, A.W., Jonker, C., Bouter, L.M., & Tilburg, W. (2000). 
Depressive symptoms and risk of Azheimer's Disease in more highly educated older 
people. Journal of the American Geriatrics Society, 48, 1092-1097.  Retrieved from 
http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1532-5415 
 
Gillin, J.C., Duncan, W.C., Murphy, D.L., Post, R.M., Wehr, T.A., Goodwin, F.K., Wyatt, 
R.J., Bunney, W.E. (1981). Age-related changes in sleeping in depressed and normal 
subjects. Psychiatry Research, 4, 73-78.  Retrieved from 
http://www.journals.elsevier.com/psychiatry-research/ 
 
Goldberg, D., Bridges, K., Duncan-Jones, P., & Grayson, D. (1988). Detecting anxiety and 
depression in general medical settings. British Medical Journal, 297(6653), 897-899. 
Retrieved from: http://www.bmj.com/   
 
Grandner, M.A., Martin, J.L., Patel, N.P., Jackson, N.J., Gehrman, P.R., Pien, G., Perlis, 
M.L., Xie, D., Sha, D., Weaver, T., & Gooneratne, N.S. (2012). Age and sleep 
disturbances among American men and women: Data from the U.S behavioral risk 
factor surveillance study. Sleep, 35, 395-406. doi: 
http://dx.doi.org/10.5665/sleep.1704 
156 
 
Haimov, I., Hanuka, E., & Horowitz, Y. (2008). Chronic insomnia and cognitive functioning 
among older adults. Behavioral Sleep Medicine, 6, 32-54.  
doi: 10.1080/15402000701796080 
 
Hamilton, M. (1960). A rating scale for depression. Journal of Neurology, Neurosurgery and 
Psychiatry, 23, 56-62. Retrieved from http://jnnp.bmj.com/ 
 
Henderson, A.S., Jorm, A.F., Korten, A.E., Jacomb, P., Christensen, H., & Rodgers, B. 
(1998). Symptoms of depression and anxiety during adult life: Evidence for a decline 
in prevalance with age. Psychological Medicine, 28, 1321-1328. Retrieved from 
http://journals.cambridge.org/action/displayJournal?jid=PSM 
 
Hillman, C.H., Erickson, K.I., & Kramer, A.F. (2008). Be smart, exercise your heart:  
Exercise effects on brain and cognition. Nature Reviews Neuroscience, 9, 58-65.  
doi: 10.1038/nrn2298 
 
IBM SPSS. (2011). IBM SPSS Missing Values 20. Retrieved from  
http://public.dhe.ibm.com/software/analytics/spss/documentation/statistics/20.0/en/cli
ent/Manuals/IBM_SPSS_Missing_Values.pdf 
 
Jack, C. R., Petersen, R.C., Xu, Y.C., O'Brien, P.C., Smith, G.E., Ivnik, R.J., Boeve, B.F., 
Waring, S.C., Tangalos, E.G., & Kokmen, E. (1999). Prediction of AD with MRI-
based hippocampal volume in Mild Cognitive Impairment. Neurology, 52, 1397-1403. 
doi: 10.1212/WNL.52.7.1397 
  
 
157 
 
Jack, C.R., Knopman, D.S., Jagust, W.J., Shaw, L.M., Aisen, P.S., Weiner, M.W., Petersen, 
R.C., & Trojanowski, J.Q. (2010). Hypothetical model of dynamic biomarkers of the 
Alzheimer’s pathological cascade. Lancet Neurology 9, 119-128. doi: 10.1016/S1474-
4422(09)70299-6 
 
Jorm, A.F. (2001). History of depression as a risk factor for dementia: An updated review. 
Australian and New Zealand Journal of Psychiatry, 35, 776-781. doi: 10.1046/j.1440-
1614.2001.00967.x 
 
Jorm, A.F., Anstey, K.J., Christensen, H., & Rodgers, B. (2004). Gender differences in 
cognitive abilities: The mediating role of health state and health habits. 
 Intelligence 32, 7-23. doi: 10.1016/j.intell.2003.08.001 
 
Jorm, A.F., Dear, K.B., Burgess, N.M. (2005). Projections of future numbers of dementia  
cases in Australia with and without prevention. Australian and New Zealand Journal 
of Psychiatry, 39, 959-963. doi: 10.1080/j.1440-1614.2005.01713.x 
 
 
Jorm, A.F., Windsor, T.D., Dear, K.B.G., Anstey, K.J., Christensen, H., & Rodgers, B. 
(2005). Age group differences in psychological distress: The role of psychological 
risk factors that vary with age. Psychological Medicine, 35, 1253-1263. doi: 
10.1017/S0033291705004976 
 
Kaplan, E. F., Goodglass, H., & Weintraub, S. (1991). The Boston Naming Test. Boston: 
Psychological Corporation. 
 
158 
 
Koloski, N. A., Smith, N., Pachana, N.A., & Dobson, A. (2008). Performance of the 
Goldberg Anxiety and Depression Scale in older women. Age and Ageing, 37, 464-
467. doi: 10.1093/ageing/afn091 
 
Kral, V. A. (1962). Senescent forgetfulness: Benign and malignant. Canadian Medical 
Association Journal, 86(6), 257-260. Retrieved from: http://www.cmaj.ca/ 
 
Kroenke, K., Spitzer, R.L., Williams, J.B.W., & Lowe, B. (2010). The Patient Health 
Questionnaire somatic, anxiety and depressive symptom scales: A systematic review. 
General Hospital Psychiatry 32, 345-359. doi: 10.1016/j.genhosppsych.2010.03.006 
 
Kroger, E., Andel, R., Lindsay, J., Benounissa, Z., Verreault, R., & Laurin, D. (2008). Is 
complexity of work associated with risk of dementia? American Journal of 
Epidemiology, 167, 820-830. doi: 10.1093/aje/kwe382 
 
Lamers, F., Jonkers, C.C.M., Bosma, H., Penninx, B.W.J.H., Knottnerus, J.A., & Van Eijk, J. 
(2008). Summed score of the Patient Health Questionnaire -9 was a reliable and valid 
method for depression screening in chronically ill elderly patients. Journal of Clinical 
Epidemiology, 61, 679-687. doi: 10.1016/j.jclinepi.2007.07.018 
 
Laurin, D., Verreault, R., Lindsay, J., MacPherson, K., & Rockwood, K. (2001). Physical 
activity and risk of cognitive impairment and dementia in elderly persons. Archives of 
Neurology, 58(3), 498-504.  
Retrieved from http://www.archneur.jamnetwork.com/journal.aspx 
 
  
 
159 
 
Leonard, B. E. (2007). Inflammation, depression and dementia: Are they connected? 
Nuerochemical Research, 32, 1749-1756. doi: 10.1007/s11064-007-9385-y 
 
Levi, S., Le Roux, N., Eugene, E., & Poncer, J.C. (2015). Benzodiazepine ligands rapidly 
influence GABBA receptor diffusion and clustering at hippocampal inhibitory 
synapses. Neuropharmacology, 88, 199-208. doi: 10.1016/j.neuropharm.2014.06.002 
 
Lezak, M. D. (1995). Neuropsychological Assessment (3rd ed.). Oxford: Oxford University 
Press. 
 
Li, G., Wang, L.Y., Shofer, J.B., Thompson, M.L., Peskind, E.R., McCormick, W., Bowen, 
J.D., Crane, P.K., & Larson, E.B. (2011). Temporal relationship between depression 
and dementia. Archives of General Psychiatry, 68, 970-977.  
doi: 10.1001/archgenpsychiatry.2011.86 
 
Liversedge, S.P., & Findlay, J.M. (2000). Saccadic eye movements and cognition Trends in 
Cognitive Sciences 4, 6-14. Retrieved from http://www.cell.com/trends/cognitive-
sciences/home 
 
Maclean, M. H., Arnell, K.M., & Busseri, M.A. (2010). Disposition affect predicts temporal 
attention costs in the attentional blink paradigm. Cognition and Emotion, 24, 1431-
1438. doi: 10.1080/02699930903417897 
 
160 
 
Mata, J., Thompson, R.J., Jaeggi, S.M., Buschkuehl, M., Jonides, J., & Gotlib, I.H. (2012). 
Walk on the bright side: Physical activity and affect in major depressive disorder. 
Journal of Abnormal Psychology, 121, 297-308. doi: 10.1037/a0023533 
 
 
Matthews, F.E., Chatfield, M., Freeman, C., McCracken, C., & Brayne, C. (2004). Attrition 
and bias in the MRC cognitive function and ageing study: An epidemiological 
investigation. BMC Public Health, 4, 1-10.  
doi: 10.1186/1471-2458-4-121471-2458-4-12 
 
Mayberg, H. S., Liotti, M., Brannan, S.K., McGinnis, S., Mahurin, R.K., Jerabek, P.A., Silva, 
J.A., Tekell, J.L., Martin, C.C., Lancaster, J.L., & Fox, P.T. (1999). Reciprocal 
limbic-cortical function and negative mood: Converging PET findings in depression 
and normal sadness. The American Journal of Geriatric Psychiatry, 156(5), 675-682. 
Retrieved from http://ajp.psychiatryonline.org/journal.aspx?journalid=13 
 
Mazzoni, G., Gori, S., Formicola, G., Gneri, C., Massetani, R., Murri, L., & Salzarulo, P. 
(1999). Word recall correlates with sleep cycles in elderly subjects. Journal of Sleep 
Research, 8, 185-188. doi: 10.1046/j.1365-2869.1999.00154.x 
 
Miranda, R., Gallagher, M., Bauchner, B., Vaysman, R., & Morroquin, B.  
(2011). Cognitive inflexibility as a prospective prodictor of suicidal ideation among 
young adults with a suicide attempt history. Depression and Anxiety, 29, 180-186. doi: 
10.1002/da.20915   
 
Morris, J. C. (1993). The Clinical Dementia Rating (CDR): Current version and scoring rules. 
Neurology, 43(11), 2412-2414. Retrieved from http://www.neurology.org/  
  
 
161 
 
Morris, J. C., Heyman, A., & Mohs, R.C. (1989). The consortium to establish a registry for 
Alzheimer's disease (CERAD). Clinical and neuropsychological assessment of 
Alzheimer's disease Neurology, 39(9), 1159-1165. Retrieved from: 
http://www.neurology.org/ 
 
Nutt, D., Demyttenaere, K., Janka, Z., Aarre, T., Bourin, M., Canonico, P.L., Carrasco, J.L.,  
& Stahl, S. (2007). The other face of depression, reduced positive affect: the role of 
catecholamines in causation and cure. Journal of Psychopharmacology, 21, 461-471. 
doi: 10.1177/0269881106069938 
 
Ohayon, M.M. (2008). From wakefulness to excessive sleepiness: What we know and still 
need to know. Sleep Medicine Reviews, 12, 129-141. doi: 10.1016/j.smrv.2008.01.001 
 
Ottenbacher, K.J. (1998). Quantative evaluation of multiplicity in epidemiology and public 
health research. American Journal of Epidemiolgy, 147, 615-619.  Retrieved from: 
http://www.ncbi.nlm.nih.gov/pubmed/9554599 
 
Ownby, R. L., Crocco, E., Acevedo, A., John, V., & Loewenstein, D. (2006). Depression and 
the risk for Alzheimer Disease. Archives of General Psychiatry, 63, 530-538. doi: 
10.1001/archpsych.63.5.530 
 
Pallant, J. (2011). SPSS survival manual (4th ed.). Sydney, Australia: Allen & Unwin. 
 
162 
 
Pasco, J.A., Jacka, F.N., Williams, L.J., Brennan, S.L., Leslie, E., & Berk, M. (2011). Don’t 
worry, be active: Positive affect and habiutal physical activity. Australian and New 
Zealand Journal of Psychiatry, 45, 1047-1052. doi: 10.3109/00048674.2011.621063 
 
Paterniti, S., Dufouil, C., & Alperovitch, A. (2002). Long-term benzodiazepine use and 
cognitive decline in the elderly: The epidemiology of vascular aging study. Journal of 
Clinical Psychopharmacology, 22(3), 285-293. Retrieved from 
http://journals.lww.com/psychopharmacology/pages/default.aspx 
 
Paykel, E. S. (1977). Depression and appetite. Journal of Psychosomatic Research, 21, 401-
407. doi: http://dx.doi.org/10.1016/0022-3999(77)90049-6 
 
Penedo, F. J., & Dahn, J.R. (2005). Exercise and well-being: A review of mental and physical  
health benefits associated with physical activity. Current Opinion in Psychiatry, 
18(2), 189-193. Retrieved from http://journals.lww.com/co-
psychiatry/Pages/default.aspx 
 
Peterson, R. C., Smith, G.E., Waring, S.C., Ivnik, R.J., Tangalos, E.G., & Kokmen, E. 
(1999). Mild Cognitive Impairment: Clinical characterization and outcome. Archives 
of Neurology, 56(3), 303-308. Retrieved from http://archneur.jamanetwork/ 
 
Peterson, R.C. (2004). Mild cognitive impairment as a diagnostic entity. Journal of  
Internal Medicine, 256, 183-194. Retrieved from 
http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1365-
2796;jsessionid=162A28F901B296C78035ADFC31D25DF1.d03t02 
 
  
 
163 
 
Peterson, R.C., Caracciolo, B., Brayne, C., Gauthier, S., Jelic, V., & Fratiglioni, L. (2014). 
Mild cognitive impairment: a concept in evolution. Journal of Internal Medicine, 275, 
214-226. doi: 10.111/joim.12190 
 
Power, B.D., Alfonso, H., Flicker, L., Hankey, G.J., Yeap, B.B., Almeida, O.P. (2011). Body 
adiposity in later life and the incidence of dementia: The Health in Men Study. PLOS 
One, 6, 1-7. doi: 10.1371/journal.pone.0017902 
 
Priester, M.J., & Clum, G.A. (1993). Perceived problem solving ability as a  
predictor of depression, hopelessness, and suicide ideation in a college population. 
Journal of Counseling Psychology, 40, 79-85.  doi: 10.1037/0022- 0167.40.1.79. 
 
Prince, M., Albanese, E., Guerchet, M., & Prina, M. (2014). World Alzheimer Report 2014: 
Dementia and risk reduction an analysis of protective and modifiable risk factors. 
London: Alzheimer’s Disease International (ADI).  
 
 Prinz, P.N. (2004). Age impairments in sleep, metabolic and immune functions. 
Experimental Gerontology, 39, 1739-1743. doi: 10.1016/j.exger.2004.06.023 
 
Radloff, L.S. (1977). The CES-D Scale: A self-report depression scale for research in the 
general population. Applied Psychological Measurment, 1, 385-401. Retreived from  
http://www.sagepub.com/journalsProdDesc.nav?ct_p=&prodId=Journal200934 
 
  
164 
 
Ravaglia, G., Forti, P., Lucicesare, A., Rietti, E., Pisacane, N., Mariani, E., & Dalmonte, E. 
(2008). Prevalent depressive symptoms as a risk factor for conversion to mild 
cognitive impairment in an elderly italian cohort. The American Journal of Geriatric 
Psychiatry, 16, 834-843. doi: http://dx.doi.org/10.1097/JGP.0b013e318181f9b1 
 
Reitan, R. M. (1958). Validity of the Trail Making Test as an indicator of organic brain 
syndrome. Perceptual Motor Skills, 8(3), 271-276. doi: 10.2466/pms.1958.8.3.271  
 
Roberts, R.O., Geda, Y.E., Knopman, D.S., Cha, R.H., Pankratz, V.S., Boeve, B.F., 
Tangalos, E.G., Ivnik, R.J., Rocca, W.A., & Petersen, R.C. (2012). The incidence of 
MCI differs by subtype and is higher in med: the Mayo Clinic Study of Ageing. 
Neurology, 78, 342-351. doi: 10.1212/WNL.0b013e3182452862 
 
Rosenberg, P. B., Mielke, M.M., Xue, Q.L., & Carlson, C. (2010). Depressive symptoms 
predict incident cognitive impairment in cognitive healthy women. The American 
Journal of Geriatric Psychiatry, 18, 204-211. doi: 10.1097/JGP.0b013e3181c53487 
 
Rowe, G., Hirsh, J.B., & Anderson, A.K. (2007). Positive affect increases the breadth of 
attentional selection. Proceedings of National Academy of Sciences, 104, 383-388. 
doi: 10.1073/pnas.0605198104 
 
Rothman, K.J. (1990). No adjustments are needed for multiple comparisons. Epidemiology, 1, 
43-46. Retrieved from: http://www.ncbi.nlm.nih.gov/pubmed/2081237 
 
  
 
165 
 
Santangelo, G., Vitale, C., Trojano, L., Longo, K., Cozzolino, A., Grossi, D., Barone, P. 
(2009). Relationship between depression and cognitive dysfunctions in Parkinson's 
disease without dementia. Journal of Neurology, 256, 632-638. doi: 10.1007/s00415-
009-0146-5 
 
Sattler, C., Toro, P., Schonknecht, P., & Schroder, J. (2012). Cognitive activity, education 
and socioeconomic status as preventive factors for mild cognitive impairment and 
Alzheimer’s disease. Psychiatry Research, 196, 90-95. doi: 
10.1016/j.psychres.2011.11.012 
 
Saunders, N. L. J., & Summers, M.J.  (2011). Longitudinal deficits to attention, executive, 
and working memory in subtypes of mild cognitive impairment. Neuropsychology, 
25, 237-248. doi: 10.1037/a0021134 
 
 
Schafer, J.L., & Graham, J.W. (2002). Missing data: Our view of the state of the art. 
Psychological Methods, 7, 147-177. doi: 10.1037//1082-989X.7.2.147 
 
 
Schwarz, N. (1990) Feelings as information: Information and motivational functions of 
affective states. In E.T., Higgins & R. Sorrentino (Eds.), Handbook of motivation and 
cognition: Foundations of social behaviour (pp. 527-561). New York: Guilford Press. 
 
Sobin, C., & Sackeim, H.A. (1997). Psychomotor symptoms of depression. The American 
Journal of Psychiatry 154, 4-17.  Retrieved from http://ajp.psychiatryonline.org/ 
 
166 
 
Smith, A. (1982). Symbol Digit Modalities Test (SDMT) Manual, revised edition. Los 
Angeles: Western Psychological Services. 
 
Spinhoven, P., Elizinga, B.M., Hovens, J.G.F.M., Roelofs, K., Van Oppen, P., Zitman, F.G., 
& Penninx, B.W.J.H. (2011). Positive and negative life events and personality traits in 
predicting course of depression and anxiety. Acta Psychiatrica Scandinavica, 124, 
462-473. doi: 10.1111/j.1600-0447.2011.01753.x 
 
Spitzer, R. L., Kroenke, K., & Williams, J. B. (1999). Validity and utility of a self report 
version of PRIME-MD: the PHQ primary care study. The Journal of the American 
Medical Association (JAMA), 282, 1737-1744. doi: 10.1001/jama.282.18.1737.  
Spitzer, R.L., Williams, J.B.W., Kroenke, K., Hornyak, R., & McMurray, MD. 
(2000). Validity and utility of the PRIME-MD Patient Health Questionanaire in 
assessment of 3000 obstetric-gynecologic patients: The PRIME-MD Patient Health 
Questionnaire Obstetrics-Gynecology Study. American Journal of Obstetrics and 
Gynecology, 183, 759-769. doi: 10.1067/mob.2000.106580 
 
Spoletini, I., Marra, C., Di Iulio, F., Gianni, W., Sancesario, G., Giubilei, F., Trequattrini, A., 
Bria, P., Caltagirone, C., & Spalletta, G. (2008). Facial emotion recognition deficit in 
Amnestic Mild Cognitive Impairment and Alzheimer Disease. The American Journal 
of Geriatric Psychiatry, 16. doi: 10.1097/JGP.0b013e318165dbce. 
 
 
 
  
 
167 
 
Stafford, M., Hemingway, H., Stansfield, S.A., Brunner, E., & Marmot, M. (1998). 
Behavioural and biological correlates of physical functioning in middle aged office 
workers: The UK Whitehall II Study. Journal of Epidemiology and Community 
Health, 52, 353-358. doi:10.1136/jech.52.6.353 
 
Steffens, D. C., Otey, E., Alexopoulos, G.S., Butters, M.A., Cuthbert, B., Ganguli, M., 
Gedas, Y., Hendrie, H., Krishnan, R., Kumar, A., Lopez, O., Lyketsos, C., Mast, B.T., 
Morris, J., Norton, M.C., Peavy, G.M., Peterson, R.C., Reynolds, C.F., Sallowat, S., 
Welsh-Bohmer, K.A., & Yesavage, J. (2006). Perspectives on depression, mild 
cognitive impairment, and cognitive decline. Archives of General Psychiatry, 63,  
130-138. doi: 10.1001/archpsyc.63.2.130 
 
Stewart, R., Masaki, K., Xue, Q-L., Peila, R., Petrovitch, H., White, L.R., & Launer, L.J. 
(2005). A 32-year prospective study of change in body weight and incident dementia: 
The Honolulu-Asia Aging Study. JAMA Neurology, 62, 55-60. Retrieved from 
http://archneur.jamanetwork.com/journal.aspx 
 
Taler, V. P., N.A. (2008). Language performance in Alzheimer’s disease and mild cognitive 
impairment: A comparative review. Journal of Clinical and Experimental 
Neuropsychology, 30, 501-556. doi: 10.1080/13803390701550128 
 
Tifin, J. (1968). Purdue Pegboard. Examiners Manual. Rosemont: London House. 
 
Tsuno, N., Besset, A., & Ritchie, K. (2005). Sleep and depression. Journal of Clinical 
Psychiatry, 66, 1254-1269. doi: 10.4088/JCP.v66n1008 
168 
 
Twisk, J. W. R. (2003). Applied Longitudinal Data Analysis for Epidemiology: A Practical 
Guide. Cambridge United Kingdom: Cambridge University Press. 
 
Valenzuela, M. J., & Sachdev, P. (2006). Brain reserve and cognitive decline: A non-
parametric systematic view. Psychological Medicine, 36, 1065-1073. doi: 
10.1017/S0033291706007744 
 
Van Dongen, H. P. A., Maislin, G., Mullington, J.M., & Dinges, D.F. (2003). The cumulative 
cost of additional wakefulness: Dose-response effects on neurobehavioral functions 
and sleep physiology from chronic sleep restriction and total sleep deprivation. Sleep, 
26(2), 117-126. Retreived from http://www.journalsleep.org/ 
 
Videbech, P., & Ravnkilde, B. (2004). Hippocampal volume and depression: A meta-analysis 
of MRI studies. The American Journal of Psychiatry, 161, 1957-1966.                   
doi: 10.1176/appi.ajp.161.11.1957 
 
Virtanen, M., Singh-Manoux, A., Ferrie, J.E., Gimeno, D., Marmot, M.G., Elovainio, M., 
Jokela, M., Vahtera, J., & Kivimaki, M. (2009). Long working hours and cognitive 
function: The Whitehall II Study. The American Journal of Epidemiology, 169, 596-
605. doi: 10.1093/aje/kwn382 
 
Wang, H.X., Karp, A., Winblad, B., & Fratiglioni, L. (2002). Late-life engagement in social 
and leisure activities is associated with decreased risk of dementia: A longitudinal 
study from the Kungsholmen Project. American Journal of Epidemiology, 155, 1081-
1087. Retrieved from http://aje.oxfordjournals.org/ 
  
 
169 
 
Watson, D., Clark, L.A., & Tellegen, A. (1988). Development and validation of brief 
measure of positive and negative affect: The PANAS scales. Journal of Personality 
and Social Psychology, 54, 1063-1070. doi: 10.1037/0022-3514.54.6.1063 
 
Williams, J.B.W. (2001). Standardizing the Hamilton Depression Rating Scale: Past, present 
and future. European Archives of Psychiatry and Clinical Neuroscience, 251, 6-12. 
Retrieved from http://www.springer.com/medicine/psychiatry/journal/406 
 
Wimo, A., Jonsson, L., Bond, J., Prince, M., & Winblad, B. (2013). The worldwide economic  
impact of dementia 2010. Alzheimers & Dementia: The journal of the alzheimers 
association, 9, 1-11. doi: 10.1016/j.jalz.2012.11.006 
 
World Health Organization (WHO) Collaborating Centre for Evidence in Mental Health 
Policy. (2004). Treatment Protocol Project. Management of Mental Disorders (4
th
 ed). 
Sydney, Australia.  
 
Winbald, B., Plamer, K., Kivipelto, M., Jelic, V., Fratiglioni, L., Wahlund, L., Nordberg, A., 
Backman, L., Albert, M., Almkvist, O., Arai, H., Basun, H., Blennow, K., De Leon, 
M., Decarli, C., Erkinjuntti, T., Giacobini, E., Graff, C., Hardy, J., Jack, C., Jorm, A., 
Ritchie, K., Van Duijn, C., Visser, P., & Peterson, R.C. (2004). Mild cognitive 
impairment –beyond controversies, towards a consensus: report of the international 
working group on mild cognitive impairment. Journal of Internal Medicine, 256, 240-
246. doi: 10.1111/j.1365-2796.2004.01380.x 
 
170 
 
Yaffe, K., Blackwell, T., Gore, R., Sands, L., Reus, V., & Browner, W.S. (1999). Depressive 
symptoms and cognitive decline in nondemented elderly women. Archives of General 
Psychiatry, 56, 425-430. doi: 10.1001/archpsych.56.5.425 
  
  
 
171 
 
Appendices 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
172 
 
Appendix A. Structured Clinical Assessment for Dementia 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
173 
 
Structured Clinical Assessment for Dementia 
 
XII.  Diagnostic Formulation 
 
This is a summary section, to be completed after evaluating all information.  The neuropsychological 
and neuroimaging data should be available for this.   
 
 
DSM-V Major Neurocognitive Disorder     
                
A Both of the following:       
 
 No Yes u/k  
                
A1. 
Concern of self or informant of significant cognitive 
decline 0 1 8 
A2. Substantial impairment on at least one domain:   0 1 8  
                
a)    Complex Attention        
b)    Executive Function        
c)     Learning and Memory        
d)    Language          
e)    Perceptual Motor        
f)     Social cognition        
                
B A1 & A2 each interfere with independence       
  at a minimum requiring assistance with complex IADLs 0 1 8 
                
C 
Not exclusively during 
delirium       0 1 8 
                
D Not due to an Axis I disorder (depression, Schizophrenia) 0 1 8 
     
Does participant meet DSM-V Major Neurocognitive 
Disorder?       0 1 8 
     
If dementia absent, go to Minor Cognitive Disorder. 
DSM-V Minor Neurocognitive Disorder       
                 
A Both of the following:         No Yes u/k   
                
A1. 
Concern of self or informant of significant cognitive 
decline 0 1 8 
A2. Substantial impairment on at least one domain:   0 1 8  
                
a)     Complex Attention        
b)    Executive Function        
c)     Learning and Memory        
d)    Language          
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e)     Perceptual Motor        
f)     Social cognition        
                
B A1 & A2 each DO NOT interfere with independence     
  
complex IADLs preserved but need greater effort or 
compensation 0 1 8 
                
C 
Not exclusively during 
delirium       0 1 8 
                
D Not due to an Axis I disorder (depression, Schizophrenia) 0 1 8 
                
Does participant meet criteria for 
a Minor N-C Disorder?       0 1 8 
 
 
1. DSM-IV Dementia 
 
Q901A Both of the following:       No Yes u/k 
 
 A1. Memory Impairment      0 1 8 
 
 A2. One (or more) of following: 
 
a) Aphasia   
b) Apraxia 
c) Agnosia 
d) Disturbance executive functioning 
 
Q901B A1 & A2 each cause significant social/occup. 
  dysfunction & represent a decline    0 1 8 
 
Q901E Not exclusively during delirium      0 1 8 
 
Q901F Not due to an Axis I disorder (depression, 
Schizophrenia)       0 1 8 
 
 
Q91 Does participant meet DSM-IV criteria for Dementia?   0 1 8 
 
If Yes, 
 
Q91a Age of onset ____________ years 
 
 Associated with       
          No      Yes      u/k 
Q91b  Delirium     0 1 8 
Q91c  Delusions     0 1 8 
Q91d  Depressed Mood    0 1 8 
 
 
If dementia absent, go to Mild Cognitive Disorder. 
 
2. Alzheimer’s Disease Diagnosis (NINCDS  -  ADRDA criteria) 
 
If DSM-IV diagnosis of Dementia, does participant meet following criteria: 
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1. Probable AD        No   Yes   u/k 
 
Q92a Progressive worsening  of memory and/or language,   0 1 8 
motor skills or perception. 
 
Q92b       Onset between 40 & 90 years.     0 1 8 
 
Q92c Absence of systemic disorders or other brain    0 1 8 
diseases that may account for cognitive deficits. 
 
Supported by  (not essential) 
  
Q92d  Family history of similar disorders    0 1 8 
 
Q92e  Normal LP       0 1 8 
 
Q92f  Nil or non-specific EEG abnormality    0 1 8 
 
Q92g  CT/MRI  atrophy, especially if progressive   0 1 8 
 
 
2. Possible AD 
 
Q92h  If (a) & (b) above, but systemic or neurologic    0 1 8 
disorder not sufficient to cause dementia  
OR 
 
Q92i  onset, presentation, or course aytpical    0 1 8 
 
Q93a  Does participant meet criteria for AD. - Probable   0 1 8 
 
Q93b                                                     (or)       - Possible  0 1 8 
 
 
 
3.  Other Disorders causing Dementia 
 
Encircle the appropriate items below & state whether the item is likely to be contributing to the 
dementia, or to be the major causative factor.   (see back of page for diagnosis).      
           
                 Yes    Yes     Yes  
       Absent   Major   sec   not related  
      
Q94a Cerebrovascular disease 0 1    2       3   ___________________ 
 
Q94b Major Depression  0 1    2       3   ___________________ 
 
Q94c Drug/substance toxicity,  0 1    2       3   ___________________ 
delirium 
 
Q94d Alcohol Abuse/Dep  0 1    2       3   ___________________ 
 
Q94e Parkinson’s Disease  0 1    2       3   ___________________ 
 
Q94f Thyroid Disease  0 1    2       3   ___________________ 
 
Q94g B12 deficiency   0 1    2       3   ___________________ 
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Q94h Head trauma   0 1    2       3   ___________________ 
 
Q94i Down Syndrome  0 1    2       3   ___________________ 
 
Q94j Mental Retardation  0 1    2       3   ___________________ 
 
Q94k Other Psychiatric Disorder 0 1    2       3   ___________________ 
(e.g. Schizophrenia) 
 
Q94l Huntington’s Disease  0 1    2       3   ___________________ 
 
Q94m Fronto-temporal dementia 0 1    2       3   ___________________ 
 
Q94n HIV/AIDS   0 1    2       3   ___________________ 
 
Q94o Syphilis    0 1    2       3   ___________________ 
 
Q94p Prog Supranunclear Palsy 0 1    2       3   ___________________  
 
Q94q Normal Pressure Hydrocephalus0 1    2       3   ___________________ 
 
Q94r Other neurolologic/medical 0 1    2       3   ___________________ 
disorder (e.g. brain tumour,  
multiple sclerosis, metabolic disorder,  
CNS infection etc.) 
 
If yes to items above, specify basis of diagnosis.______________________ 
 
________________________________________________________________ 
 
________________________________________________________________ 
 
________________________________________________________________ 
 
________________________________________________________________ 
 
________________________________________________________________ 
 
________________________________________________________________ 
 
________________________________________________________________ 
 
________________________________________________________________ 
 
If yes to A, E or M, go to the Criteria for these disorders. 
 
4. Vascular Dementia  (NINDS-AIREN Criteria) 
 
4.1 Probable V-D         No   Yes   u/k 
 
Q95a1  1. Dementia present       0 1 8 
Memory impaired, plus  
Two or more other cognitive domains impaired 
 
Q95a2 Cardiovascular disease present.      0 1 8 
 
Q95a3 a)Focal signs on neurol exam consistent with CVD   0 1 8 
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Q95a  b)  Neuroimaging evidence (CT/MRT)    0 1 8 
               (from one of the following)           No      Yes      u/k 
Q95b1 multiple large infarcts    0 1 8 
Q95b2 single strategic impact    0 1 8 
Q95b3 multiple lacunes    0 1 8 
Q95b4 extensive white matter lesions  0 1 8 
 
                                                                                     No   Yes   u/k 
Q95c 2. Relationship between CVD & Dementia                         0      1    8 
      (from one of the following}    No      Yes      u/k 
      Q95c1 Onset of dementia within 3 months of stroke  0 1 8 
      Q95c2 Abrupt deterioration     0 1 8 
      Q95c3 Fluctuating, step-wise progression   0 1 8 
 
Q95d  3. Participant does not have a gradual & early onset  0 1 8 
of memory deficits & slow progression of deficits 
in language, praxia, and gnosis without  
corresponding brain lesions 
 
4.2  Possible VaD   
 
  As above, but one of the following is ‘Yes” 
 
Q96a  Brain atrophy       0 1 8 
Q96b  Absence of clear temporal relationship    0 1 8 
Q96c  Subtle onset and variable course with    0 1 8 
       evidence of CVD 
 
 
Does participant meet criteria for VaD?   Q97a  Probable 0 1 8 
 
                                                                       Q97b  Possible 0 1 8 
 
       
 
5. Dementia with Lewy Bodies    (McKeith et al, 1994) 
 
   
Q98a  Dementia present      0 1 8 
 
Q98b Fluctuating cognitive impairment affecting    0 1 8 
memory & other higher cortical functions 
 
Q98c At least one of the following:      0 1 8 
 
Q98c1 Varied/auditory hallucinations    0 1 8 
   with or without delusions 
 
Q98c2 Mild spontaneous EPS or neuroleptic-   0 1 8 
sensitivity 
 
Q98c3 Repeated unexplained falls and/or   0 1 8 
transient clouding or LOC 
 
 
Q98d  Clinical features persistent over many months   0 1 8 
 
Q98e  No medical cause of delirium     0 1 8 
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Q98f  No history or clinical evidence of    0 1 8 
       cerebral ischaemic changes  
 
 
Q99 Does participant meet criteria for DLB?    0 1 8 
 
6.  Dementia with Parkinson’s Disease     No   Yes   u/k 
 
Q100a  Does participant have PD?     0 1 8 
 
    At least 2 of the following [if not treated with L-Dopa] 
 
Q100a1 Tremor at rest    0 1 8 
 
Q100a2 Rigidity     0 1 8 
 
Q100a3 Shuffling gait    0 1 8 
 
Q1004 Bradykinesia    0 1 8 
   
Q100a5 Postural instability   0 1 8 
 
Q100b  Does participant have one of the following features:  0 1 8 
 
Q100b1 Non-response to L-Dopa  0 1 8 
 
 Q100b2 Gaze palsy    0 1 8 
 
Q100c Was participant free of EPSE – inducing   0 1 8 
medication for past 6 months? 
 
Q100d Did the PD begin one year of more before   0 1 8 
dementia recognized? 
 
Q101  If yes to 1, 3 & 4, diagnose PD with dementia   0 1 8 
 
Q102  If yes to all four items, diagnose Atypical PD with dementia 0 1 8 
 
Q103  If only one item of (1) endorsed, diagnose  ‘Associated EPS’ 0 1 8 
 
 
 
7. Fronto-Temporal Dementia   {Consensus Criteria} 
 
Q104a Insidious onset and slow progression of deficits    0 1 8 
 
Q104b1 (A)  Early behaviour disorder characterized by loss of personal   0 1 8 
Or social awareness, disinhibition, mental rigidity, stereotyped  
behaviour, impulsivity, &/or lack of insight 
         (or) 
Q104b2 (B) Progressive speech impairment     0 1 8 
 
Q104c Neuroimaging evidence (CT/MRI and/or SPECT/PET)  0 1 8 
of predominant frontal and/or anterior temporal lobe abnormality 
 
Q104d Neuropsychology: significant failure on “frontal tests” in the   0 1 8 
absence of severe amnesia, aphasia or perceptuo-spatial disorder. 
 
Supportive Features 
Q105a Onset < 65 years       0 1 8 
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Q105b Positive Family History       0 1 8 
 
Q105c Motor neurone disease (bulbar palsy, muscular    0 1 8 
  weakness & wasting, fasciculations) 
 
 
Q106  Does participant meet criteria for FTD?   0 1 8 
 
 
8. Amnestic Disorder  (DSM-IV)      No   Yes   u/k 
 
Q107a Memory impairment       0 1 8 
Q107b Causes significant impairment of social/occupational   0 1 8 
functioning & decline from previous level      
Q107c Not exclusively due to delirium or dementia    0 1 8 
Q107d Direct physiological consequence of medical condition   0 1 8 
 
Q108  Does participant meet criteria for Amnestic Syndrome 0 1 8 
 
9.  Mild Neurocognitive Disorder (DSM-IV) 
Q109a Two or more of the following impairments, lasting > 2 weeks  0 1 8 
  
Q109b1 Memory (reduced learning or recall of information)   0 1 8 
Q109b2 Executive functioning       0 1 8 
Q109b3 Attention or speed of information processing    0 1 8 
Q109b4 Perceptual – motor abilities      0 1 8 
Q109b5 Language (e.g. comprehension, word finding)    0 1 8 
 
Q109c A neurological or general medical disorder is     0 1 8 
judged to be aetiologically related  
 
Q109d Neuropsychological testing supports abnormality   0 1 8 
or decline in performance 
 
Q109e Deficits cause distress or impairment in    0 1 8 
social/occupational/other functions 
 
Q109f Does not meet criteria for delirium, dementia    0 1 8 
amnestic syndrome, and not better accounted 
for by another mental disorder (e.g. Major Depression, 
or Substance-Related Disorder) 
 
 
Q110  Does participant meet criteria for a Mild N-C Disorder?  0 1 8 
 
10.  Other Cognitive Disorder (DSM-IV) 
 
Q111  Participant has mild neurocognitive impairment due to  
medical condition       0    1 8 
 
Q112  Does not meet criteria for any of the above   0    1 8 
 
Q113  Does participant meet criteria for Other Cognitive Disorder? 0 1 8 
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11.  Age Associated Memory Impairment (Crook et al. 1986) 
 
Q114  Participant complains of memory loss (include loss reflected in   
everyday problems such as remembering names, misplacing  
objects, remembering multiple items in shopping lists, problems 
remembering telephone numbers or postcodes, difficulty 
recalling information quickly). Onset of memory loss must be 
described as gradual (see Q20).     0    1 8 
 
Q115  Memory performance below 6 on the immediate CVLT  0    1 8 
 
Q116 Spot-The-Word score over 49     0 1 8 
 
Q117 MMSE score 24 or above      0 1 8 
 
Q118 No evidence of delirium, confusion (see Q22a)   0 1 8 
 
Q119 No neurological disorder that could produce cognitive 
deterioration as determined by history, clinical neurological 
examination, and, if indicated, neuroradiologic examination. 
eg. AD, Parkinson’s disease, stroke, intracranial 
haemorrhage, local brain lesions including tumors, and 
normal pressure hydrocephalus  
          0 1 8 
Q120  No history of any infective or inflammatory brain disease  0 1 8 
 
Q121  No evidence of significant cerebral vascular pathology as determined by neurological 
examination 
        0 1 8 
 
Q122 No history of repeated minor head injury or a period of unconsciousness lasting an hour or 
more  
        0 1 8 
 
Q123 No current psychiatric diagnosis of depression, mania or major psychiatric disorder  
(see q23a to q26i, q28a) 
      0 1 8 
 
Q124 No diagnosis or history of alcoholism or drug abuse   0 1 8 
 
Q125      No evidence of depression as determined by clinical examination  0 1 8 
for DSM_IV depression 
 
Q126  No evidence of medical disorder that could produce cognitive  0 1 8 
deterioration including renal, respiratory, cardiac, and 
hepatic disease, diabetes mellitus unless well controlled, 
endocrine, metabolic, or haematologic disturbances; and 
malignancy not in remission for more than two years.  
Determination should be based on complete medical history, 
clinical examination and appropriate lab tests   
 
Q127 No evidence of any psychotrophic drug or any other drug that may significantly affect 
cognitive functioning during the month prior to psychometric testing (see q67) 
 
        0 1 8 
 
Q128  Participant meets all criteria and thus meets criteria for AAMI  0 1 8 
 MCI Criteria No Yes 
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1 Participant is not normal and not demented 0 1 
 If q1 = 1, go to q2   
2 Is cognitive decline:   
2a Self and/or informant report and impairment on objective cognitive tasks? 0 1 
2b Evidence of decline over time on objective cognitive tasks 0 1 
2c 
Preserved basic activities of daily living/  
Minimal impairment in complex instrumental functions  
0 1 
3 Diagnosis: Does participant have MCI? (If 2a or 2b=1; and 2c =1) 0 1 
 If q3 =1, go to q4   
4 
 
MCI SUBTYPES 
  
 Does the participant have:   
4a Memory impairment 0 1 
 
If q4a=0, go to q8 
If q4a=1, go to q5 
  
5 AMNESTIC SUBTYPE   
5a Frontal executive function impairment 0 1 
5b Language impairment 0 1 
5c Visuospatial function impairment 0 1 
 
If only one of q5a or q5b or q5c =1, go to q6 
If two or more of q5a or q5b or q5c=1, go to q7 
  
6 Diagnosis: Amnestic single domain 0 1 
7 Diagnosis: Amnestic multiple domain 0 1 
8 NON-AMNESTIC SUBTYPE   
8a Frontal executive function impairment 0 1 
8b Language impairment 0 1 
8c Visuospatial function impairment 0 1 
 
If only one of q8a or q8b orq8c =1, go to q9  
If two or more of q8a or q8b or q8c =1, go to q10 
  
9 Diagnosis: Non-amnestic single domain  0 1 
10 Diagnosis: Non-amnestic multiple domain  0 1 
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13.  Aging-Associated Cognitive Decline (Levy et al., 1994) 
 
Q135  Report by participant or informant that cognitive (memory and/or other) function has 
declined         0    1 8 
 
Q136  Onset is gradual and has been present for at least six months 0    1 8 
 
Q137 Difficulties in one of the following areas: memory and learning; attention and 
concentration; thinking, (eg. Problem solving, abstraction); language (eg. Comprehension, 
word finding); visuospatial functioning      
         0    1 8 
 
Q138 There is an abnormality of performance on quantitative cognitive assessments for which 
age and education norms are available for relatively healthy individuals.  Performance 
must be below 1SD on one of the following tests: SDMT, CVLT immediate, and MMSE 
adjusted for education.   
  
 Education level 
1 
Education level 
2 
Education level 
3 
SDMT 36 40 43 
CVLT immediate 4 5 5 
MMSE 27 28 29 
 
          0    1 8 
 
Q139 None of the present existing: dementia, MCD (i.e. no objective evidence from physical and 
neurological examination or lab tests and no history of cerebral disease, damage, or 
dysfunction or of systemic physical disorder known to cause cerebral dysfunction) 
depression, anxiety, or other significant psychiatric disorders, organic amnestic syndrome, 
delirium, postencephalic syndrome; post concussional syndrome, cognitive impairment 
due to psycho-active substance abuse or the effects of any centrally active drug. 
  
 
         0    1 8 
 
Q140  Participant meets all criteria and thus meets criteria for AACD 0 1 8 
 
14.  Mild Cognitive Difficulties (CMHR impairment) 
 
  Participant has a MCD due to one or more of  
Q141  Memory impairment      0    1 8 
Q142  Aphasia       0    1 8 
Q143  Apraxia        0    1 8 
Q144  Agnosia       0    1 8 
Q145  Executive functioning disturbance    0    1 8 
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Appendix B. Overall Diagnostic Criteria for Cognitive Disorders Across Waves 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
184 
 
Overall Diagnostic Criteria for Cognitive Disorders Across Waves 
 
Diagnostic criteria for amnestic MCI (waves 1 and 2)  
1.  Memory complaint preferably corroborated by an informant 
2.  Objective memory impairment  
3. Normal general cognitive function (MMSE 26 or above and overall IQ not significantly 
affected) 
4.  Intact activities of daily living 
 
Diagnostic criteria for MCI (waves 3)  
1. Not normal, absence of dementia 
2. Cognitive decline 
 a) subjective (self and/or informant report) 
     b) objective 
3. Some decline in function  
4. Preserved basic ADL/minimal impairment in complex IADLs 
  
 
Diagnostic criteria for AAMI (all waves)  
1.  Subject complaints of memory loss 
2.  Memory performance below 6 on the immediate California 
Verbal Learning Test 
3.  Spot-The-Word score over 49 
4.  MMSE score 24 or above 
5.  No evidence of delirium, confusion 
6.  No neurological disorder that could produce cognitive deterioration as determined by 
history, clinical neurological examination and, if indicated, neuroradiologic examination 
7.  No history of any infective or inflammatory brain disease 
8.  No evidence of significant cerebral vascular pathology as determined by neurological 
examination 
9.  No history of repeated minor head injury or a period of unconsciousness lasting an hour or 
more 
10. No current psychiatric diagnosis of depression, mania or major psychiatric disorder 
11. No diagnosis or history of alcoholism or drug abuse 
12. No evidence of depression as determined by clinical examination for DSM-IV depression 
13. No evidence of medical disorders that could produce cognitive deterioration 
14. No evidence of any psychotropic drug or any other drug that may significantly affect 
cognitive functioning during the month prior to psychometric testing 
 
Diagnostic criteria for AACD (all waves)  
1. Report by subject or informant that cognitive (memory and/or other) function has declined 
2. Onset is gradual and has been present for at least 6 months 
3. Difficulties in one of the following areas: memory and learning; attention and 
concentration; thinking; language; visuospatial functioning 
4. There is an abnormality of performance on quantitative cognitive assessments for which 
age and education norms are available for relatively healthy individuals. Performance 
must be below 1 SD on one of the following tests: Symbol-Digit Modalities Test, 
California Verbal Learning Test and MMSE adjusted for education 
5. None of the present existing: dementia, mild cognitive disorder (i.e.,no objective evidence 
from physical and neurological examination or lab tests and no history of cerebral disease, 
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damage or dysfunction or of systemic physical disorder known to cause cerebral 
dysfunction); depression; anxiety or other significant psychiatric disorders; organic 
amnestic syndrome, delirium, post-encephalitic syndrome; post-concussional syndrome; 
cognitive impairment due to psychoactive substance abuse or the effects of any centrally 
active drug. 
 
DSM-IV-TR Diagnostic criteria for MND (all waves)  
1. Two or more of the following impairments, lasting more than 2 weeks 
a. Memory (reduced learning or recall of information) 
b. Executive functioning 
c. Attention or speed of information processing 
d. Perceptual-motor abilities  
e. Language (e.g., comprehension, word finding) 
2. A neurological or general medical disorder is judged to be aetiologically related 
3. Neuropsychological testing supports abnormality or decline in performance 
4. Deficits cause distress or impairment in social/occupational/other functions 
5. Does not meet criteria for delirium, dementia, amnestic syndrome, and not better 
accounted for by another mental disorder 
 
DSM-IV-TR Diagnostic criteria for other cognitive disorder (all waves)  
1.  Subject has mild neurocognitive impairment due to medical condition 
2.  Does not meet criteria for MND 
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Appendix C. Brief Patient Health Questionnaire (BPHQ) 
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Brief Patient Health Questionnaire (BPHQ) 
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Appendix D. Goldberg and Anxiety Depression Scale (GADS) 
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Goldberg and Depression Scale (GADS) 
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Appendix E. Phi Coefficents for Covariates in Model 3 
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 Exercise Employment Anx 
Med 
Dep  
Med 
Partner  
Status 
Smoke High 
Blood 
pressure 
Diabetes Stroke Heart Disease 
Exercise 
 
 .055 .064 .067 .068 .080 .113 .064 .051 .078 
Employment 
 
.055  .042 .038 -.078 .044 .063 .029 .066 .081 
Anx med 
 
.064 .042  .480 -.015 .025 .057 .039 .075 .048 
Dep med 
 
.067 .038 .480  .015 .025 .035 .059 .075 .033 
Partner status .068 -.078 -.015 -.015  -.117 -.025 .019 -.025 .002 
Smoke 
 
.080 .004 .025 .025 -.117  -.047 .001 .003 -.010 
High Blood 
Pressure 
 
.113 .063 .057 .035 -.025 -.047  .151 .131 .210 
Diabetes 
 
.064 .029 .039 .059 .019 .001 .151  .044 .094 
Stroke 
 
.051 .066 .075 .075 -.025 .003 .131 .044  .155 
Heart 
Disease 
.078 .081 .048 .033 .002 -.010 .210 .094 .155  
 
 
          
 
 
Phi coefficient result analysing the association between covariates in model 3 
Note. Anx med = Anxiety medication; Dep med =Depression medication. Cohens criteria for effect size: .10 
(small effect), .30 (medium effect) and .50 (large effect).  
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 Appendix F. Positive And Negative Affect Scale (PANAS) 
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PANAS Questionnaire 
 
This scale consists of a number of words that describe different feelings and 
emotions. Read each item and then list the number from the scale below 
next to each word. Indicate to what extent you feel this way right now, 
that is, at the present moment OR indicate the extent you have felt this 
way over the past week (circle the instructions you followed when taking 
this measure). 
 
 
           1                                 2                    3                       4                     5 
Very Slightly or Not         A Little       Moderately     Quite a Bit      Extremely 
       at All 
 
 
_________ 1. Interested                                     _________ 11. Irritable 
_________ 2. Distressed                                    _________ 12. Alert 
_________ 3. Excited                                        _________ 13. Ashamed 
_________ 4. Upset                                            _________14. Inspired 
_________ 5. Strong                                          _________ 15. Nervous 
_________ 6. Guilty                                           _________16. Determined 
_________ 7. Scared                                          _________ 17. Attentive 
_________ 8. Hostile                                         _________ 18. Jittery 
_________ 9. Enthusiastic                                  _________19. Active 
_________ 10. Proud                                          _________20. Afraid 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
